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A B S T R A C T
Background
The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) to treat uncomplicated Plas-
modium falciparum (P falciparum) malaria. Concerns about artemisinin resistance have led to global initiatives to develop new partner
drugs to protect artemisinin derivatives in ACT. Pyronaridine-artesunate is a novel ACT.
Objectives
To evaluate the efficacy of pyronaridine-artesunate compared to alternative ACTs for treating people with uncomplicated P falciparum
malaria, and to evaluate the safety of pyronaridine-artesunate and other pyronaridine treatments compared to alternative treatments.
Search methods
We searched theCochrane InfectiousDiseasesGroup SpecializedRegister; CochraneCentral Register of ControlledTrials (CENTRAL),
published in the Cochrane Library; MEDLINE; Embase; and LILACS. We also searched ClinicalTrials.gov, the WHO International
Clinical Trials Registry Platform Search Portal, and the International Standard Randomized Controlled Trial Number (ISRCTN)
registry for ongoing or recently completed trials. The date of the last search was 8 May 2018.
Selection criteria
Efficacy analysis: randomized controlled trials (RCTs) of pyronaridine-artesunate for treating uncomplicated P falciparum malaria.
Safety analysis: RCTs of pyronaridine-artesunate or pyronaridine for treating P falciparum or P vivax malaria.
Data collection and analysis
For this update, two review authors independently re-extracted all data and assessed certainty of evidence. We meta-analysed data to
calculate risk ratios (RRs) for treatment failures between comparisons, and for safety outcomes between and across comparisons.
1Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Main results
We included 10 relevant studies. Seven studies were co-funded by Shin Poong Pharmaceuticals which manufactures the drug. Three
studies were funded by government agencies.
For efficacy analysis we identified five RCTs with 5711 participants. This included 4465 participants from 13 sites in Africa, and 1246
participants from five sites in Asia. It included 541 children aged less than five years.
For polymerase chain reaction (PCR)-adjusted failures at day 28, pyronaridine-artesunate may have fewer failures compared to
artemether-lumefantrine (RR 0.59, 95% confidence interval (CI) 0.26 to 1.31; 4 RCTs, 3068 participants, low-certainty evidence),
artesunate-amodiaquine (RR 0.55, 95% CI 0.11 to 2.77; 1 RCT, 1245 participants, low-certainty evidence), and mefloquine plus
artesunate (RR 0.37, 95% CI 0.13 to 1.05; 1 RCT, 1117 participants, low-certainty evidence).
For unadjusted failures at day 28, pyronaridine-artesunate may have fewer failures compared to artemether-lumefantrine (RR 0.27,
95% CI 0.13 to 0.58; 4 RCTs, 3149 participants, low-certainty evidence), and probably has fewer failures compared to artesunate-
amodiaquine (RR 0.49, 95% CI 0.30 to 0.81; 1 RCT, 1257 participants, moderate-certainty evidence) and mefloquine plus artesunate
(RR 0.36, 95% CI 0.17 to 0.78; 1 RCT, 1120 participants, moderate-certainty evidence).
For PCR-adjusted failures at day 42, pyronaridine-artesunate may make little or no difference compared to artemether-lumefantrine
(RR 0.86, 95% CI 0.49 to 1.51; 4 RCTs, 2575 participants, low-certainty evidence) and artesunate-amodiaquine (RR 0.98, 95% CI
0.20 to 4.83; 1 RCT, 1091 participants, low-certainty evidence), but may have higher failures than mefloquine plus artesunate (RR
1.80, 95% CI 0.90 to 3.57; 1 RCT, 1037 participants, low-certainty evidence). Overall, pyronaridine-artesunate had a PCR-adjusted
treatment failure rate of less than 5%.
For unadjusted failures at day 42, pyronaridine-artesunate may have fewer failures compared to artemether-lumefantrine (RR 0.61,
95% CI 0.46 to 0.82; 4 RCTs, 3080 participants, low-certainty evidence), may make little or no difference compared to mefloquine
plus artesunate (RR 0.84, 95% CI 0.54 to 1.31; 1 RCT, 1059 participants, low-certainty evidence), and probably makes little or
no difference compared to artesunate-amodiaquine (RR 0.98, 95% CI 0.78 to 1.23; 1 RCT, 1235 participants, moderate-certainty
evidence).
For the safety analysis of severe adverse events and liver function, we identified eight RCTs with 6614 participants comparing pyronar-
idine-artesunate to other antimalarials, four of which were not in the previous version of this review. A further two RCTs, comparing
pyronaridine alone to other treatments, contributed to the synthesis of all adverse events.
Raised alanine aminotransferase (ALT) greater than five times the upper limit of normal (> 5 xULN) ismore frequent with pyronaridine-
artesunate compared to other antimalarials (RR 3.34, 95% CI 1.63 to 6.84; 8 RCTS, 6581 participants, high-certainty evidence).
There is probably little or no difference for raised bilirubin > 2.5 x ULN between pyronaridine-artesunate and other antimalarials (RR
1.03, 95% CI 0.49 to 2.18; 7 RCTs, 6384 participants, moderate-certainty evidence). There was one reported case in which raised
ALT occurred with raised bilirubin, meeting criteria for moderate drug-induced liver injury. No study reported severe drug-induced
liver injury. Electrocardiograph (ECG) abnormalities were less common with pyronaridine-artesunate compared to other antimalarials.
We identified no other safety concerns.
Authors’ conclusions
Pyronaridine-artesunate was efficacious against uncomplicated P falciparum malaria, achieved a PCR-adjusted treatment failure rate of
less than 5% at days 28 and 42, and may be at least as good as, or better than other marketed ACTs.
Pyronaridine-artesunate increases the risk of episodes of raised ALT > 5 x ULN. This meets criteria for mild drug-induced liver injury.
On one instance this was linked to raised bilirubin, indicating moderate drug-induced liver injury. No episodes of severe drug-induced
liver injury were reported. The findings of this review cannot fully inform a risk-benefit assessment for an unselected population.
Readers should remain aware of this uncertainty when considering use of pyronaridine-artesunate in patients with known or suspected
pre-existing liver dysfunction, and when co-administering with other medications which may cause liver dysfunction.
P L A I N L A N G U A G E S U M M A R Y
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum (P falciparum) malaria
What is the aim of this review?
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The aim of this Cochrane Review was to find out if the antimalarial drug pyronaridine-artesunate is effective and safe to treat
uncomplicated cases of an important type of malaria (P falciparum). We collected and analysed all relevant studies to answer this
question and found 10 studies.
Key messages
Pyronaridine-artesunate is effective in treating uncomplicated P falciparum malaria. Pyronaridine-artesunate is generally safe, but some
people who receive it have blood tests suggesting liver damage. This appears to neither be long-lasting nor make people ill.
What was studied in the review?
The World Health Organization (WHO) recommends that malaria is treated with combinations of drugs called artemisinin-based
combination therapies (ACTs). Pyronaridine-artesunate is a new ACT. New ACTs are needed to treat malaria that has become resistant
to currently available ACTs, and to help prevent malaria becoming more resistant to treatment.
We compared pyronaridine-artesunate to other ACTs to evaluate its efficacy against P falciparum malaria, and compared pyronaridine-
artesunate and pyronaridine alone to other drugs to evaluate its safety.
What are the main results of the review?
We included 10 relevant studies. Seven studies were co-funded by Shin Poong Pharmaceuticals which manufactures the drug. Three
studies were funded by government agencies.
Three studies compared pyronaridine-artesunate to artemether-lumefantrine in adults and children of all ages in Africa and Asia.
One study compared pyronaridine-artesunate to artesunate-amodiaquine in adults and older children in Africa. One study compared
pyronaridine-artesunate to mefloquine plus artesunate in adults and older children in Africa and Asia. We included another five studies
when we looked at the safety of the drug.
Pyronaridine-artesunate effectively treated uncomplicated P falciparum malaria, and may be at least as good as or better than existing
ACTs (low- to moderate-certainty evidence).
Pyronaridine-artesunate increases the risk of having blood tests which suggest mild liver injury (moderate- to high-certainty evidence).
We did not find evidence that any such liver injury was severe or irreversible. We do not know how pyronaridine-artesunate might
affect people who already have liver damage.
We found two trials that exclusively recruited children under 12, with a total of 732 participants. Using the data from these trials, we
did not find differences in treatment efficacy or safety between pyronaridine-artesunate and artemether-lumefantrine.
How up-to-date is the review?
We searched for studies that had been published up to 8 May 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pyronaridine-artesunate (PY-AS) compared to artemether- lumefantrine (AL) for adults and children with uncomplicated Plasmodium falciparum malaria
Patient or population: adults and children with uncomplicated P falciparum malaria
Setting: malaria transmission sett ings
Intervention: pyronaridine-artesunate (PY-AS)
Comparison: artemether-lumefantrine (AL)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with AL Risk with PY-AS
Total failure: day 28
(PCR-adjusted)
15 per 1000 9 per 1000
(4 to 19)
RR 0.59
(0.26 to 1.31)
3068
(4 RCTs)
⊕⊕©©
LOWa,b,c
Due to indirectness and
imprecision
Compared to AL, PY-AS
may have fewer PCR-
adjusted failures at day
28
Total failure: day 42
(PCR-adjusted)
23 per 1000 20 per 1000
(12 to 35)
RR 0.86
(0.49 to 1.51)
2575
(4 RCTs)
⊕⊕©©
LOWa,b
Due to indirectness and
imprecision
There may be lit t le or
no dif ference in PCR-
adjusted failures at day
42 between PY-AS and
AL
Total failure: day 28
(unadjusted)
126 per 1000 34 per 1000
(16 to 73)
RR 0.27
(0.13 to 0.58)
3149
(4 RCTs)
⊕⊕©©
LOWa,d,e
Due to indirectness and in-
consistency
Compared to AL, PY-AS
may have fewer unad-
justed failures at day 28
Total failure: day 42
(unadjusted)
254 per 1000 155 per 1000
(117 to 208)
RR 0.61
(0.46 to 0.82)
3080
(4 RCTs)
⊕⊕©©
LOWa,d,e
Due to indirectness and in-
consistency
Compared to AL, PY-AS
may have fewer unad-
justed failures at day 42
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Serious adverse events
(42 days)
3 per 1000 3 per 1000
(1 to 12)
RR 0.90
(0.19 to 4.22)
2004
(3 RCTs)
⊕⊕©©
LOWf
Due to imprecision
We do not know if there
is a dif ference in seri-
ous adverse events be-
tween PY-AS and AL
First treatment, ALT in-
crease > 5 × ULN (42
days)
3 per 1000 9 per 1000
(3 to 22)
RR 2.92
(1.15 to 7.41)
3341
(4 RCTs)
⊕⊕©©
LOWa,g
Due to indirectness and
imprecision
Compared to AL, PY-
AS may lead to higher
events of ALT increase
> 5 × ULN. (Aggregate
analysis indicates this
est imate may be accu-
rate)
First treatment, AST in-
crease > 5 × ULN (42
days)
4 per 1000 9 per 1000
(3 to 23)
RR 2.20
(0.83 to 5.82)
3327
(4 RCTs)
⊕©©©
VERY LOWa,b,h
Due to indirectness, incon-
sistency, and imprecision
We do not know if there
is a dif ference in AST
between PY-AS and AL
First treatment, biliru-
bin increase > 2.5 × ULN
(42 days)
6 per 1000 5 per 1000
(2 to 12)
RR 0.82
(0.33 to 2.04)
3130
(3 RCTs)
⊕⊕©©
LOWa,b
Due to indirectness and
imprecision
We do not know if there
is a dif ference in biliru-
bin between PY-AS and
AL
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: AL: artemether-lumefantrine;ALT: alanine aminotransferase; AST: aspartate transaminase; CI: conf idence interval; PCR: polymerase chain react ion; PY-AS:
pyronaridine-artesunate; RCT : randomized controlled trial; RR: risk rat io; ULN: upper lim it of normal
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by 1 for serious indirectness: the trials included adults and children and had sites in Af rica and Asia. However
across the trials, only 115 children and 0 adults were randomized to pyronaridine-artesunate in Asia. Further adequately
powered studies in adults and children in Asia would be needed to fully apply this result .
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bDowngraded by 1 for serious imprecision: the CI includes both no ef fect and clinically signif icant ef fect.
cCertainty of the evidence grade dif fers f rom the 2014 review version due to addit ional data: the previous review reported no
substant ial dif f erence between PY-AS and AL in reference to this outcome and therefore did not downgrade for imprecision. In
this update we report a reduced rate in the PY-AS arm. Because we concluded that there may be a dif ference, we necessarily
downgraded for the imprecision.
dCertainty of the evidence grade dif fers f rom the 2014 review version due to addit ional data: the introduct ion of more data
increased the heterogeneity between the included trials.
eDowngraded by 1 for serious inconsistency: there was quant itat ive heterogeneity between studies.
fDowngraded by 2 for very serious imprecision: the low number of events recorded in the studies is insuf f icient for conf ident ly
est imating the ef fect size.
gDowngraded by 1 for serious imprecision: the CI is wide and includes a clinically signif icant ef fect, and almost no ef fect.
hDowngraded by 1 for serious inconsistency: there was qualitat ive heterogeneity between studies.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Malaria poses a global health challenge, with an estimated 216
million cases and 445,000 deaths in 2016. Plasmodium falciparum
(P falciparum) is the most important species of malaria, causing
99% of malaria cases in the World Health Organization (WHO)
Africa region, and 66% in the South-East Asia region (WHO
2017).
The WHO defines uncomplicated malaria by the absence of clin-
ical features of severe malaria, in the presence of an asexual P falci-
parum parasitaemia (WHO 2015). Severe malaria is P falciparum
parasitaemiawith one ormore of: impaired consciousness, prostra-
tion, multiple convulsions, acidosis, hypoglycaemia, severe malar-
ial anaemia, renal impairment, jaundice, pulmonary oedema, sig-
nificant bleeding, shock, raised lactate, or a parasitaemia of greater
than 10%. If untreated, uncomplicated malaria can develop into
severe malaria.
The WHO has recommended artemisinin-based combination
therapies (ACTs) as first-line treatment of uncomplicated P falci-
parum malaria since 2006, recognising the risk of resistance with
monotherapy (WHO 2006). Artemisinin resistance has emerged
in South-East Asia, initially from the Thai-Cambodian border,
and has since become prevalent in Laos, Myanmar, Thailand, and
Vietnam (Dondorp 2009; Noedl 2008). This resistance remains a
key concern, as further spread of artemisinin resistance could lead
to high mortality (Lubell 2014). These concerns have led to global
initiatives to contain the spread of artemisinin resistance, which
includes the development of new drugs to partner and protect the
artemisinin derivatives in ACT (WHO 2011).
Description of the intervention
The WHO currently recommends the following five ACTs for
first-line treatment of malaria.
• Artemether-lumefantrine
• Artesunate-amodiaquine
• Artesunate-mefloquine
• Artesunate-sulphadoxine-pyrimethamine
• Dihydroartemisinin-piperaquine
The artemisinin in ACTs rapidly clears parasites from the blood.
It also kills some sexual forms of the parasite, and may reduce
onward transmission to mosquitoes. The longer-acting partner
drug clears residual infections, and protects against resistance to
artemisinin (WHO2015).Drug combinationswith longhalf-lives
(artesunate-mefloquine and dihydroartemisinin-piperaquine) can
provide a period of post-treatment prophylaxis which may last for
up to six weeks (Sinclair 2009).
Pyronaridine is a potential partner drug for artesunate. Researchers
in China developed pyronaridine during the mid-1970s, using
the nucleus of an earlier antimalarial compound (mepacrine) with
an added amodiaquine side-chain (Fu 1991). Clinicians there-
after used pyronaridine extensively as monotherapy for P falci-
parum and P vivax infections in China (Chen 1992). Concerns
about observed in vitro resistance to pyronaridine lead Chinese re-
searchers to use pyronaridine in combinations with sulphadoxine
and pyrimethamine, and primaquine (Fu 1991).
A public-private partnership including the Medicines for Malaria
Venture (MMV) and Shin Poong Pharmaceuticals Incorporated
developed pyronaridine-artesunate in combination from2002 on-
wards (MMV 2002), with its first national registration in 2011
(with the Korean Food and Drug Administration). For uncom-
plicated malaria, the treatment is taken once-daily for three days.
Treatment is provided as tablets for adults and children over 20
kg, or in granules for children and infants between 5 kg and 20
kg.
How the intervention might work
The mode of action of pyronaridine is unclear, with several pos-
sible mechanisms (Croft 2012). Pyronaridine has been shown to
have potent in vitro activity versus P falciparum (Basco 1992;
Chen 1992; Childs 1988; Pradines 1998; Ringwald 1999), even
in strains with resistance to other antimalarials, including chloro-
quine, cycloguanil, amodiaquine, and sulfadoxine-pyrimethamine
(Chavalitshewinkoon-Petmitr 2000; Kurth 2009; Price 2010). In
vitro studies also indicate synergy between pyronaridine and arte-
sunate versus parasites which are resistant to either agent (Peters
1997; Vivas 2008).
Why it is important to do this review
In the absence of resistance, ACTs are effective drugs. However,
with emerging resistance to the above currently recommended
ACTs, it is necessary to identify new drug combinations with
equivalent efficacy. This review is an update of a Cochrane Review
first published in 2007 (Unnikrishnan 2007), and previously up-
dated in 2014 (Bukirwa 2014). The latest update of this review
concluded that pyronaridine-artesunate performed well in these
trials compared to artemether-lumefantrine and mefloquine plus
artesunate. At day 28, polymerase chain reaction (PCR)-adjusted
treatment failure (where PCR is used to confirm recrudescence
rather than reinfection) was below the 5% standard set by the
WHO. However, the review recommended further efficacy and
safety studies in African and Asian children to clarify whether the
combination is an option for first-line treatment of uncomplicated
P falciparum malaria.
Following this review, the latest edition of the WHO guidelines
for the treatment of malaria did not recommend pyronaridine-
artesunate for general use (WHO 2015). The Guideline Develop-
ment Group recommended further data were required for efficacy
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in children less than five years of age, and safety, including safety
of repeat dosing. They noted the undesirable effects of elevated
liver function tests.
Since the previous update andWHOGuidelines, theWest African
Network for Clinical Trials of Antimalarial Drugs has published a
new study of pyronaridine-artesunate (Sagara 2018), and the Eu-
ropean Medicines Agency (EMA) has adopted a positive scientific
opinion of pyronaridine-artesunate (EMA 2015). In view of this,
we have updated the review to inform future guideline develop-
ment.
O B J E C T I V E S
To evaluate the efficacy of pyronaridine-artesunate compared to
alternative ACTs for treating people with uncomplicated P fal-
ciparum malaria, and to evaluate the safety of pyronaridine-arte-
sunate and other pyronaridine treatments compared to alternative
treatments.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Adults and children with uncomplicated Plasmodium falciparum
(P falciparum) malaria, as confirmed by either microscopy or rapid
diagnostic tests.
For an additional safety analysis we extended the inclusion criteria
to adults and children with P vivax malaria.
Types of interventions
Intervention
• Pyronaridine-artesunate
Control
• World Health Organization (WHO)-recommended
artemisinin-based combination therapies (ACTs) for treating
malaria
For the analysis of adverse events, we extended the inclusion criteria
to all RCTs comparing pyronaridine alone or in combination with
any other antimalarial.
Types of outcome measures
Primary outcomes
• Total treatment failure at day 28 (PCR-adjusted and
unadjusted)
• Total treatment failure at day 42 (PCR-adjusted and
unadjusted)
Secondary outcomes
• Early treatment failure (WHO 2009):
◦ danger signs or severe malaria on day 1, 2 or 3, in the
presence of parasitaemia
◦ parasitaemia on day 2 higher than on day 0,
irrespective of axillary temperature
◦ parasitaemia on day 3 with axillary temperature ≥
37.5 °C
◦ parasitaemia on day 3 ≥ 25% of count on day 0
Adverse events (safety analysis)
• Serious adverse events (leading to death, requiring
hospitalization or prolongation of existing hospitalization, are
life threatening, or result in persistent or significant disability or
incapacity)
• Adverse events leading to withdrawal from treatment
(discontinuation of trial drug or withdrawal from trial)
• Elevated liver function tests
• Other adverse events
Comment on outcome measures
We base our primary outcome measures on WHO recommen-
dations (WHO 2003; WHO 2009), which advise a 28-day fol-
low-up to capture most failures, and 42-day follow-up to capture
failures for drugs with a longer elimination half-life (mefloquine
and piperaquine). This is also consistent with previous Cochrane
Reviews. We do not report ‘adequate clinical and parasitological
response’ as this is defined in terms of absence of failure and there-
fore represents duplication.
The previous published protocol for this review listed a priori sec-
ondary outcomes to include parasite clearance, fever clearance, and
gametocyte carriage (Bukirwa 2014). The protocol did not clearly
define these outcomes, including whether they refer to durations,
rates, or proportions of patients at given time points. We encoun-
tered considerable heterogeneity in these measures between stud-
ies, and therefore present a narrative synthesis.
We encountered heterogeneity in the threshold at which elevated
liver function tests were deemed by study authors to be significant,
which we have detailed in Table 1. The reader should note that
these thresholds do not necessarily correspondwith internationally
accepted definitions of drug-induced liver injury (Aithal 2011,
summarized in Appendix 1).
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Search methods for identification of studies
We sought to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
The review authors and the Cochrane Infectious Diseases Group
(CIDG) Information Specialist, Vittoria Lutje (VL), attempted
to identify all relevant trials regardless of language or publication
status (published, unpublished, in press, and in progress). The
date of the last search was 8 May 2018.
VL searched the following databases using the search terms and
strategy described inAppendix 2: theCochrane InfectiousDiseases
Group Specialized Register; Cochrane Central Register of Con-
trolled Trials (CENTRAL), published in the Cochrane Library;
MEDLINE ( PubMed, from 1966); Embase ( OVID; from1947);
and LILACS ( BIREME; from 1982). We also searched Clini-
calTrials.gov ( clinicaltrials.gov), the WHO International Clini-
cal Trial Registry Platform (ICTRP; www.who.int/ictrp/search/
en), and the International Standard Randomized Controlled Trial
Number ( ISRCTN) registry ( www.isrctn.com/) for ongoing
or recently completed trials using ’pyronaridine’, ’pyramax’, and
’malaria’ as search terms.
Searching other resources
Conference proceedings
The previous authors of this review searched conference proceed-
ings for relevant abstracts (Bukirwa 2014).We did not handsearch
conference proceedings for this update as relevant abstracts are
likely to be indexed and detected by the electronic search.
Reference lists
We checked the reference lists of all trials identified by the above
methods.
Contacting organizations and experts
We did not formally contact experts for this update.
Data collection and analysis
Selection of studies
For this review update, Joseph Pryce (JP) and Paul Hine (PH)
independently screened the results of the search update to identify
potentially relevant trials and obtain the full-text reports of these
trials. JP and PH used a standard eligibility form to assess newly
identified studies. Therewere nodisagreements.Due to the change
in authorship, and to ensure validity, we rescreened all the results
of the search, and verified the eligibility of previously included
studies. We documented the reason for excluding trials in the
‘Characteristics of excluded studies’ table.We prepared a PRISMA
diagram to summarise the identification, screening, and inclusion
of studies in this review (Moher 2009).
Data extraction and management
For this update, to ensure accuracy and consistency, the new au-
thors (JP and PH) independently re-extracted all data using a new
data extraction form.
Unadjusted total failure rate: day 28, day 42
We extracted the following data, and summed it, to form the
numerator.
• Early treatment failure.
• Late clinical failure.
• Late parasitological failure.
We aimed to extract the following data, and subtract it from the
number of participants randomized, to form the denominator.
• Those found not to be fulfilling inclusion criteria after
randomization.
• Those voluntarily withdrawing consent.
• Those lost to follow-up.
• Those violating protocol, including (but not limited to)
missed or vomited doses, those failing to complete treatment,
and those taking additional antimalarials.
PCR-adjusted total failure rate: day 28, day 42
We aimed to extract the following data, and sum it, to form the
numerator.
• Early treatment failure due to PCR-confirmed
recrudescence.
• Late clinical failure due to PCR-confirmed recrudescence.
• Late parasitological failure due to PCR-confirmed
recrudescence.
We aimed to extract the following data, and subtract it from the
number of participants randomized, to form the denominator.
• Those with indeterminate PCR results.
• Those with missing PCR results.
• Those with PCR-confirmed new infections.
• Those found not to be fulfilling inclusion criteria after
randomization.
• Those voluntarily withdrawing consent.
• Those lost to follow-up.
• Those violating protocol, including (but not limited to)
missed or vomited doses, those failing to complete treatment,
and those taking additional antimalarials.
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Adverse events data
For adverse events, we extracted the number of people experiencing
the events in each study as the numerator. In contrast to the efficacy
analysis, we extracted the number of people who received at least
one dose of the study drug as the denominator. Recognising that
studies often use different terminology to describe adverse events,
we referenced the Medical Dictionary for Regulatory Activities to
find the preferred term (MedDRA 2018), and grouped adverse
events according to MedDRA’s “High Level Term” descriptors.
Comment on data extraction
This approach is based on standard WHO definitions (WHO
2003; WHO 2009). The WHO protocol has a primary goal to
“provide guidance in obtaining the minimum essential informa-
tion about the clinical and parasitological response to antimalarial
drugs among populations at greatest risk of severe morbidity or
mortality due to malaria” (WHO 2003). Many antimalarial effi-
cacy studies have used adapted versions of this protocol since its
publication. Within this protocol, a high number of randomized
participants are excluded from the final efficacy outcome as losses
to follow-up or voluntary or involuntary withdrawals.
In some instances, we could not extract the individual components
required to form the denominator. We discuss this issue further in
‘Dealing with missing data’ below.
The primary outcomes relate to failure due to P falciparum. The
denominators for each include participants developing P vivax
parasitaemia that continued to be followed up within the trial.
Assessment of risk of bias in included studies
For this review update, JP and PH assessed the risk of bias for the
new trial inclusion using the Cochrane tool for assessing risk of
bias (Higgins 2011). JP and PH assigned a judgement of ‘high
risk’, ‘low risk’, and ‘unclear risk’ to each domain recording these
in ‘Risk of bias’ tables, and a summary ‘Risk of bias’ graph.
For efficacy, we assessed the following domains.
• Sequence generation.
• Allocation concealment.
• Blinding of participants, trial personnel and outcome
assessors.
• Incomplete outcome data.
• Selective reporting.
• Other sources of bias.
For adverse events, we assessed the two following domains, selected
based on Cochrane and PRISMA recommendations (Loke 2007;
Zorzela 2016).
• Adverse event detection.
• Incomplete reporting of adverse events.
Appendix 3 gives examples of ‘Risk of bias’ assessment decisions.
Measures of treatment effect
We extracted data from each included trial to calculate risk ratios
(RRs) for dichotomous data, and mean differences (MDs) for
continuous data. We present all measures with the corresponding
95% confidence interval (CI).
Unit of analysis issues
We did not encounter any unit of analysis issues.
Dealing with missing data
In the event of missing or unclear data, we contacted trial au-
thors for clarifications or to provide further information. It was
not always possible to extract each data item required to itemise
the denominator for treatment failures, particularly where study
authors reported amalgamations of the denominator component.
Where this was the case, we kept clear records of inferences made
to inform the denominator data.
Assessment of heterogeneity
We visually inspected the forest plots for overlapping CIs as an
indicator of clinical heterogeneity. We also took into account Chi
2 and I2 tests of heterogeneity. We considered a Chi2 test P < 0.1
and/or an I2 statistic > 75%as indicating substantial heterogeneity.
If we judged there to be substantial heterogeneity we did not pool
the results in a meta-analysis, and instead presented a narrative
synthesis of the findings.
Assessment of reporting biases
There were too few trials to examine funnel plot asymmetry for
evidence of small trial effects or publication bias.
Data synthesis
We analysed data using Review Manager 2014. For the primary
analysis we stratified by comparator ACT. We performed meta-
analysis where appropriate after assessment and investigation of
heterogeneity. In the first instance, we used a fixed-effect model.
Where there was evidence of heterogeneity, we used a random-ef-
fects model, and applied this consistently across similar outcomes.
We deemed it inappropriate to combine continuous data for the
outcomes of parasite clearance, fever clearance and gametocyte
carriage, due to heterogeneity in the measurements of these out-
comes.
Subgroup analysis and investigation of heterogeneity
We intended to explore causes of heterogeneity using subgroup
analysis of age, country and geographic region. We deemed that
there were too few trials to use these subgroup analyses. However,
to explore the applicability of the evidence to child populations,
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we presented the findings from a subset of trials that exclusively
recruited paediatric participants.
Sensitivity analysis
We planned to conduct a series of sensitivity analyses as detailed
in Appendix 4. The aim of this was to restore the integrity of
the randomizations process by adding excluded groups back into
the analysis in a stepwise fashion. However, as we were unable
to reliably extract data pertinent to the missing or indeterminate
PCR values, we did not conduct the sensitivity analysis.
Certainty of the evidence
We assessed the certainty of the evidence using the GRADE ap-
proach (Schünemann 2013). We appraised the certainty of the
evidence in relation to the following criteria.
• Study design
• Risk of bias
• Inconsistency
• Indirectness
• Imprecision
• Other considerations (including publication bias)
We used GRADEpro GDT 2015 to create ‘Summary of findings’
tables for each comparison included in the review. We included
our primary outcomes and adverse event outcomes, and used the
tables to guide our conclusions.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies sections.
Results of the search
The search (dated 8May 2018) identified 40 database records and
12 trials registry records. After contacting authors of a relevant
registered trial, we obtained one additional published record. JP
and PH independently screened all titles. This process replaced
that of the previous version of this review (Bukirwa 2014), as we
are a new authorship team.
We identified 31 potentially relevant full-text records through ti-
tle and abstract screening. We excluded 10 records after further
assessment (see ‘Characteristics of excluded studies’ table).
This process identified 21 records, relating to 10 studies, which
we included in qualitative and quantitative synthesis (see
Characteristics of included studies).We identified four studies that
were not included in the previous version of this review (Nelwan
2015; Roth 2018; Sagara 2018; Shin 2011).
The Sagara 2018 trial compared different drug combinations at
different sites, but presented the results in an aggregated analysis,
in which the numbers of outcome events were summarized across
sites. We were concerned that this presented an unpredictable bias
and so contacted the trial authors to obtain data disaggregated to
site level for the efficacy and raised liver enzyme outcomes.Wewere
therefore able to present the data from individual sites separately
in the meta-analysis. However, we did not have disaggregated data
for the outcomes of serious adverse events or adverse events leading
to withdrawal of treatment. We therefore present these outcomes
in narrative form. Further details of the comparisons examined
and the number of participants are provided in the ‘Characteristics
of included studies’ tables for each site.
Figure 1 illustrates the search results in a flow diagram (PRISMA).
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Figure 1. Study flow diagram.
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Included studies
Studies meeting the inclusion criteria for efficacy
outcomes
Five studies met the inclusion criteria for efficacy outcomes
(Kayentao 2012; Roth 2018; Rueangweerayut 2012; Sagara 2018;
Tshefu 2010; see Characteristics of included studies). Each of the
studies had a length of follow-up of 42 days.
Comparison 1: Pyronaridine-artesunate versus artemether-
lumefantrine
Four randomized controlled trials (RCTs) evaluated this compar-
ison (Kayentao 2012; Roth 2018; Sagara 2018; Tshefu 2010).
Sample sizes ranged from 197 participants in Roth 2018 to 1323
participants in Sagara 2018, yielding a total number of 3327 for
inclusion in quantitative synthesis. Two studies were multicen-
tred in Africa and Asia (Kayentao 2012; Tshefu 2010), one was
multicentred in Africa (Sagara 2018), and one was a single-centre
in Africa (Roth 2018). None of the studies described the P fal-
ciparum resistance profile to currently available antimalarials. In
total, 3128 (94%) participants were recruited in Africa, and 213
(6%) participants were recruited in Asia.
Two studies included adults and children (Sagara 2018; Tshefu
2010), and two studies included children only (Kayentao 2012;
Roth 2018). In total, 541 (16%) participants were aged less than
five years. All studies included both male and female participants.
In total 1568 (47%) participants were female.
All studies used three-day regimens of pyronaridine-artesunate
with dose adjusted according to weight. There were minimal dif-
ferences in dose by weight. The two paediatric trials used granule
formulation.
All studies reported “adequate clinical and parasitological re-
sponse” rate) at day 28 and day 42, PCR-adjusted and unadjusted.
All studies also reported parasite clearance time (defined as first
dose to aparasitaemia), and fever clearance time (defined as first
dose to apyrexia).
Comparison 2: Pyronaridine-artesunate versus artesunate-
amodiaquine
OneRCT evaluated this comparison, taking place inmultiple cen-
tres inWest Africa (Sagara 2018). The study did not describe the P
falciparum resistance profile to currently available antimalarials. In
total, 1317 participants randomized to this comparison received at
least one study treatment. Of these, 477 (36%) participants were
aged less than five years, and 658 (50%) participants were female.
Both pyronaridine-artesunate and artesunate-amodiaquine were
administered once-daily for three days at doses according to body-
weight.
Comparison 3: Pyronaridine-artesunate versus mefloquine
plus artesunate
A single trial evaluated this comparison (Rueangweerayut 2012).
The sample size was 1271 participants. Most participants (1033,
81.3%) were from Asia (Cambodia, India, Thailand, and Viet-
nam), with a smaller number (238, 18.7%) from Africa (Burk-
ina Faso, Ivory Coast, and Tanzania). Malaria endemicity was de-
scribed by the trial authors as high in most sites. In Cambodia,
significantly extended parasite clearance times (for both treatment
arms) were suggestive of in vivo resistance to artemisinin. The re-
sistance in the other sites or to other antimalarials was not de-
scribed. The trial planned to recruit participants aged between
three to 60 years, the youngest participant was five years old.
Both pyronaridine-artesunate and mefloquine plus artesunate
were administered once-daily for three days. The trial did not
use a fixed dose combination of mefloquine and artesunate. The
mefloquine dose ranged from 6.2 mg/kg to 12.5 mg/kg and the
artemether dose ranged from 2.2 mg/kg to 5.0 mg/kg.
Studies meeting the inclusion criteria for safety
outcomes
In addition to the five studies meeting the inclusion criteria for
efficacy, we included five further studies which met the inclusion
criteria for safety outcomes. Two studies had a follow-up period
of 14 days (Ringwald 1996; Ringwald 1998), two had a follow-up
of 42 days (Poravuth 2011; Shin 2011), and one study followed
up for one year (Nelwan 2015).
Of these, we included three in ameta-analysis pertaining to serious
adverse events and liver function tests (Nelwan 2015; Poravuth
2011; Shin 2011), in addition to the studies included in the effi-
cacy analysis. These three studies contributed a further 666 partic-
ipants to themeta-analysis, and included participants with P vivax
malaria recruited from sites in Asia. One study included only adult
male soldiers (Nelwan 2015). No participants were aged less than
five years. Two studies excluded participants with existing hepatic
impairment (Nelwan 2015; Poravuth 2011). Further details of the
inclusion and exclusion criteria are provided in the ‘Characteristics
of included studies’ tables.
TheNelwan 2015 study compared pyronaridine-artesunate versus
artesunate alone or dihydroartemisinin-piperaquine. The other
two studies were based on the same protocol (Poravuth 2011; Shin
2011), and compared pyronaridine-artesunate versus chloroquine.
We included two further studies (Ringwald 1996; Ringwald
1998), contributing a further 184 participants, in the analy-
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sis of other adverse events; these studies compared pyronaridine
monotherapy to chloroquine.
As is common to clinical trials, patients with known or suspected
pre-existing liver dysfunction were excluded. Concomitant parac-
etamol (acetaminophen) administration was allowed in at least
two of the trial protocols (Poravuth 2011, Sagara 2018), but the
remaining trials do not record whether concomitant paracetamol
was allowed or to the extent that it was used.
Excluded studies
We excluded 10 records after further assessment (see
Characteristics of excluded studies).
Two were quasi-RCTs, three were RCTs that were not relevant to
this review, and five were not RCTs.
Risk of bias in included studies
See Figure 2.
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Figure 2. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Seven studies reported the use of computer generated alloca-
tion sequences (Kayentao 2012; Poravuth 2011; Roth 2018;
Rueangweerayut 2012; Sagara 2018; Shin 2011; Tshefu 2010).
The Nelwan 2015 study reported “statistician block-allocated
treatment”. Two studies reported block randomization, but it is
unclear how blocks were generated (Ringwald 1996; Ringwald
1998). We judged random sequence generation to present a low
risk of bias across studies.
Five studies concealed allocation using sealed opaque envelopes
(Nelwan 2015; Poravuth 2011; Roth 2018; Sagara 2018; Shin
2011). Three studies concealed allocation using individually num-
bered treatment packs (Kayentao 2012; Rueangweerayut 2012;
Tshefu 2010). Two studies reported central randomization in cor-
respondence with the previous authors of this review (Ringwald
1996; Ringwald 1998). We judged allocation concealment to
present a low risk of bias across studies.
Blinding
Five studies reported that the participants were blinded to treat-
ment allocation (Poravuth 2011; Ringwald 1996; Ringwald 1998;
Roth 2018; Tshefu 2010). Six studies reported that the inves-
tigators performing clinical assessments were blinded to treat-
ment allocation (Kayentao 2012; Poravuth 2011; Roth 2018;
Rueangweerayut 2012; Shin 2011; Tshefu 2010). Eight stud-
ies reported that the investigators performing parasitological as-
sessments were blinded to treatment allocation (Kayentao 2012;
Nelwan 2015; Poravuth 2011; Roth 2018; Rueangweerayut 2012;
Sagara 2018; Shin 2011; Tshefu 2010).
Notwithstanding the different degrees to which studies were
blinded, we judged there to be a low risk of performance bias and
detection bias in relation to the outcomes assessed.
Incomplete outcome data
All of the included trials reported attrition with details of all ran-
domized participants. Our analysis focused on evaluable partici-
pants. We did not have concerns that there was differential loss to
follow-up between interventions.
Selective reporting
We located trial registrationdocuments for eight studies (Kayentao
2012; Nelwan 2015; Poravuth 2011; Roth 2018; Rueangweerayut
2012; Sagara 2018; Shin 2011; Tshefu 2010). These appeared to
be free of selective reporting based on comparison of registration
documents and trial protocols, where available. Though trial regis-
tration documents were not available for the remaining two stud-
ies (Ringwald 1996; Ringwald 1998), we also considered them to
be at low risk of reporting bias, as all the expected outcomes were
reported.
Other potential sources of bias
Seven of the 10 included studies were funded by the public-pri-
vate partnership ofMedicines forMalaria Venture and Shin Poong
Pharmaceuticals (Kayentao 2012; Nelwan 2015; Poravuth 2011;
Rueangweerayut 2012; Sagara 2018; Shin 2011; Tshefu 2010).
The Medicines for Malaria Venture and/or Shin Poong Pharma-
ceuticals employed study authors in six of these studies (Kayentao
2012; Poravuth 2011; Rueangweerayut 2012; Sagara 2018; Shin
2011; Tshefu 2010). We considered this to pose low risk of bias as
all authors took responsibility for reporting accuracy, apart from
in one study (Shin 2011), where the lead authors were Shin Poong
Pharmaceuticals employees.
Of the remaining three studies not funded by Medicines for
Malaria Venture and Shin Poong Pharmaceuticals, one assessed
pyronaridine-artesunate (Roth 2018); the other two assessed py-
ronaridine monotherapy (Ringwald 1996; Ringwald 1998), and
did not contribute to the main analyses.
We considered one study to have unclear risk of other bias in
relation to bioavailability of lumefantrine (Tshefu 2010).
Adverse event monitoring (detection bias)
Seven studies provided unclear descriptions, definitions, or sched-
ules for adverse adventmonitoring, and therefore we deemed them
to have unclear risk of detection bias for adverse events (Kayentao
2012; Nelwan 2015; Poravuth 2011; Ringwald 1996; Ringwald
1998; Roth 2018; Rueangweerayut 2012). We deemed the re-
maining studies to be at low risk of detection bias for adverse events
(Sagara 2018; Shin 2011; Tshefu 2010).
Incomplete adverse event reporting (reporting bias)
In five studies we identified unclear reporting of adverse events,
with differences in reporting numbers or thresholds, and deemed
these to have unclear risk of reporting bias for adverse events
(Nelwan 2015; Ringwald 1996; Ringwald 1998; Roth 2018;
Rueangweerayut 2012). We judged the remaining studies to be
at low risk of reporting bias for adverse events (Kayentao 2012;
Poravuth 2011; Sagara 2018; Shin 2011; Tshefu 2010).
Effects of interventions
See: Summary of findings for the main comparison
Pyronaridine-artesunate (PY-AS) compared to artemether-
lumefantrine (AL) for adults and children with uncomplicated
Plasmodium falciparum malaria; Summary of findings
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2 Pyronaridine-artesunate (PY-AS) compared to artesunate-
amodiaquine (AS-AQ) for adults and childrenwith uncomplicated
Plasmodium falciparum malaria; Summary of findings 3
Pyronaridine-artesunate (PY-AS) compared to mefloquine plus
artesunate (MQ+AS) for adults and children with uncomplicated
Plasmodium falciparum malaria; Summary of findings 4
Pyronaridine-artesunate (PY-AS) compared to other antimalarials
for adults and children with uncomplicated malaria
Comparison 1. Pyronaridine-artesunate versus
artemether-lumefantrine
Four studies with 3341 participants contributed data to this com-
parison (Kayentao 2012; Roth 2018; Sagara 2018; Tshefu 2010).
Total treatment failure (PCR-adjusted)
In the pooled analysis, there were fewer PCR-adjusted treatment
failures at day 28 following treatment with pyronaridine-arte-
sunate compared to artemether-lumefantrine, but the CI crossed
the line of no effect (risk ratio (RR) 0.59, 95% CI 0.26 to 1.31;
4 trials, 3068 participants; Analysis 1.2). There was little or no
difference at day 42 (RR 0.86, 95%CI 0.49 to 1.51; 4 trials, 2575
participants; Analysis 1.1).
The PCR-adjusted treatment failure rate for pyronaridine-arte-
sunate was less than 5% in all trials at day 28. At day 42, the
PCR-adjusted treatment failure rate for pyronaridine-artesunate
was slightly greater than 5% in two studies (Kayentao 2012, 18
events for 275 evaluable patients, 6.5%; Roth 2018, 4 events for
77 evaluable patients, 5.2%).
Total treatment failure (PCR-unadjusted)
In the pooled analysis, there were fewer PCR-unadjusted treat-
ment failures following treatment with pyronaridine-artesunate
compared to artemether-lumefantrine at day 28 (RR 0.27, 95%
CI 0.13 to 0.58; 4 trials, 3149 participants; Analysis 1.3) and at
day 42 (RR 0.61, 95%CI 0.46 to 0.82, 4 trials, 3080 participants;
Analysis 1.4).
Early treatment failure
There were two events of early treatment failure which occurred
in one trial (Kayentao 2012), both in the pyronaridine-artesunate
arm (RR 2.53, 95% CI 0.12 to 52.39; 4 trials, 3149 participants;
Analysis 1.5).
Serious adverse events
We were unable to include the data on serious adverse events
from one multicentre trial in the meta-analysis because the data
were not disaggregated by trial site (Sagara 2018), and participant
randomizationdidnot take place independently from site. Instead,
we have summarized the number and nature of the serious adverse
events in the trial in Table 2. Across the other trials included in the
quantitative synthesis, there were six serious adverse events, with
four occurring in patients in the pyronaridine-artesunate arm and
two in patients in the artemether-lumefantrine arm. There was no
significant difference between treatments (RR 0.90, 95% CI 0.19
to 4.22; 3 trials, 2004 participants; Analysis 1.6).
Adverse events leading to withdrawal from treatment
We were unable to include data from one trial (Sagara 2018), for
the same reason as given above. Across the other trials included in
quantitative synthesis, there were 37 events leading to withdrawal
from treatment, with 27 occurring in patients in the pyronaridine-
artesunate arm and 10 in patients in the artemether-lumefantrine
arm. There was no significant difference between treatments (RR
1.41, 95% CI 0.68 to 2.90; 3 trials, 2004 participants; Analysis
1.7).
Elevated liver function tests
Following first treatment, the proportion of participants with
raised alanine aminotransferase (ALT) greater than five times
the upper limit of normal (> 5 x ULN) was higher in those
treated with pyronaridine-artesunate compared to artemether-
lumefantrine (RR 2.92, 95% CI 1.15 to 7.41; 4 trials, 3327 par-
ticipants; Analysis 1.8, Figure 3). There were 0 events in either
arm of one study (Roth 2018), so this did not contribute to the
relative risk calculation.
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Figure 3. Forest plot of comparison 1: Pyronaridine-artesunate versus artemether-lumefantrine, outcome
1.8: ALT increase > 5 × ULN, first treatment.
Therewas no significant difference in raised aspartate transaminase
(AST) > 5 x ULN (RR 2.20, 95% CI 0.83 to 5.82; 4 trials, 3327
participants; Analysis 1.9) or bilirubin > 2.5 x ULN (RR 0.82,
95% CI 0.33 to 2.04; 3 trials, 3130 participants; Analysis 1.10)
between pyronaridine-artesunate and artemether-lumefantrine.
One trial investigated the rate of elevated liver function tests in
patients receiving second or subsequent treatments with pyronar-
idine-artesunate compared to artemether-lumefantrine (Sagara
2018). The rates of such events were low in each treatment arm.
In a pooled analysis across the trial sites we detected no significant
differences in the number of raised ALT (> 5 x ULN), AST (> 5 x
ULN), or bilirubin (> 2.5 x ULN) events between pyronaridine-
artesunate and artemether-lumefantrine (1 trial, 865 participants;
Analysis 1.11; Analysis 1.12; Analysis 1.13).
Subgroup analysis
When we included only the two trials which studied paediatric
populations exclusively (Kayentao 2012; Roth 2018), we did not
find differences in efficacy or safety outcomes between pyronar-
idine-artesunate and artemether-lumefantrine (2 trials, 732 par-
ticipants in safety analysis; Analysis 1.14; Analysis 1.15; Analysis
1.16; Analysis 1.17; Analysis 1.18; Analysis 1.19).We were unable
to extract disaggregated data for children from the other two trials
(Sagara 2018; Tshefu 2010).
There were not enough studies to perform further subgroup anal-
yses or investigation of heterogeneity.
Narrative synthesis of other reported outcomes
Three studies also reported fever and parasite clearance times,
which were broadly comparable between pyronaridine-artesunate
and artemether-lumefantrine (Table 3). Differences in reporting
precluded quantitative synthesis.
Comparison 2. Pyronaridine-artesunate versus
artesunate-amodiaquine
One study with 1336 participants contributed data to this com-
parison (Sagara 2018). We extracted data disaggregated by site as
described in Results of the search, and presented them separately
in our meta-analyses.
Total treatment failure (PCR-adjusted)
In the pooled analysis across the multiple sites, there were fewer
PCR-adjusted treatment failures at day 28 for pyronaridine-arte-
sunate compared to artesunate-amodiaquine, but the CI crossed
the line of no effect (RR 0.55, 95% CI 0.11 to 2.77; 1 trial, 1245
participants; Analysis 2.1). There was little or no difference in
PCR-adjusted treatment failure at day 42 (RR 0.98, 95% CI 0.20
to 4.83; 1 trial, 1091 participants; Analysis 2.2).
The PCR-adjusted treatment failure rate for pyronaridine-arte-
sunate was less than 5% in all sites at both day 28 and day 42.
Total treatment failure (PCR-unadjusted)
In pooled analysis, pyronaridine-artesunate had fewer PCR-unad-
justed treatment failures compared to artesunate-amodiaquine at
day 28 (RR 0.49, 95% CI 0.30 to 0.81; 1 trial, 1257 participants;
Analysis 2.3). At day 42, there was little or no difference (RR 0.98,
95% CI 0.78 to 1.23; 1 trial, 1235 participants; Analysis 2.4).
Early treatment failure
Therewas no early treatment failure reported in either the pyronar-
idine-artesunate arm or the artesunate-amodiaquine arm across all
study sites (1336 participants, 1 trial).
Serious adverse events, adverse events leading to
withdrawal from treatment
Wewere unable to include the trial’s data on serious adverse events
and adverse events leading to withdrawal in a meta-analysis, for
the reason given above. We summarized the number and nature
of the serious adverse events in the trial in Table 2.
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Elevated liver function tests
Following first treatment, there was no significant difference in
raised ALT > 5 x ULN (RR 1.41, 95% CI 0.28 to 7.09; 1 trial,
1317 participants; Analysis 2.5), raised AST > 5 x ULN (RR 0.40,
95% CI 0.08 to 2.07; 1 trial, 1317 participants, Analysis 2.6), or
raised bilirubin > 2.5 x ULN (RR 0.99, 95% CI 0.06 to 15.76;
1 trial, 1317 participants; Analysis 2.7) between pyronaridine-
artesunate and artesunate-amodiaquine.
Similarly, on second or subsequent treatments, we detected no sig-
nificant difference in the number of raised ALT (> 5 x ULN), AST
(> 5 x ULN) or bilirubin (> 2.5 x ULN) events between pyronari-
dine-artesunate and artesunate-amodiaquine treatment arms (784
participants, 1 trial (Analysis 2.8; Analysis 2.9; Analysis 2.10).
Comparison 3. Pyronaridine-artesunate versus
mefloquine plus artesunate
One study with 1271 participants contributed data to this com-
parison (Rueangweerayut 2012).
Total treatment failure (PCR-adjusted)
There were fewer PCR-adjusted treatment failures at day 28 for
pyronaridine-artesunate compared to mefloquine plus artesunate,
but the CI crossed the line of no effect (RR 0.37, 95% CI 0.13
to 1.05; 1 trial, 1117 participants; Analysis 3.1). There were more
PCR-adjusted treatment failures at day 42 for pyronaridine-arte-
sunate compared tomefloquine plus artesunate, but theCI crossed
the line of no effect (RR 1.80, 95% CI 0.90 to 3.57; 1 trial, 1037
participants; Analysis 3.2).
The PCR-adjusted treatment failure rate for pyronaridine-arte-
sunate was less than 5% at day 28. At day 42, the PCR-adjusted
treatment failure rate for pyronaridine-artesunate was slightly
greater than 5% (37 events for 698 evaluable patients, 6.5%).
Total treatment failure (PCR-unadjusted)
Pyronaridine-artesunate had fewer PCR-unadjusted treatment
failures compared to mefloquine plus artesunate at day 28 (RR
0.36, 95% CI 0.17 to 0.78; 1 trial, 1120 participants; Analysis
3.3). At day 42, there was little or no difference between pyronar-
idine-artesunate and mefloquine plus artesunate (RR 0.84, 95%
CI 0.54 to 1.31; 1 trial, 1059 participants; Analysis 3.4).
Early treatment failure
There was one early treatment failure in the mefloquine plus arte-
sunate arm of the study, and none in the pyronaridine-artesunate
arm.
Serious adverse events, adverse events leading to
withdrawal from treatment
There was little or no difference in serious adverse events between
pyronaridine-artesunate andmefloquine plus artesunate (RR1.00,
95% CI 0.25 to 3.97; 1 trial, 1271 participants; Analysis 3.5).
There was no significant different in adverse events leading to
withdrawal from treatment (1271 participants, 1 trial; Analysis
3.6).
Elevated liver function tests
There were higher rates of raised ALT > 5 x ULN in the pyronar-
idine-artesunate arm compared to the mefloquine plus artesunate
arm, but the CIs crossed the line of no effect (RR 7.48, 95% CI
0.99 to 56.45; 1 trial, 1271 participants; Analysis 3.7). We did
not find a significant difference for the rate of raised AST > 5 x
ULN (RR9.49, 95%CI 0.55 to 162.64; 1 trial, 1271 participants;
Analysis 3.8) or bilirubin > 2.5 x ULN (RR 3.49, 95% CI 0.43 to
28.29; 1 trial, 1271 participants; Analysis 3.9).
Narrative synthesis of other reported outcomes
The Rueangweerayut 2012 study also reported fever, parasite and
gametocyte clearance times, which were broadly comparable be-
tween pyronaridine-artesunate and mefloquine plus artesunate
(Table 4).
Comparison 4. Pyronaridine-artesunate versus any
other antimalarial
Eight RCTs with 6614 participants contributed data to a safety
meta-analysis in which we compared pyronaridine-artesunate to
any other antimalarial. The comparators were artesunate alone,
artemether-lumefantrine, dihydroartemisin-piperaquine, chloro-
quine, mefloquine plus artesunate, and artesunate-amodiaquine.
For the Sagara 2018 trial, we extracted data disaggregated by site,
as described in Results of the search, and we present them sepa-
rately in meta-analysis.
An additional two RCTs compared pyronaridine monotherapy to
chloroquine (Ringwald 1996; Ringwald 1998), and contributed
to the quantitative and qualitative synthesis of other adverse events
(excluding serious adverse events or liver enzymes).
All trials contributing to the safety meta-analysis excluded partic-
ipants with baseline hepatic impairment.
Serious adverse events
We detected little or no difference in the rate of serious adverse
events with pyronaridine-artesunate compared to other antimalar-
ials (RR 1.24, 95% CI 0.54 to 2.84; 7 trials, 3941 participants;
Analysis 4.1). We were unable to include data from the Sagara
2018 trial in this meta-analysis, as explained above.
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To provide a narrative synthesis, we summarized the nature and
number of serious adverse events in Table 2. In the pyronaridine-
artesunate arm, we judged 10 of 26 serious adverse events across 10
trials to be related to treatmentwith pyronaridine-artesunate or py-
ronaridine alone (Kayentao 2012; Nelwan 2015; Poravuth 2011;
Ringwald 1996; Ringwald 1998; Roth 2018; Rueangweerayut
2012; Sagara 2018; Shin 2011; Tshefu 2010), with each of these
coming in the Sagara 2018 trial. In comparison, we judged two of
four events in the artemether-lumefantrine arm (Kayentao 2012;
Sagara 2018; Tshefu 2010), three of three in the artesunate-amodi-
aquine arm (Sagara 2018), and two of three in the mefloquine
plus artesunate arm (Rueangweerayut 2012), to be related to the
treatment. We did not judge the sole serious adverse event seen
with dihydroartemisinin-piperaquine and the three seen in the
artesunate only arm to be related to treatment (Nelwan 2015). No
serious adverse events were seen in the chloroquine arm (Poravuth
2011; Ringwald 1996; Ringwald 1998; Roth 2018).
Adverse events leading to withdrawal from treatment
We detected little or no differences in the rate of adverse events
leading to withdrawal from treatment with pyronaridine-arte-
sunate compared to other antimalarials (RR 1.06, 95% CI 0.58
to 1.94; 6 trials, 3911 participants; Analysis 4.2).
Elevated liver function tests
Quantitative synthesis
Different studies defined rises in ALT, AST, and bilirubin as im-
portant at different levels, ranging from 3 x ULN to 10 x ULN.
The differences between definitions of important rises are shown
in Table 1.
Following first treatment, pyronaridine-artesunate was associated
with a greater incidence of raised ALT > 5 x ULN compared to
other antimalarials (RR 3.34, 95% CI 1.63 to 6.84; 8 trials, 6581
participants; Analysis 4.3, Figure 4). Pyronaridine-artesunate was
also associated with a greater incidence of raised AST > 5 x ULN
compared to other antimalarials, but the CIs crossed the line of no
effect (RR 1.80, 95% CI 0.89 to 3.65; 8 trials, 6581 participants;
Analysis 4.4).We detected little or no difference in raised bilirubin
> 2.5 x ULN events (RR 1.03, 95% CI 0.49 to 2.18; 7 trials, 6384
participants; Analysis 4.5).
Figure 4. Forest plot of comparison 4: Pyronaridine-artesunate versus other antimalarials, outcome: 4.3
ALT increase > 5 × ULN, first treatment.
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For second or subsequent treatments, we detected no significant
differences in the number of raised ALT (> 5 x ULN), AST (>
5 x ULN) or bilirubin (> 2.5 x ULN) events between pyronari-
dine-artesunate and other antimalarials (1649 participants, 1 trial;
Analysis 4.6; Analysis 4.7; Analysis 4.8). There were small num-
bers in each arm.
A sensitivity analysis confined to only those trials which used the
same grading for severely raised ALT also found that those treated
with pyronaridine-artesunate had a greater incidence of raisedALT
> 5 x ULN compared to other antimalarials (RR 4.07, 95% CI
1.83 to 9.05; 4 trials, 5672 participants; Analysis 4.9).
Qualitative (narrative) synthesis
Ringwald 1996 reported that five out of 40 participants given
pyronaridine had elevated bilirubin levels compared to zero out
of 41 given chloroquine. It should be noted, however, that this
study used pyronaridine monotherapy, and a higher dose than that
which is currently recommended. The report did not give any
further details of the extent of the increase.
As an indication of the magnitude of ALT increases, the high-
est reported ALT values in individual studies were 612 IU/L in
Rueangweerayut 2012 and 1229 IU/L in Sagara 2018. These were
in individual patients, and are not indicative of the population
as a whole. The study with the longest follow-up recruited 180
participants (Nelwan 2015). In the 60 participants receiving py-
ronaridine-artesunate, observed increases in the median ALT and
AST values had returned to baseline by day 14, and no clinical
consequences of these liver enzyme increases were reported over
one year of follow-up. None of the 60 participants experienced
raised ALT or AST > 5 x ULN. It should be noted, however,
that this was a study of pyronaridine-artesunate plus primaquine,
which could impact the findings. Sagara 2018 reported one case in
which raised ALT occurred with raised bilirubin in a two-year old
girl. The safety monitoring board concluded that this event was
an acute hepatocellular liver injury, and was reported as a serious
adverse event (Table 2).
Other adverse events
We have summarized all other reported adverse events in Analysis
4.10. To enable graphical display of these adverse events by
MedDRA 2018 system organ class and higher level term, we
present the results in a forest plot based onmeta-analysed subtotals
inFigure 5, based onPRISMAguidance (Zorzela 2016). Therewas
a lower risk of electrocardiograph (ECG) abnormality, including
QT prolongation, with pyronaridine-artesunate compared to each
of the other antimalarials used as comparator drugs. A summary
of the proportion of participants experiencing ECG abnormalities
in each treatment group is provided in Table 5. The greatest differ-
ences were seen in the Sagara 2018 study when pyronaridine-arte-
sunate was compared to artemether-lumefantrine and artesunate-
amodiaquine. The rates of observed QT prolongation were much
higher in this study compared to other included studies.
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Figure 5. A comparison of adverse events following treatment with pyronaridine-artesunate versus other
antimalarials, based on the reporting guidelines in PRISMA harms (Zorzela 2016). Adverse events are
categorized according to MedDRA 2018 system organ class and higher level terms. Where specific lower level
terms were reported, we have used footnotes to indicate the condition described. Where trials reported more
than one lower level term belonging to the same higher level term, we reported the lower level term with the
highest frequency.
aIncludes basophilia and monocytosis.
bAsymptomatic unifocal ventricular ectopics.
cIncludes dizziness and palpitations.
dEar pain.
e“Chills”.
f Influenza-like illness.
gChest pain.
hProlonged QTc, t wave inversion.
iElevated CPK.
jWeight decreased.
kThrombocytopaenia.
lHypoalbuminaemia.
mRaised creatinine.
nNeck pain.
oThroat pain, cold, postnasal drip.
pDark urine.
22Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
For most types of adverse event, rates were similar between py-
ronaridine-artesunate and comparators. Differences observed in-
cluded the following.
• Lower risk of cardiac symptoms. This category included
dizziness and palpitations. The difference observed related to
high instances of dizziness in the control group (mefloquine plus
artesunate) in one study (Rueangweerayut 2012).
• Lower risk of pruritis. This occurred in comparisons to
chloroquine, for which pruritis is a commonly recognized
adverse event.
• Higher risk of diarrhoea: most cases of diarrhoea were
contributed by one study, which was a monotherapy study using
higher doses of pyronaridine than currently recommended
(Ringwald 1996).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Pyronaridine-artesunate (PY-AS) compared to artesunate-amodiaquine (AS-AQ) for adults and children with uncomplicated Plasmodium falciparum malaria
Patient or population: adults and children with uncomplicated P falciparum malaria
Setting: malaria transmission sett ings
Intervention: pyronaridine-artesunate (PY-AS)
Comparison: artesunate-amodiaquine (AS-AQ)
Outcomesa Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with artesunate-
amodiaquine (AS-AQ)
Risk with pyronaridine-
artesunate (PY-AS)
Total failure: day 28
(PCR-adjusted)
8 per 1000 4 per 1000
(1 to 22)
RR 0.55
(0.11 to 2.77)
1245
(1 RCT)
⊕⊕©©
LOWb,c
Due to indirectness and
imprecision
Compared to AS-AQ,
PY-AS may have fewer
PCR-adjusted failures
at day 28
Total failure: day 42
(PCR-adjusted)
6 per 1000 5 per 1000
(1 to 27)
RR 0.98
(0.20 to 4.83)
1091
(1 RCT)
⊕⊕©©
LOWb,d
Due to indirectness and
imprecision
There may be lit t le or
no dif ference in PCR-
adjusted failures at day
42 between PY-AS and
AS-AQ
Total failure: day 28
(unadjusted)
75 per 1000 37 per 1000
(22 to 61)
RR 0.49
(0.30 to 0.81)
1257
(1 RCT)
⊕⊕⊕©
MODERATEb
Due to indirectness
Compared to AS-AQ,
PY-AS probably has
fewer unadjusted fail-
ures at day 28
Total failure: day 42
(unadjusted)
195 per 1000 192 per 1000
(152 to 240)
RR 0.98
(0.78 to 1.23)
1235
(1 RCT)
⊕⊕⊕©
MODERATEb
Due to indirectness
There is probably lit t le
or no dif ference in un-
adjusted failures at day
42 between PY-AS and
AS-AQ
2
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First treatment, ALT in-
crease > 5 × ULN (42
days)
1 per 1000 1 per 1000
(0 to 7)
RR 1.41
(0.28 to 7.09)
1317
(1 RCT)
⊕⊕©©
LOWb,e
Due to indirectness and
imprecision
Compared to AL, PY-AS
may have lead to higher
events of ALT increase
> 5 × ULN. (Aggregate
analysis indicates this
est imate may be accu-
rate)
First treatment, AST in-
crease > 5 × ULN (42
days)
4 per 1000 2 per 1000
(0 to 8)
RR 0.43
(0.08 to 2.07)
1317
(1 RCT)
⊕©©©
VERY LOWb,f
Due to indirectness and
imprecision
We do not know if there
is a dif ference in AST
between PY-AS and AS-
AQ
First treatment, biliru-
bin increase > 2.5 × ULN
(42 days)
1 per 1000 1 per 1000
(0 to 16)
RR 0.99
(0.06 to 15.76)
1317
(1 RCT)
⊕©©©
VERY LOWb,f
Due to indirectness and
imprecision
We do not know if there
is a dif ference in biliru-
bin between PY-AS and
AS-AQ
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: ALT: alanine aminotransferase; AS-AQ: artesunate-amodiaquine; AST: aspartate transaminase; CI: conf idence interval; PCR: polymerase chain react ion; PY-
AS: pyronaridine-artesunate; RCT : randomized controlled trial; RR: risk rat io; ULN: upper lim it of normal
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aSerious adverse events data were not available disaggregated by site to allow inclusion in this comparison.
bDowngraded by 1 for serious indirectness: the data are drawn f rom one study, conducted in six sites in three countries in
West Af rica. Further studies in Asia would be needed to fully apply this result .
cDowngraded by 1 for serious imprecision: the CI is large and includes both no ef fect and clinically important ef fects.
dDowngraded by 1 for serious imprecision: the ef fect est imate is close to no ef fect, but the CI is wide.
eDowngraded by 1 for serious imprecision: the low number of events recorded in the study is insuf f icient for conf ident ly
est imating the ef fect size. However, aggregate analysis of ALT increase across dif ferent comparator drugs provides indirect
evidence that the point est imate may be accurate.2
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fDowngraded by 2 for very serious imprecision: the CI is very large and includes both no ef fect and clinically important
ef fects.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Pyronaridine-artesunate (PY-AS) compared to mefloquine plus artesunate (MQ+AS) for adults and children with uncomplicated Plasmodium falciparum malaria
Patient or population: adults and children with uncomplicated P falciparum malaria
Setting: malaria transmission sett ings
Intervention: pyronaridine-artesunate (PY-AS)
Comparison: mef loquine plus artesunate (MQ+AS)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with meflo-
quine plus artesunate
(MQ+AS)
Risk with pyronaridine-
artesunate
(PY-AS)
Total failure: day 28
(PCR-adjusted)
22 per 1000 8 per 1000
(3 to 23)
RR 0.37
(0.13 to 1.05)
1117
(1 RCT)
⊕⊕©©
LOWa,b,c
Due to indirectness and
imprecision
Compared to MQ+AS,
PY-AS may have fewer
PCR-adjusted failures
at day 28
Total failure: day 42
(PCR-adjusted)
29 per 1000 53 per 1000
(27 to 105)
RR 1.80
(0.90 to 3.57)
1037
(1 RCT)
⊕⊕©©
LOWa,b
Due to indirectness and
imprecision
Compared to MQ+AS,
PY-AS may have more
PCR-adjusted failures
at day 42
Total failure: day 28
(unadjusted)
41 per 1000 15 per 1000
(7 to 32)
RR 0.36
(0.17 to 0.78)
1120
(1 RCT)
⊕⊕⊕©
MODERATEa
Due to indirectness
Compared to MQ+AS,
PY-AS probably has
fewer unadjusted fail-
ures at day 28
Total failure: day 42
(unadjusted)
83 per 1000 70 per 1000
(45 to 109)
RR 0.84
(0.54 to 1.31)
1059
(1 RCT)
⊕⊕©©
LOWa,b,d
Due to indirectness and
imprecision
There is probably lit t le
or no dif ference in un-
adjusted failures at day
42 between PY-AS and
MQ+AS
2
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Serious adverse events
(42 days)
7 per 1000 7 per 1000
(2 to 28)
RR 1.00
(0.25 to 3.97)
1271
(1 RCT)
⊕⊕©©
LOWa,b
Due to indirectness and
imprecision
There may be lit t le or
no dif ference in se-
rious adverse events
between PY-AS and
MQ+AS
First treatment, ALT in-
crease > 5 × ULN (42
days)
2 per 1000 18 per 1000
(2 to 133)
RR 7.48
(0.99 to 56.45)
1271
(1 RCT)
⊕⊕©©
LOWa,e
Due to indirectness and
imprecision
Compared to MQ+AS,
PY-AS may lead to
higher events of ALT in-
crease > 5 × ULN. (Ag-
gregate analysis indi-
cates this est imate may
be accurate)
First treatment, AST in-
crease > 5 × ULN (42
days)
0 per 1000 0 per 1000
(0 to 0)
RR 9.49
(0.55 to 162.64)
1271
(1 RCT)
⊕©©©
VERY LOWa,f
Due to indirectness and
imprecision
We do not know if
there is a dif ference
in AST between PY-AS
and MQ+AS
First treatment, biliru-
bin increase > 2.5 × ULN
(42 days)
2 per 1000 8 per 1000
(1 to 67)
RR 3.49
(0.43 to 28.29)
1271
(1 RCT)
⊕©©©
VERY LOWa,f
Due to indirectness and
imprecision
We do not know if there
is a dif ference in biliru-
bin between PY-AS and
MQ+AS
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: ALT: alanine aminotransferase; AST: aspartate transaminase; CI: conf idence interval; MQ+AS: mef loquine plus artesunate; PCR: polymerase chain react ion;
PY-AS: pyronaridine-artesunate; RCT : randomized controlled trial; RR: risk rat io; ULN: upper lim it of normal
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by 1 for serious indirectness: of the 1271 children and adults aged greater than 5 years enrolled in this trial,
81.3% (1033) were enrolled and treated in trial sites in Asia (Cambodia, India, Thailand, and Vietnam), and only 18.7% (237)2
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in Af rica (Burkina Faso, Ivory Coast, and Tanzania). Further studies in Af rican children are necessary to fully apply this
result .
bDowngraded by 1 for serious imprecision: the CI is large and includes both no ef fect and clinically important ef fects.
cCertainty of the evidence grade dif fers f rom the 2014 review version due to addit ional data: the previous review reported
no substant ial dif f erence between PY-AS and MQ+AS in reference to this outcome and therefore did not downgrade for
imprecision. In this update we report a reduced rate in the PY-AS arm. Because we concluded that there may be a dif ference,
we necessarily downgraded for the imprecision.
dCertainty of the evidence grade dif fers f rom the 2014 review version due to alterat ions in the data extract ion protocol: the CI
has become less precise, and our decision has greater consistency with other outcome certainty grades.
eDowngraded by 1 for serious imprecision: the low number of events recorded in the study is insuf f icient for conf ident ly
est imating the ef fect size. However, aggregate analysis of ALT increase across dif ferent comparator drugs provides indirect
evidence that the point est imate may be accurate.
fDowngraded by 2 for very serious imprecision: the CI is very large and includes both no ef fect and clinically important
ef fects.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Pyronaridine-artesunate (PY-AS) compared to other antimalarials for adults and children with uncomplicated malaria
Patient or population: adults and children with uncomplicated malaria
Setting: high and low transmission sett ings for P falciparum and P vivax malaria
Intervention: pyronaridine-artesunate (PY-AS)
Comparison: other ant imalarials
Outcomesa,b,c Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with other anti-
malarials
Risk with pyronaridine-
artesunate (PY-AS)
Serious adverse events 5 per 1000 7 per 1000
(3 to 15)
RR 1.24
(0.54 to 2.84)
3941
(7 RCTs)
⊕⊕⊕©
MODERATEd
Due to imprecision
There was probably lit -
t le or no dif ference in
the rate of serious ad-
verse events with PY-
AS compared to other
ant imalarials
First treatment, ALT in-
crease > 5 × ULN
2 per 1000 7 per 1000
(3 to 14)
RR 3.34
(1.63 to 6.84)
6614
(8 RCTs)
⊕⊕⊕⊕
HIGHe
ALT increase > 5 ×
ULN is more f requent
with PY-AS compared
to other ant imalarials
First treatment, AST in-
crease > 5 × ULN
3 per 1000 5 per 1000
(3 to 11)
RR 1.80
(0.89 to 3.65)
6614
(8 RCTs)
⊕⊕⊕©
MODERATEf
Due to imprecision
There is probably a
small increased risk of
AST increase > 5 × ULN
with PY-AS compared
to other ant imalarials
First treatment, biliru-
bin increase > 2.5 × ULN
4 per 1000 4 per 1000
(2 to 9)
RR 1.03
(0.49 to 2.18)
6417
(7 RCTs)
⊕⊕⊕©
MODERATEd
Due to imprecision
There is probably lit -
t le or no dif ference for
bilirubin between PY-
AS and other ant imalar-
ials
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Subsequent treatment
(s), ALT > 5 × ULN
4 per 1000 8 per 1000
(3 to 23)
RR 2.18
(0.76 to 6.27)
1649
(1 RCT)
⊕⊕©©
LOWd,f
Due to imprecision and in-
directness
There may be an in-
creased risk of raised
ALT with subsequent
treatments with PY-AS
compared to other ant i-
malarials
Subsequent treatment
(s), AST > 5 × ULN
6 per 1000 11 per 1000
(4 to 27)
RR 1.82
(0.74 to 4.44)
1649
(1 RCT)
⊕⊕©©
LOWd,f
Due to imprecision and in-
directness
There may be an in-
creased risk of raised
AST with subsequent
treatments with PY-AS
compared to other ant i-
malarials
Subsequent treatment
(s), bilirubin > 5 × ULN
8 per 1000 9 per 1000
(3 to 24)
RR 1.13
(0.42 to 3.01)
1649
(1 RCT)
⊕⊕©©
LOWd,f
Due to imprecision and in-
directness
There may be lit t le or
no dif ference for biliru-
bin between PY-AS and
other ant imalarials
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: ALT: alanine aminotransferase; AST: aspartate transaminase; CI: conf idence interval; PY-AS: pyronaridine-artesunate; RCT : randomized controlled trial; RR:
risk rat io; ULN: upper lim it of normal
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOnly adverse event outcomes were considered for this comparison.
bA comparison of pyronaridine-artesunate versus other ant imalarials for f requency of ECG abnormalit ies is reported in Table
5.
cThe length of follow-up varies between specif ic studies. Follow-up t imes are reported for individual studies in the
‘Characterist ics of included studies’ tables.
dDowngraded by 1 for serious imprecision: the CI includes both no ef fect and clinically important ef fects.
eNot downgraded: although the CI is wide, there were few events.
fDowngraded by 1 for serious indirectness: only 232 children aged less than f ive years were included in this study.31
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D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; Summary of findings 4.
Summary of efficacy findings
Overall, pyronaridine-artesunate appears to have similar effi-
cacy to other artemisinin-based combination therapies (ACTs)
(artemether-lumefantrine, artesunate-amodiaquine, mefloquine
plus artesunate). In most included trials, pyronaridine-artesunate
had a lower than 5% PCR-adjusted treatment failure rate at day
28 and day 42.
Treatment with pyronaridine-artesunate may lead to fewer PCR-
adjusted failures at day 28 compared to artemether-lumefantrine,
artesunate-amodiaquine, and mefloquine plus artesunate (low-
certainty evidence). In all these instances, the CIs cross the line of
no effect.
Treatment with pyronaridine-artesunate may lead to fewer PCR-
unadjusted failures at day 28 compared to artemether-lume-
fantrine (low certainty evidence), and probably leads to fewer fail-
ures compared to artesunate-amodiaquine and mefloquine plus
artesunate (moderate-certainty evidence). The PCR-unadjusted
outcome reflects the post-treatment effect of the drug in prevent-
ing new infections.
Pyronaridine-artesunate may have little or no difference on the
rate of PCR-adjusted failure at day 42 compared to artemether-
lumefantrine or artesunate-amodiaquine (low-certainty evidence),
but may lead to higher rates of failure than mefloquine plus arte-
sunate (low-certainty evidence).
Pyronaridine-artesunate may lead to a lower rate of PCR-unad-
justed treatment failure at day 42 compared to artemether-lume-
fantrine (low-certainty evidence), suggesting that the drug combi-
nation may reduce the likelihood of reinfection during the treat-
ment period. Pyronaridine may little or no difference compared to
mefloquine plus artesunate (low-certainty evidence), and probably
makes little or no difference compared to artesunate-amodiaquine
(moderate-certainty evidence).
Summary of safety findings
Raised ALT > 5 x ULN is more frequent with pyronaridine-arte-
sunate compared to other antimalarials (high-certainty evidence).
Raised AST > 5 x ULN is probably also more frequent (moderate-
certainty evidence), but the CI crosses the line of no effect. There
is probably little or no difference for raised bilirubin > 2.5 x ULN
between pyronaridine-artesunate and other antimalarials (mod-
erate-certainty evidence). There was one reported case in which
raised ALT occurred with raised bilirubin. Qualitative evidence
from one trial, with a cohort of 180 participants and a follow-up
of one year, indicated that raised liver enzymes were not prolonged
and did not lead to clinical sequelae, though it should be noted
that pyronaridine-artesunate was administered concurrently with
primaquine.
ECG abnormalities were less commonly seen with pyronaridine-
artesunate compared to other antimalarials. For the remaining
safety outcomes, there appears to be little or no difference in
the safety of pyronaridine-artesunate compared to other ACTs
(artemether-lumefantrine, artesunate-amodiaquine, mefloquine
plus artesunate, dihydroartemisinin-piperaquine) or non-ACTan-
timalarials (artesunate alone, chloroquine).
Overall completeness and applicability of
evidence
Completeness and applicability of efficacy findings
Five trials contributed 5711 participants to quantitative synthesis
for efficacy analyses in this review. There were 4465 participants
from 13 trial sites in Africa (Burkina Faso, DRC, Gabon, Cote
d’Ivoire, Kenya, Mali, Tanzania, The Gambia, Ghana, Mozam-
bique, Senegal, Guinea, Mali), and 1246 participants from five
sites in Asia (the Philippines, Cambodia, Indonesia, Thailand,
Vietnam). The large number of included sites broadens the appli-
cability of the efficacy findings. The actual number of participants
recruited at country level was small, precluding evaluation of effi-
cacy at country level.
A key limitation on the applicability of review findings on effi-
cacy is the age of the participants, as the included trials mostly
recruited older children and adults. The two new studies included
in the efficacy analysis in this update have contributed an addi-
tional 375 children under five years who received pyronaridine-
artesunate and 409 who received comparator drugs. However, the
total number of participants definitively aged less than five years
remains at just 527 in the pyronaridine-artesunate arm and 472
in the comparator arm.
Trials additionally reported a number of outcomes relating to fever
clearance, parasite clearance, and gametocyte carriage, which did
not form a priori outcomes for this version of the review, in a
change to the previously published protocol. We encountered dif-
ferent modes of reporting these outcomes, different units of mea-
surement, and incomplete reporting of these outcomes. This lim-
its the contribution of these outcomes to the evidence.
Completeness and applicability of safety findings
Eight trials contributed to quantitative synthesis for key safety
outcomes in this review (serious adverse events and liver function
tests), and a further two trials contributed data to an analysis of all
safety outcomes. All trials contributing to the safety meta-analysis
excluded participants with baseline hepatic impairment, and most
trials listed viral hepatitis as a specific exclusion criterion. Simi-
larly, Sagara 2018 excluded patients with raised liver enzymes from
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second and subsequent treatments. Screening for baseline hepatic
impairment, or for hepatic impairment during treatment, may not
be feasible in many malaria-endemic settings where resources are
limited. This may limit the applicability of the findings.
Four trials explicitly listedHIV as an exclusion criterion (Kayentao
2012; Poravuth 2011; Sagara 2018; Tshefu 2010). Such exclusions
represent standard practice for phase III trials. Given the high
seroprevalence of such conditions in malaria-endemic areas, this
may limit the applicability of the safety findings. However, there
was no reported screening for these conditions in any of the trials,
meaning that it is likely that some patients with undiagnosed HIV
were included. In a safety study in healthy volunteers (Morris
2012), of 17 healthy volunteers receiving pyronaridine-artesunate
and ritonavir, five volunteers experienced ALT > 3 x ULN. The
WHO recommends ritonavir as part of second-line antiretroviral
therapy. Thus a commonly prescribed antiretroviral may increase
the risk of raised ALT.
Certainty of the evidence
We assessed the certainty of the evidence in this review using the
GRADE approach and presented it in Summary of findings for the
main comparison, Summary of findings 2, Summary of findings
3, and Summary of findings 4.
With respect to the efficacy of pyronaridine-artesunate, the studies
included in this review provided moderate- to low-certainty evi-
dence due to inconsistency, with frequent quantitative and quali-
tative heterogeneity between studies, and indirectness, given that
children under five years are under-represented (especially inAsia).
With respect to the safety of pyronaridine-artesunate, we judged
the certainty of evidence in relation to raised ALT to be high, and
did not downgrade for imprecision, as although the CI is wide,
there were few events. We found moderate-certainty evidence that
pyronaridine-artesunate increases the proportion of patients expe-
riencing raised AST > 5 x ULN, and moderate-certainty evidence
that treatment has little or no difference on the proportion of pa-
tients experiencing raised bilirubin > 2.5 x ULN.We downgraded
both outcomes for imprecision.
Potential biases in the review process
This represents the third update of this review. For this review we
repeated the screening process, increasing the likelihood that we
identified all relevant studies.
The largest included trial in this review, Sagara 2018, did not
randomize patients to all comparisons at all sites, and we were
unable to obtain disaggregated data for all outcomes at all sites.
However, we were able to do so for the outcomes most pertinent
to this review (efficacy and liver function data) so do not consider
that this introduces significant bias to the review process.
As shown in Table 1, different trial authors used different grading
for the severity of adverse events. Most trial authors considered
ALT > 5 x ULN as important, and reported at this threshold.
The three studies which reported at a lower threshold recorded
zero events, so we retained these in the analysis for completeness
(Nelwan 2015; Roth 2018; Shin 2011). Kayentao 2012 reported
at a higher threshold, and so may under-detect events. When we
performed a sensitivity analysis excluding these four trials, the risk
ratio (RR) was similar (Analysis 4.9). The reader should note that
the grading for raised ALT does not correspond with international
definitions for drug-induced liver injury (Aithal 2011; Appendix
1). Similarly, the thresholds for raised bilirubin also differed, both
from each other and from the 2 x ULN used in international def-
initions of moderate or severe drug-induced liver injury (Aithal
2011; Appendix 1). As we are unable to provide case-by-case anal-
ysis for raised ALT > 5 x ULN, we cannot exclude the possibility
that in some instances these occurred in conjunction with symp-
toms of bilirubin > 2 x ULN (given that the reported threshold
was 2.5 in most studies). Qualitative synthesis did not suggest this
was the case.
We had planned to conduct a sensitivity analysis altering the de-
nominator for the efficacy outcomes according to Appendix 4.
However, we were unable to reliably extract data pertinent to miss-
ing or indeterminate PCR values. As PCR is unlikely to differen-
tially misclassify recrudescences as reinfections between compar-
ison groups, we do not feel this is likely to introduce bias to the
main outcome of PCR-adjusted treatment failure.
For the safety analysis we usedMedDRA 2018 to create analogous
definitions to allow comparison. This may lead tomisclassification
and loss of detail. However, we feel that the overview ismore useful
and meaningful to the clinical reader. The methodology of this
review is not a primary adverse effects review, and as such does
not include safety data from non-comparative or non-randomized
studies, which such a review might include. This limits the depth
to which this review can comment on the extent and implications
of safety findings, but does not effect the certainty of the evidence
presented.
Agreements and disagreements with other
studies or reviews
Our search identified an individual patient data analysis pub-
lished by authors from Medicines for Malaria Venture and Shin
Poong Pharmaceuticals, who developed the pyronaridine-arte-
sunate combination (Duparc 2013). The efficacy analysis in
Duparc 2013 included four of the RCTs included in our review
(Kayentao 2012; Poravuth 2011; Rueangweerayut 2012; Tshefu
2010). The safety analysis included an additional two studies:
a non-randomized dose-finding study excluded from this review
(Ramharter 2008), and a randomized dose-finding study that was
published as a conference abstract which assessed pyronaridine-
artesunate without a comparator (Looareesuwan 2007). This in-
tegrated analysis is not a formal systematic review, and as such
did not have an a priori protocol or a formal search strategy. It
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did not make assessments of risk of bias. It is unclear whether the
authors have included all potentially relevant studies or whether
it represents a convenience sample of available data at the time of
the analysis. The safety findings of this integrated analysis do not
report relative risks or anticipated absolute effects of raised ALT,
instead reporting incidence at day three and day seven. The day
seven incidence of 0.9% (24/2709) is similar to our anticipated
absolute effect of 0.8%.
Our review agrees with the conclusion from this integrated analy-
sis (Duparc 2013), that pyronaridine-artesunate has good efficacy
for uncomplicated P falciparum malaria. The authors conclude
that pyronaridine-artesunate was well tolerated with a similar ad-
verse event profile to comparators, and note that pyronaridine-
artesunate was associated with transient increases in transaminases
in a relatively small proportion of patients, although do not caveat
this statement with reference to the exclusion criteria within the
clinical trials. When interpreting the conclusion in Duparc 2013,
readers should consider that the further data from Sagara 2018
excluded participants who had raised liver enzyme events on first
treatment from any subsequent treatments, and this may limit ap-
plicability.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Pyronaridine-artesunate was efficacious against uncomplicated P
falciparummalaria, achieved a PCR-adjusted treatment failure rate
of < 5% at days 28 and 42, and may be at least as good as or better
than existing artemisinin-based combination therapies (ACTs).
Pyronaridine-artesunate causes a three-fold increase in the risk of
raised ALT > 5 x ULN. This meets clinical chemistry criteria for
drug-induced liver injury (Aithal 2011; Appendix 1). In the ab-
sence of raised bilirubin > 2 x ULN, and in the absence of symp-
toms, this corresponds to mild drug-induced liver injury only.
There was one reported case in which raised ALT occurred with
raised bilirubin, meeting criteria for moderate drug-induced liver
injury.
We conclude that although raised ALT is a safety signal indicating
a theoretical risk of severe drug-induced liver injury, no such cases
have been reported amongst over 6000 otherwise healthy trial
participants to date. As such, the raised ALTmay reflect a capacity
for pyronaridine-artesunate to cause onlymild, asymptomatic, and
reversible injury. WHO 2015 guidelines stated that pyronaridine-
artesunate may be considered in areas of multiple drug resistance.
Our review indicates that this is an appropriate recommendation,
as the benefit in this clinical scenario clearly outweighs a theoretical
risk.
The findings of this review cannot fully inform a risk-benefit as-
sessment for an unselected population. Readers should remain
aware of this uncertainty when considering use of pyronaridine-
artesunate in patients with known or suspected pre-existing liver
dysfunction, and when co-administering with other medications
which may cause liver dysfunction.
Implications for research
Raised ALT > 5 x ULN is a safety signal which warrants further
evaluation in cohort studies. Of note, Shin Poong Pharmaceutical
Company Ltd and Medicines for Malaria Venture are conducting
an ongoing hepatic safety study (NCT03201770). This aims to
recruit 8572 malaria episodes and will analyse safety in people
with baseline ALT elevations.
There is limited published data in children aged less than five
years of age. NCT03201770 intends to recruit a greater number
of children who are < 1 year of age, which may help redress this.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kayentao 2012
Methods RCT
Duration: 1 year, November 2007 to November 2008
Participants Children with P falciparum malaria
Number: 535, randomized 2:1
Inclusion criteria: age ≤ 12 years; bodyweight 5 kg - 25 kg; fever or history of fever
within 24 hours
Exclusion criteria: severe/complicated malaria; mixed Plasmodium infection; other clin-
ically significant disorder; severe vomiting; severe diarrhoea; viral hepatitis/HIV; malnu-
trition; QTc ≥ 450 ms; other febrile conditions; hepatic impairment (AST/ALT > 2.5x
ULN); renal impairment; electrolyte imbalance; anaemia (Hb < 8 g/dL); allergy to study
drugs; antimalarial therapy in previous 2 weeks, investigational drug in previous 4 weeks;
taking any drug metabolized by cytochrome enzyme CYP2D6; previous participation
in pyronardine-artesunate studies; pregnancy/lactation; unable to comply with follow-
up visits
Diagnosis: microscopy (asexual parasite density 1000-200,000/µL blood)
Children under 5: 152 (pyronaridine-artesunate); 64 (artemether-lumefantrine)
Interventions • Pyronaridine-artesunate granule formulation (60 mg:20 mg) once-daily for 3
days. Dose according to bodyweight: 5 kg - 9 kg one sachet; 9 kg - 17 kg 2 sachets; 17
kg - 25 kg, 3 sachets. Range = 6.7/2.2 mg/kg/dose to 13.3/4.4 mg/kg/dose
• Artemether-lumefantrime crushed tablets (20 mg/120 mg) twice daily for 3 days
at recommended intervals. Dose according to bodyweight: 5 kg -15 kg one tablet, 15
kg -25 kg 2 tablets. Range = 1.3/8.0 mg to 3.0/24.0 mg/kg/dose
Outcomes • ACPR day 28 PCR-adjusted
• ACPR day 28 unadjusted
• ACPR day 42 PCR-adjusted
• ACPR day 42 unadjusted
• Parasite clearance time (from first dose to aparasitaemia)†, ‡
• Fever clearance time (from first dose to apyrexia)†, ‡
• Proportion of patients with parasite clearance on days 1, 2, and 3, ‡
• Proportion of patients with fever clearance on days 1, 2, and 3, ‡
• Gametocyte density, ‡
• Proportion of patients with gametocytes
• Adverse events (including laboratory and ECG abnormalities)
†Two consecutive normal readings taken between 7 and 25 hours apart
‡Not assessed in quantitative synthesis in this review
Notes Location: Africa (n = 514, 96%) and Asia (n = 21, 4%). Africa: Burkina Faso, DRC,
Gabon, Côte d’Ivoire, Kenya, Mali. Asia: the Philippines
Setting: Local hospitals and clinics
Malaria endemicity: high
Resistance profile: not described
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Kayentao 2012 (Continued)
Source of funding:Medicines forMalaria Venture, Shin Poong Pharmaceutical Company
Ltd, Seoul, Republic of Korea
Follow-up: 42 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization sched-
ule
Allocation concealment (selection bias) Low risk Individually numbered treatment packs of
similar appearance masked on allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients not blinded (“drugs given open-
label”)
Clinical and parasitological assessments
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report lists reasons for attrition and exclu-
sions
Selective reporting (reporting bias) Low risk Prospectively registered. Report includes all
prestated outcomes of interest
Other bias Low risk 3 authors declared conflicting interests
(employees of funders); blind to treatment
allocation
Adverse event monitoring (detection bias)
Adverse Events
Unclear risk Authors do not fully describe method for
detection of adverse events, includes bio-
chemical and ECG monitoring
Authors do not give definitions of all ad-
verse events.
Uses higher ULN values for grading of
hepatic enzyme severity compared to other
studies
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk All adverse events reported. Supplementary
tables detail laboratory variables at each as-
sessment
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Nelwan 2015
Methods RCT
Duration: 1 year, 4 months. March 2013 to July 2014
Participants Adult soldiers with P vivax malaria
Number: 180
Inclusion criteria: age 18 - 65 years; travelled to NE Papua within 12 months; body-
weight 40 kg - 90 kg
Exclusion criteria: G6PD deficiency; P falciparum monoinfection, hospitalization,
anaemia (Hb < 7 g/dL), planned absence from military base; clinically significant disor-
ders; QTc ≥ 450 ms; family history prolonged QTc/sudden death; concomitant drugs
known to prolong QT; hepatic impairment (AST/ALT > 2.5 x ULN); renal impairment;
viral hepatitis; allergy to study drugs; previous participation; recent antimalarials
Diagnosis: microscopy of P vivax, confirmed by a second microscopist
Interventions • Artesunate tablets (200 mg day 0, 100 mg days 1-6), followed by primaquine
• Pyronaridine-artesunate tablets (180 mg:60 mg) once-daily for 3 days. Dose
according to bodyweight: 24 kg - 45 kg 2 tablets, 45 kg - 65 kg 3 tablets, ≥ 65 kg 4
tablets. Concurrent primaquine.
• Dihydroartemisinin-piperaquine tablets (40 mg:320 mg) once-daily for 3 days.
Dose according to bodyweight: < 75 kg - 3 tablets, ≥ 75 kg - 4 tablets. Concurrent
primaquine.
Outcomes • Adverse events
• Relapse of P vivax* (incidence density)
*Not assessed in quantitative synthesis in this review
Notes Location: Indonesia, in travellers returning from Papua
Setting: army base
Malaria endemicity: no known risk of malaria in study site
Resistance profile: the infections were by the chloroquine-resistant and primaquine-
tolerant Chesson-like P vivax strains
Source of funding: sponsored by the ALERT Asia Foundation (Indonesia), funded by
Medicines for Malaria Venture (Switzerland)
Follow-up: 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Statistician block-allocated treatment as-
signments by varying blocking number at
random”
Allocation concealment (selection bias) Low risk Sealed envelope
Blinding (performance bias and detection
bias)
All outcomes
Low risk Unclear if participants or assessing clini-
cians were blinded
Parasitological assessments blinded
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Nelwan 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report lists reasons for attrition and exclu-
sions
Selective reporting (reporting bias) Low risk Prospective registration, reports all a priori
outcomes
Other bias Low risk MMV played an advisory role, but had no
role in study conduct or analysis
Adverse event monitoring (detection bias)
Adverse Events
Unclear risk Authors do not fully describe schedule for
detection of adverse events, includes bio-
chemical and ECG monitoring
Authors do not clearly define adverse
events, including significant raise in hep-
atic enzymes
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Unclear risk Reports numbers of adverse events by
grade, but do not define grading used
Poravuth 2011
Methods RCT
Duration: 1 year, March 2007 to March 2008
Participants Adults and children with P vivax malaria
Number: 456
Inclusion criteria: age 3 - 60 years; fever or history of fever within 24 hours; bodyweight
20 kg - 90 kg
Exclusion criteria: severe/complicated malaria; mixed Plasmodium infection; severe
vomiting; other clinical condition recurring hospitalization; other clinically significant
disorder; viral hepatitis/HIV; malnutrition; QTc ≥ 450 ms; other febrile conditions;
hepatic impairment (AST/ALT > 2.5 x ULN); renal impairment; anaemia (Hb < 8 g/dL)
; allergy to study drugs; antimalarial therapy in previous 2 weeks (or antibacterial with
antimalarial effect); investigational drug in previous 4 weeks; previous participation in
pyronaridine-artesunate studies; pregnancy/lactation; unable to comply with follow-up
visits
Diagnosis: microscopy of P vivax (parasite density ≥ 250/mL blood, including > 50%
asexual parasites)
Interventions • Pyronaridine-artesunate tablets (180 mg:60 mg) once-daily for 3 days. Dose
according to bodyweight: 20 kg - 25 kg one tablet; 26 kg - 44 kg two tablets; 65 kg -
90 kg, 3 tablets. Range = 7.2/2.4 to 13.8/4.6 mg/kg/dose
• Chloroquine 620 mg on day 0 and 1, and 310 mg on day 2. The chloroquine
target dose for children was 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2
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Poravuth 2011 (Continued)
Outcomes • Adverse events
• Cure rate day 14*
• Cure rates day 21, 35, and 42*
• Fever clearance time (from first dose to apyrexia)†*
• Proportions afebrile and aparasitaemic on days 1, 2, and 3*
*Not assessed in quantitative synthesis in this review
†Two consecutive normal readings taken between 7 and 25 hours apart
Notes Location: Asia (Cambodia, India, Indonesia, and Thailand)
Setting: local hospitals
Malaria endemicity: high
Resistance profile: not described
Source of funding:Medicines forMalaria Venture, Shin Poong Pharmaceutical Company
Ltd, Seoul, Republic of Korea
Follow-up: 42 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization
scheme
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Doubly-dummy - study drug andmatching
placebo, packaged similarly
All study investigators, laboratory techni-
cians, and patients blind to treatment as-
signment
Investigator calculated the appropriate dose
and study drug was administered by a dif-
ferent member of staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report lists reasons for attrition and exclu-
sions
Selective reporting (reporting bias) Low risk Prospectively registered. Report includes all
prestated outcomes of interest
Other bias Low risk 3 authors declared conflicting interests
(employees of funders); blind to treatment
allocation
Adverse event monitoring (detection bias)
Adverse Events
Unclear risk Authors do not fully describe method for
detection of adverse events, but describe in-
terval for ECG assessment. Authors do not
give definitions of all adverse events
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Poravuth 2011 (Continued)
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk All-cause adverse events enumerated. Re-
port table only includes adverse events oc-
curring in ≥ 2% (or ≥ 1% if judged to be
drug-related)
Ringwald 1996
Methods RCT
Duration: 1 year, 1 month: April 1994 to May 1995
Participants Adults (> 15 years) with P falciparum malaria
Number: 96
Inclusion criteria: fever or history of fever within 24 hours
Exclusion criteria: severe/complicatedmalaria; mixed Plasmodium infection; recent self-
medication; pregnancy
Diagnosis: thin film microscopy of P falciparum (asexual parasite density > 5000/µL
blood)
Interventions • Pyronaridine: 32 mg/kg in divided doses over 3 days: 16 mg/kg on day 0; 8 mg/
kg on days 1 and 2
• Chloroquine: 25 mg/kg in divided doses over 3 days: 10 mg/kg on days 0 and 1; 5
mg/kg on day 2
Outcomes • Adverse events
• Fever clearance (time from onset of treatment until temp remained below 37.5°C)
*
• Parasite clearance (time until the first negative tick blood smear, with subsequent
smears negative)*
• Early treatment failure*
• Parasitaemia on day 14*
• Gametocyte carriage at day 14*
• In vitro drug susceptibility*
*Not assessed in quantitative synthesis in this review
Notes Location: Cameroon
Setting: dispensary (outpatients)
Malaria endemicity: high
Resistance profile: 57% of isolates chloroquine-resistant
Source of funding: FrenchMinistere de laCo-operation (Grant 93A43); pyronaridinewas
supplied by the Institute of Parasitic Diseases, Chinese Academy of PreventiveMedicine,
Shangai, China
Follow-up: 14 days
Risk of bias
Bias Authors’ judgement Support for judgement
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Ringwald 1996 (Continued)
Random sequence generation (selection
bias)
Low risk Block randomization (blocks of 10); from
communication with authors recorded by
previous version of this review
Allocation concealment (selection bias) Low risk Central randomization; from communica-
tion with authors recorded by previous ver-
sion of this review
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinded, but tablets were different and pa-
tients treated with chloroquine suffered
pruritis; fromcommunicationwith authors
recorded by previous version of this review
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report lists reasons for attrition and exclu-
sions; unlikely to have differentially influ-
enced liver toxicity outcomes used in this
review
Selective reporting (reporting bias) Low risk Trial not prospectively registered, trial pro-
tocol not available. However, all outcomes
stated in methods reported
Other bias Low risk None identified
Adverse event monitoring (detection bias)
Adverse Events
Unclear risk Authors do not fully describe method for
detection of adverse events. Authors do not
give definitions of all adverse events
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Unclear risk Authors give brief narrative description of
adverse events only. Report does not detail
extent of elevation in liver transaminases or
the proportions retested at day 14
Ringwald 1998
Methods RCT
Duration not stated. Year 1996
Participants Children (< 15 years) with P falciparum malaria
Number: 88
Inclusion criteria: fever or history of fever within 24 hours
Exclusion criteria: severe/complicatedmalaria; mixed Plasmodium infection; recent self-
medication; pregnancy; anaemia (Hb < 5g/dL), moderate to severe malnutrition
Diagnosis: thin film microscopy of P falciparum (asexual parasite density > 5000/µL
blood)
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Ringwald 1998 (Continued)
Interventions • Pyronaridine: 32 mg/kg in divided doses over 3 days: 16 mg/kg on day 0; 8 mg/
kg on days 1 and 2
• Chloroquine: 25 mg/kg in divided doses over 3 days: 10 mg/kg on days 0 and 1; 5
mg/kg on day 2
Outcomes • Adverse events
• Fever clearance (time from onset of treatment until temp remained below 37.5°C)
*
• Parasite clearance (time until the first negative tick blood smear, with subsequent
smears negative)*
• Early treatment failure*
• Parasitaemia on day 14*
• Gametocyte carriage at day 14*
*Not assessed in quantitative synthesis in this review
Notes Location: Cameroon
Setting: dispensary (outpatients)
Malaria endemicity: high
Resistance profile: 49% of isolates chloroquine-resistant
Source of funding: FrenchMinistere de laCo-operation (Grant 93A43); pyronaridinewas
supplied by the Institute of Parasitic Diseases, Chinese Academy of PreventiveMedicine,
Shangai, China
Follow-up: 14 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization (blocks of 10); from com-
munication with authors recorded by previous
version of this review
Allocation concealment (selection bias) Low risk Central randomization; from communication
with authors recordedby previous versionof this
review
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinded, but tablets were different and patients
treated with chloroquine suffered pruritis; from
communication with authors recorded by pre-
vious version of this review
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report and subsequent correspondence from
authors lists reasons for attrition and exclusions;
unlikely to have differentially influenced liver
toxicity outcomes used in this review
Selective reporting (reporting bias) Low risk Trial not prospectively registered, trial protocol
not available. However, all outcomes stated in
methods reported
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Ringwald 1998 (Continued)
Other bias Low risk None identified
Adverse event monitoring (detection bias)
Adverse Events
Unclear risk Authors do not fully describe method for de-
tection of adverse events. Authors do not give
definitions of all adverse events
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Unclear risk Authors give brief narrative description of ad-
verse events only. Report does not detail extent
of elevation in liver transaminases or the pro-
portions retested at day 14
Roth 2018
Methods RCT
Duration: 1 year, 5 months. October 2015 to June 2016, January 2017 to August 2017
Participants Children with P falciparum malaria
Number: 197
Inclusion criteria: age 6 months - 12 years; bodyweight ≥ 5 kg
Exclusion criteria: severe/complicated malaria; non-falciparum/mixed Plasmodium in-
fection; other clinically significant disorder; malnutrition; hepatic impairment (AST/
ALT not specified); renal impairment; anaemia (Hb <6 g/dL); allergy to study drugs;
current participation in other antimalarial study; previous participation in study, not
available for follow-up
Diagnosis: microscopically-confirmed P falciparum monoinfection (asexual parasite
density 1000 µL-200,000/µL)
Children under 5: 31 (pyronardine-artesunate); 31 (artemether-lumefantrine)
Interventions • Pyronaridine-artesunate granules (60 mg:20 mg) or tablets (180 mg:60 mg) once-
daily for 3 days. Dose according to bodyweight: 5 kg - 8 kg one sachet, 8 kg -15 kg 2
sachets, 15 kg - 20 kg 3 sachets, 20 kg - 24 kg one tablet, 24 kg - 45 kg 2 tablets
• Artemether-lumefantrine crushed tablets (20 mg/120 mg) twice daily for 3 days
at recommended intervals. Dose according to bodyweight: 5 kg - 15 kg one tablet, 15
kg - 25 kg 2 tablets, 25 kg - 35 kg 3 tablets, ≥ 35 kg 4 tablets
Outcomes • ACPR* day 28 PCR-adjusted
• ACPR day 28 unadjusted
• ACPR day 42 PCR-adjusted
• ACPR day 42 unadjusted
• Parasite clearance time (from first dose to aparasitaemia)†, ‡
• Fever clearance time (from first dose to apyrexia)†
• “Transmission potential to mosquitoes” (undefined)‡
• Adverse events (including laboratory abnormalities)
• Proportion of patients with parasite clearance on days 1, 2, and 3, ‡
• Proportion of patients with fever clearance on days 1, 2, and 3, ‡
*Adequate clinical and parasitological response rate
†Two consecutive normal readings taken between 7 and 25 hours apart
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Roth 2018 (Continued)
‡Not assessed in quantitative synthesis in this review
Notes Location: Kenya
Setting: Local clinic
Malaria endemicity: high
Resistance profile: not described
Source of funding: EU FP7-Health-2013. 0-1 Project “Translation of the direct-on-
blood PCR-NALFIA system into an innovative near point-of-care diagnostic formalaria”
(DIAGMAL) [Grant Number 601714]
Follow-up: 42 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization sched-
ule provided by sponsor
Allocation concealment (selection bias) Low risk Sequentially numbered sealed opaque en-
velopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients probably not blinded (drugs were
administered by pharmacy personnel aware
of group
assignments)
Clincial and parasitological assessments
performed by study staff blinded to treat-
ment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report lists reasons for attrition and exclu-
sions
Selective reporting (reporting bias) Low risk Authors report fever clearance time which
was not in trial registration document. Un-
likely to introduce significant bias
Other bias Low risk Target recruitment not reached
Shin Poong Pharmaceutical Company
(Seoul, South Korea) provided pyronari-
dine-artesunate tablets and granules, but
had no further role in study design, data
collection, data analysis and writing of the
report
Adverse event monitoring (detection bias)
Adverse Events
Unclear risk Authors describe full schedule for ALT/
AST monitoring. Due to logistic con-
straints, ALT and AST were only measured
for the first 150 participants
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Incomplete adverse event reporting (re-
porting bias)
Adverse events
Unclear risk Authors do not give reporting threshold for
adverse events
Rueangweerayut 2012
Methods RCT
Duration: 1 year, 10 months. January 2007 to October 2008
Participants Adults and children with P falciparum malaria
Number: 1271
Inclusion criteria: age 3-60 years; bodyweight 20 kg - 90 kg; fever or history of fever
within 24 hours
Exclusion criteria: severe/complicatedmalaria; anaemia (Hb < 8 g/dL); severe vomiting;
diarrhoea; pregnancy/lactation; other clinically significant disorder; hepatic impairment
(undefined); renal impairment; antimalarial therapy in previous 2 weeks; investigational
drug in previous 4 weeks; previous participation in study; allergy to study drugs
Diagnosis: thick and thin filmmicroscopy of P falciparum (asexual parasite density 1000
mm3- 100,000 mm3 blood)
Interventions Randomized in a 2:1 ratio to:
• pyronaridine-artesunate combination (7.2: 2.4 mg/kg respectively) once a day for
three days (N = 848)
• mefloqune -artesunate combination (6.2 to 12.5 mg/kg and 2.2 to 5.0 mg/kg
respectively) once a day for three days (N = 423)
Outcomes • ACPR* day 28 PCR-adjusted
• ACPR day 28 unadjusted
• ACPR day 42 PCR-adjusted
• ACPR day 42 unadjusted
• Parasite clearance time (from first dose to aparasitaemia)†, ‡
• Fever clearance time (from first dose to apyrexia)†, ‡
• Proportion of patients with parasite clearance on days 1, 2, and 3, ‡
• Proportion of patients with fever clearance on days 1, 2, and 3, ‡
• Proportion of patients with gametocytes, ‡
• Gametocyte clearance time (not defined)‡
• Adverse events
*Adequate clinical and parasitological response rate
†Two consecutive normal readings taken between 7 and 25 hours apart
‡Not assessed in quantitative synthesis in this review
Notes Location: Asia (81%) and Africa (19%). Asia: Cambodia, India, Thailand, Vietnam.
Africa: Bukina Faso, Ivory Coast, Tanzania
Setting: local hospitals and health centres
Malaria endemicity: high
Resistance profile: in Cambodia, significantly extended parasite clearance times (for both
treatment arms) were suggestive of in vivo resistance to artemisinin
Source of funding:Medicines forMalaria Venture, Shin Poong Pharmaceutical Company
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Rueangweerayut 2012 (Continued)
Ltd, Seoul, Republic of Korea
Follow-up: 42 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization sched-
ule
Allocation concealment (selection bias) Low risk Individually numbered treatment packs
Randomization communicated by investi-
gator to a third party who administered the
correct amount of tablets
Blinding (performance bias and detection
bias)
All outcomes
Low risk Unclear if patients blinded
Outcome assessors blinded to group assign-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report lists reasons for attrition and exclu-
sions
Selective reporting (reporting bias) Low risk Prospectively registered. Report includes all
prestated outcomes of interest
Other bias Low risk Some authors employed by trial sponsors,
but all authors assumed responsibility for
reporting accuracy
Adverse event monitoring (detection bias)
Adverse Events
Unclear risk Authors do not describe methods for mon-
itoring adverse events, but includes bio-
chemical monitoring
Authors do describe time point of assess-
ments in protocol
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Unclear risk Report percentage of adverse events. Sup-
plementary data table provided. Reports
“any cause” adverse events if they occurred
in > 2% of patients. Reports “treatment re-
lated” adverse events if they occurred in >
1% of patients. Does not report method of
judging relation of adverse events to treat-
ment
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Sagara 2018
Methods RCT*
Duration: 4 years, 4 months. 24 October 2011 to 01 February 2016
*Different arms at different study centres; therefore we requested disaggregated data
Participants Adults and children with P falciparum malaria
Number: 4710 (2640 within pyronaridine-artesunate subsection)
Inclusion criteria: age > 2 years*; bodyweight≥ 15 kg (decreased to≥ 5 kg after review)
; fever or history of fever within 24 hours
Exclusion criteria: severe/complicated malaria; severe vomiting; severe diarrhoea; other
clinically significant disorder including QTc ≥ 450 ms, active TB, jaundice and others;
anaemia (Hb < 70 g/dL); other febrile conditions; allergy to study drugs; antimalarial
therapy in previous 2 weeks; investigational drug in previous 4 weeks; pregnancy/lacta-
tion; alcohol abuse; viral hepatitis/HIV; hepatic impairment (ALT > 2 x ULN); renal
impairment (1.5 x ULN)
Diagnosis: positive microscopy for Plasmodium spp. (> 0 to < 200,000 parasites/µL
blood)
*For pyronaridine-artesunate group, inclusion criteria changed during the study. (i) Beginning
of the study, inclusion age of 15 years or older and bodyweight of 24 kg or over, (ii) after 20
retreatments, inclusion age of 2 years or older and bodyweight of 15 kg or over, and (iii) After
40 retreatments, inclusion age of at least 6 months with bodyweight of 5 kg or over
Children under 5: 344 (Pyr-AS); 129 (AL); 249 (AS-AQ)
The total number of participants receiving at least one study treatment in each compar-
ison are as below
• Pyronaridine-artesunate (n = 658) versus artemether-lumefantrine (n = 665)
• Pyronaridine-artesunate (n = 659) versus artesunate-amodiaquine (n = 658)
The breakdown of total participants receiving each treatment at each site is as below
• Bobo-Dioulasso, Burkina Faso: pyronardine-artesunate (n = 212) versus
artemether-lumefantrine (n = 220)
• Ouagadougou, Burkina Faso: pyronaridine-artesunate (n = 215) versus
artesunate-amodiaquine (n = 214)
• Bougoula, Mali: 1. PY-AS (n = 214) versus AL (213); 2. PY-AS (n = 94) versus
artesunate-amodiaquine (n = 98)
• Djoliba, Mali: pyronaridine-artesunate (n = 87) versus AS-AQ (n = 85)
• Kolle, Mali: 1. pyronaridine-artesunate (n = 86) versus AL (87); 2. pyronaridine-
artesunate (n = 11) versus AS-AQ (n = 11)
• Sotuba, Mali: 1. pyronaridine-artesunate (n = 146) versus AL (145); 2.
pyronaridine-artesunate (n = 17) versus AS-AQ (n = 17)
• Mafrinyah, Guinea: pyronaridine-artesunate (n = 235) versus AS-AQ (n = 233
The total numbers of participants and numbers disaggregated by each site were obtained
from the trial authors in response to a request for further information in May 2017
Interventions • Pyronaridine-artesunate granules (60 mg:20 mg) or tablets (180 mg:60 mg) once-
daily for 3 days. Dose according to bodyweight: 5 kg - 8 kg one sachet, 8 kg - 15 kg 2
sachets, 15 kg - 20 kg 3 sachets, 20 kg - 24 kg one tablet, 24 kg - 45 kg 2 tablets, 45 kg
- 65 kg 3 tablets, ≥ 65kg 4 tablets
• Artemether-lumefantrine tablets (20 mg/120 mg) twice daily for 3 days at
recommended intervals. Dose according to bodyweight: 5 kg - 15 kg one tablet, 15 kg -
25 kg 2 tablets, 25 kg - 35 kg 3 tablets, ≥ 35 kg 4 tablets
• Amodiaquine-artesunate tablets once-daily for 3 days. Dose according to
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bodyweight: 5 kg - 9 kg one 25 mg:67.5 mg tablet, 9 kg - 18 kg one 50 mg:135 mg
tablet, 18 kg - 36 kg one 100 mg:270 mg tablet, ≥ 36 kg two 100 mg:270 mg tablets
• Dihydroartemisinin-piperaquine*
*Not compared against pyronaridine-artesunate in this trial
Outcomes • Two-year incidence rate of all repeat malaria episodes (uncomplicated and
complicated) irrespective of parasite species*
• Crude and PCR-corrected ACPR for P falciparum and crude ACPR for other
Plasmodium species at days 28 and 42, irrespective of axillary temperature, without
previous early treatment failure, late clinical failure, or late parasitological failure
• Parasite clearance time (time from first dose until parasite negative, with
aparasitaemia maintained for at least 48 hrs)*
• Reinfection and recrudescence rates over 42 days*
• Gametocyte density and carriage*
• Difference in time to the second infection between treatments*
• Difference in the mean interval between reinfection*
• Adverse events
*Not assessed in quantitative synthesis in this review
Notes Location: West Africa (Burkina Faso, Guinea, Mali), conducted by the West African
Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Setting: tertiary health facilities
Malaria endemicity: high
Resistance profile: not described
Source of funding: European and Developing Countries Clinical Trial Partnership,
Medicines for Malaria Venture, United Kingdom Medical Research Councils, Swedish
International Development Co-operation Agency, German Ministry for Education and
Research, University Claude Bernard (France), University of Science Techniques and
Technologies of Bamako, CentreNational de Recherche et de Formation sur le Paludisme
(Burkina Faso), Institut de Recherche en Sciences de la Santé (Bobo- Dioulasso, Burkina
Faso), and Centre National de Formation et de Recherche en Santé Rurale (Republic of
Guinea)
Follow-up: 42 days active; 2 year passive
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization list for
each site within each country was used;
block size of two
Allocation concealment (selection bias) Low risk Sealed, opaque, sequentially numbered en-
velopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Open-label: patients and investigators not
blinded to treatment allocation
Microscopists assessing parasite outcomes
masked to treatment allocation
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Sagara 2018 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons provided for all withdrawals across
study arms. Withdrawal numbers small
and balanced across the intervention arms
with reasons for withdrawal similar be-
tween groups
Selective reporting (reporting bias) Low risk All outcomes reported as listed in the trial
register, however day 63 outcomes are not
reported
Other bias Low risk Some authors employed by trial sponsors,
but all authors assumed responsibility for
reporting accuracy
Adverse event monitoring (detection bias)
Adverse Events
Low risk Authors report that physical examinations
made and adverse events recorded at all as-
sessments. Describes ECG and biochem-
istry monitoring schedule. Used Medical
Dictionary for Regulatory Activities (Med-
DRA)
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk Authors enumerate adverse events clearly,
and report events of interest. Provide sup-
plementary tables. We were unable to ex-
tract adverse events by study site
Sagara 2018 (Bobo-Doiulasso, Burkina Faso)
Methods RCT* - represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 232
Interventions • Pyronaridine-artesunate (n = 212)
• Artemether-lumefantrine (n = 220)
Outcomes -
Notes Location: Bobo, Burkina Faso
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Represents disaggregated data from Sagara
2018 (see above)
Allocation concealment (selection bias) Low risk -
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Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Adverse event monitoring (detection bias)
Adverse Events
Low risk -
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk -
Sagara 2018 (Bougoula, Mali)
Methods RCT* - represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 619
Interventions Comparison 1
• Pyronaridine-artesunate (n = 214)
• Artemether-lumefantrine (n = 213)
Comparison 2
• Pyronaridine-artesunate (n = 94)
• Amodiaquine-artesunate (n = 98)
Outcomes -
Notes Location: Bougoula, Mali
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Represents disaggregated data from Sagara
2018 (see above)
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk -
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Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Adverse event monitoring (detection bias)
Adverse Events
Low risk -
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk -
Sagara 2018 (Djoliba, Mali)
Methods RCT* - represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 172
Interventions • Pyronaridine-artesunate (n = 87)
• Amodiaquine-artesunate (n = 85)
Outcomes -
Notes Location: Djoliba, Mali
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Represents disaggregated data from Sagara
2018 (see above)
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
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Sagara 2018 (Djoliba, Mali) (Continued)
Adverse event monitoring (detection bias)
Adverse Events
Low risk -
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk -
Sagara 2018 (Kolle, Mali)
Methods RCT* - represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 195
Interventions Comparison 1
• Pyronaridine-artesunate (n = 86)
• Artemether-lumefantrine (n = 87)
Comparison 2
• Pyronaridine-artesunate (n = 11)
• Amodiaquine-artesunate (n = 11)
Outcomes -
Notes Location: Kolle, Mali
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Represents disaggregated data from Sagara
2018 (see above)
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Adverse event monitoring (detection bias)
Adverse Events
Low risk -
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Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk -
Sagara 2018 (Mafrinyah, Guinea)
Methods RCT* - represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 468
Interventions • Pyronaridine-artesunate (n = 235)
• Amodiaquine-artesunate (n = 233)
Outcomes -
Notes Location: Mafrinyah, Guinea
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Represents disaggregated data from Sagara
2018 (see above)
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Adverse event monitoring (detection bias)
Adverse Events
Low risk -
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk -
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Sagara 2018 (Ouagadougou, Burkina Faso)
Methods RCT* - represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 429
Interventions • Pyronaridine-artesunate (n = 215)
• Amodiaquine-artesunate (n = 214)
Outcomes -
Notes Location: Ouagadougou, Burkina Faso
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Represents disaggregated data from Sagara
2018 (see above)
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Adverse event monitoring (detection bias)
Adverse Events
Low risk -
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk -
Sagara 2018 (Sotuba, Mali)
Methods RCT* - represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 325
Interventions Comparison 1
• Pyronaridine-artesunate (n = 146)
• Artemether-lumefantrine (n = 145)
Comparison 2
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• Pyronaridine-artesunate (n = 17)
• Amodiaquine-artesunate (n = 17)
Outcomes -
Notes Location: Sotuba, Mali
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Represents disaggregated data from Sagara
2018 (see above)
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Adverse event monitoring (detection bias)
Adverse Events
Low risk -
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk -
Shin 2011
Methods RCT
Participants Adults and children with P vivax malaria
Number: 30
Interventions • Pyronaridine-artesunate tablets (180 mg:60 mg)
• Chloroquine
Outcomes • Cure rate day 14*
• Cure rates day 28 and 42*
• Fever clearance time*
• Parasite clearance time*
• Proportions aparasitaemic on days 1, 2, and 3*
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• Adverse events
*Not assessed in quantitative synthesis in this review
Notes Location: Korea
Setting: not known
Malaria endemicity: unstable
Resistance profile: not described
Source of funding: not known
Follow-up: 42 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients assigned in ascending order a randomization number
according to order recruited
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and investigators blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data available for 14 of 15 patients in pyronardine-artesunate
arm, and 15 of 15 patients in chloroquine arm
Selective reporting (reporting bias) Low risk Authors provided all data requested
Other bias Unclear risk Authors frompharmaceutical companymanufacturing pyronar-
dine-artesunate
Adverse event monitoring (detection bias)
Adverse Events
Low risk Full schedule of safety monitoring
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Low risk Authors provided all data requested
Tshefu 2010
Methods RCT
Duration: 1 year, 3 months. January 2007 to April 2008
Participants Adults and children with P falciparum malaria
Number: 1272
Inclusion criteria: age 3-60 years; bodyweight 20 kg - 90 kg; fever or history of fever
within 24 hours
Exclusion criteria: severe/complicated malaria; mixed Plasmodium infection; malnutri-
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tion; anaemia (Hb < 8 g/dL); severe vomiting; severe diarrhoea; other clinically signif-
icant disorder; hepatic impairment (limit not stated); renal impairment; other febrile
conditions; viral hepatitis/HIV; electrolyte imbalance; allergy to study drugs; antimalar-
ial therapy in previous 2 weeks, investigational drug in previous 4 weeks; taking any drug
metabolized by cytochrome enzyme CYP2D6; previous participation in pyronaridine-
artesunate studies; pregnancy/lactation
Diagnosis: microscopy (asexual parasite density 1000 µL to 100,000/µL blood)
Interventions Randomized in a 2:1 ratio to:
• pyronaridine-artesunate tablets (180 mg:60 mg) once-daily for 3 days. Dose
according to bodyweight: 20 kg - 25 kg one tablet, 26 kg - 45 kg 2 tablets, 45 kg - 65
kg 3 tablets, ≥ 65kg 4 tablets (N = 849)
• Artemether-lumefantrine tablets (20 mg/120 mg) twice daily for 3 days at
recommended intervals. Dose according to bodyweight: 20 kg - 25 kg 2 tablets, 25 kg -
35 kg 3 tablets, ≥ 35 kg 4 tablets
Outcomes • ACPR* day 28 PCR-adjusted
• ACPR day 28 unadjusted
• ACPR day 42 PCR-adjusted
• ACPR day 42 unadjusted
• Parasite clearance time (from first dose to aparasitaemia)†, ‡
• Fever clearance time (from first dose to apyrexia)†, ‡
• Proportion of patients with parasite clearance on days 1, 2, and 3, ‡
• Proportion of patients with fever clearance on days 1, 2, and 3, ‡
• Gametocyte density, ‡
• Adverse events (including laboratory and ECG abnormalities)
*Adequate clinical and parasitological response rate
†Two consecutive normal readings taken between 7 and 25 hours apart
‡Not assessed in quantitative synthesis in this review
Notes Location: Africa (n = 1080, 85%) and Asia (n = 192, 15%). Africa: DRC, The Gambia,
Ghana, Kenya, Mali, Mozambique, Senegal. Asia: Indonesia, the Phillipines
Setting: local hospitals and clinics
Malaria endemicity: high
Resistance profile: not described
Funding: Medicines for Malaria Venture, Shin Poong Pharmaceutical Company Ltd,
Seoul, Republic of Korea
Follow-up: 42 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization sched-
ule. Block randomization of 9 by study cen-
tre
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Allocation concealment (selection bias) Low risk Individually numbered treatment packs
Randomization communicated by investi-
gator to a third party who administered the
correct amount of tablets, and who was not
involved in clinical assessment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients blinded: artemether-lumefantrine
placebo dosed twice daily to main-
tain blinding. Food not required for
artemether-lumefantrine dosing to retain
blinding
Outcome assessors blinded to group assign-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report lists reasons for attrition and exclu-
sions
Selective reporting (reporting bias) Low risk Prospectively registered. Report includes
prestated outcomes of interest. Day 42 effi-
cacy outcomes and gametocyte counts not
listed in trial registration document; listed
in the report as exploratory
Other bias Unclear risk Sponsors designed the trial, were respon-
sible for data collection and analysis, and
developed the report; all authors had access
to trial data
Participants on artemether-lumefantrine
were not expected to take medication after
food; unclear if this reduced bioavailability
of lumefantrine
Adverse event monitoring (detection bias)
Adverse Events
Low risk Report that adverse events recorded during
treatment and at all follow-up visits
Incomplete adverse event reporting (re-
porting bias)
Adverse events
Unclear risk Authors report all-cause adverse events as
percentages. Report table only includes ad-
verse events occurring in≥ 5% (or≥ 1% if
judged to be drug related). Authors explain
method for determining relation to study
drug
Abbreviations: ACPR: adequate clinical and parasitological response; ALT: alanine aminotransferase; AST: aspartate transaminase; ECG:
electrocardiogram; Hb: haemoglobin; MMV: Medicines for Malaria Venture; PCR: polymerase chain reaction; QT: QT interval
on electrocardiogram; QTc: corrected QT interval on electrocardiogram; RCT: randomized controlled trial; ULN: upper limit of
normal.
63Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Huang 1988 Quasi-RCT. Randomized according to order of admission
Huang 1989 Quasi-RCT. Odd and even numbers used for allocation
Huang 1993 RCT: conducted in people with complicated falciparum malaria
Laman 2014 Trial registration (ACTRN12610000913077) planned to use pyronaridine-artesunate, but not available due
to concerns over hepatotoxicity at time of trial
Leang 2016 Not a RCT: single-arm observational study
Looareesuwan 1996 Not a RCT: clinical trial of two doses of pyronaridine monotherapy with group given second dose recruited
after results of first dose were analysed
Looareesuwan 2007 RCT: phase II dose ranging trial
Piola 2008 Not a RCT: phase II dose ranging study
Ramharter 2008 Not a RCT: open-label dose-escalation study
Sagara 2014 Not a RCT: pooled analysis
Abbreviations: RCT: randomized controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Pyronaridine-artesunate versus artemether-lumefantrine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure: day 42
(PCR-adjusted)
7 2575 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.49, 1.51]
2 Total failure: day 28
(PCR-adjusted)
7 3068 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.26, 1.31]
3 Total failure: day 28 (unadjusted) 7 3149 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.13, 0.58]
4 Total failure: day 42 (unadjusted) 7 3080 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.46, 0.82]
5 Early treatment failure 7 3149 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [0.12, 52.39]
6 Serious adverse events 3 2004 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.19, 4.22]
7 Adverse events leading to
withdrawal
3 2004 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.68, 2.90]
8 First treatment, ALT increase > 5
× ULN
7 3327 Risk Ratio (M-H, Fixed, 95% CI) 2.92 [1.15, 7.41]
9 First treatment, AST increase >
5 × ULN
7 3327 Risk Ratio (M-H, Fixed, 95% CI) 2.20 [0.83, 5.82]
10 First treatment, bilirubin
increase > 2.5 × ULN
6 3130 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.33, 2.04]
11 Subsequent treatment(s), ALT
increase > 5 × ULN
4 865 Risk Ratio (M-H, Random, 95% CI) 2.54 [0.49, 13.10]
12 Subsequent treatment(s), AST
increase > 5 × ULN
4 865 Risk Ratio (M-H, Random, 95% CI) 1.88 [0.50, 7.06]
13 Subsequent treatment(s),
bilirubin increase > 2.5 × ULN
4 865 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.16, 3.63]
14 Paediatric trials - total failure:
day 28 (PCR-adjusted)
2 684 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.13, 7.84]
15 Paediatric trials - total failure:
day 42 (PCR-adjusted)
2 558 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.41, 2.59]
16 Paediatric trials - total failure:
day 28 (unadjusted)
2 693 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.50, 1.18]
17 Paediatric trials - total failure:
day 42 (unadjusted)
2 654 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.74, 1.33]
18 Paediatric trials - first treatment,
ALT increase > 5 × ULN
2 732 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.03, 8.06]
19 Paediatric trials - first treatment,
AST increase > 5 × ULN
2 732 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.16, 14.52]
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Comparison 2. Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure: day 28
(PCR-adjusted)
6 1245 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.11, 2.77]
2 Total failure: day 42
(PCR-adjusted)
6 1091 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.20, 4.83]
3 Total failure: day 28 (unadjusted) 6 1257 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.30, 0.81]
4 Total failure: day 42 (unadjusted) 6 1235 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.78, 1.23]
5 First treatment, ALT increase > 5
× ULN
6 1317 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.28, 7.09]
6 First treatment, AST increase >
5 × ULN
6 1317 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.08, 2.07]
7 First treatment, bilirubin
increase > 2.5 × ULN
6 1317 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.06, 15.76]
8 Subsequent treatment(s), ALT
increase > 5 × ULN
6 784 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [0.48, 7.76]
9 Subsequent treatment(s), AST
increase > 5 × ULN
6 784 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.49, 6.62]
10 Subsequent treatment(s),
bilirubin increase > 2.5 × ULN
6 784 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.33, 9.83]
Comparison 3. Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure: day 28
(PCR-adjusted)
1 1117 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.13, 1.05]
2 Total failure: day 42
(PCR-adjusted)
1 1037 Risk Ratio (M-H, Random, 95% CI) 1.80 [0.90, 3.57]
3 Total failure: day 28 (unadjusted) 1 1120 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.17, 0.78]
4 Total failure: day 42 (unadjusted) 1 1059 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.54, 1.31]
5 Serious adverse events 1 1271 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.25, 3.97]
6 Adverse events leading to
withdrawal
1 1271 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.17, 2.31]
7 First treatment, ALT increase > 5
× ULN
1 1271 Risk Ratio (M-H, Fixed, 95% CI) 7.48 [0.99, 56.45]
8 First treatment, AST increase >
5 × ULN
1 1271 Risk Ratio (M-H, Fixed, 95% CI) 9.49 [0.55, 162.64]
9 First treatment, bilirubin
increase > 2.5 × ULN
1 1271 Risk Ratio (M-H, Fixed, 95% CI) 3.49 [0.43, 28.29]
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Comparison 4. Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events 7 3941 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.54, 2.84]
2 Adverse events leading to
withdrawal
6 3911 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.58, 1.94]
3 First treatment, ALT increase > 5
× ULN
14 6581 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [1.63, 6.84]
4 First treatment, AST increase >
5 × ULN
14 6581 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.89, 3.65]
5 First treatment, bilirubin
increase > 2.5 × ULN
13 6384 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.49, 2.18]
6 Subsequent treatment(s), ALT
increase > 5 × ULN
7 1649 Risk Ratio (M-H, Fixed, 95% CI) 2.18 [0.76, 6.27]
7 Subsequent treatment(s), AST
increase > 5 × ULN
7 1649 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [0.74, 4.44]
8 Subsequent treatment(s),
bilirubin increase > 2.5 × ULN
7 1649 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.42, 3.01]
9 Sensitivity analysis: first
treatment, ALT increase > 5 ×
ULN
10 5672 Risk Ratio (M-H, Fixed, 95% CI) 4.07 [1.83, 9.05]
10 Other adverse events 10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Blood and lymphatic:
anaemias
4 4517 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.86, 1.54]
10.2 Blood and lymphatic:
eosinophilic disorders
2 2543 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.86, 1.93]
10.3 Blood and lymphatic:
leukocytoses
2 2615 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.42, 1.37]
10.4 Blood and lymphatic:
neutropaenias
2 2616 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.63, 1.10]
10.5 Cardiac: cardiac
arrhythmias
1 180 Risk Ratio (M-H, Fixed, 95% CI) 5.95 [0.25, 143.93]
10.6 Cardiac: cardiac signs
and symptoms
5 2108 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.37, 0.89]
10.7 Cardiac: myocardial
disorders
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
10.8 Ear: ear disorders 1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.69]
10.9 Gastrointestinal:
diarrhoea (excl infective)
4 411 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [1.10, 5.99]
10.10 Gastrointestinal:
dyspeptic signs and symptoms
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
10.11 Gastrointestinal: GI
and abdominal pains
7 4544 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.87, 1.45]
10.12 Gastrointestinal: nausea
and vomiting symptoms
9 5534 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.71, 1.17]
10.13 General: asthenic
conditions
2 653 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.64, 2.75]
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10.14 General: general signs
and symptoms
1 535 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.54, 2.70]
10.15 General: feelings and
sensations
1 197 Risk Ratio (M-H, Fixed, 95% CI) 4.75 [0.23, 97.79]
10.16 General: febrile
disorders
2 715 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.65, 2.96]
10.17 General: pain and
discomfort
1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.91]
10.18 Infections and
infestations: eye and eyelid
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
10.19 Infections and
infestations: LRTI and lung
2 3216 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.83, 1.11]
10.20 Infections and
infestations: URTI
7 5350 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.88, 1.20]
10.21 Investigations: ECG 4 3347 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.36, 0.58]
10.22 Investigations: skeletal/
cardiac muscle analyses
2 636 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.55, 3.15]
10.23 Investigations: physical
exam
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
10.24 Investigations: platelet 2 565 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.55, 1.56]
10.25 Investigations: protein 1 535 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.36, 1.24]
10.26 Metabolism and
nutrition: appetite disorders
3 683 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.80, 2.68]
10.27 Metabolism and
nutrition: hypoglycaemia
conditions
1 535 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.50, 1.46]
10.28 Metabolism and
nutrition: metabolic disorders
1 2681 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.61, 1.29]
10.29 MSK and connective
tissue: muscle pains
3 1924 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.97, 2.01]
10.30 MSK and connective
tissue: pain and discomfort
1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.69]
10.31 Nervous system:
headaches
9 6271 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.90, 1.32]
10.32 Nervous system: sleep
disturbance
1 180 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.03, 15.99]
10.33 Nervous system:
paraesthesias and dysasthesias
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
10.34 Respiratory: coughing
and assoc symptoms
6 6412 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.82, 1.19]
10.35 Respiratory: upper
respiratory tract signs and
symptoms
3 407 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.32, 10.07]
10.36 Renal and urinary:
urinary abnormalities
1 197 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.18, 20.63]
10.37 Skin and subcutaneous
tissue: dermatitis and eczema
2 276 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.15, 6.99]
10.38 Skin and subcutaneous
tissue: pruritis
2 184 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.13, 0.49]
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10.39 Skin and subcutaneous
tissue: rashes, eruptions,
exanthems
1 197 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.18, 20.63]
10.40 Skin and subcutaneous
tissue: urticaria
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
10.41 Vascular: vascular
hypotensive disorders
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
Analysis 1.1. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 1 Total
failure: day 42 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 1 Total failure: day 42 (PCR-adjusted)
Study or subgroup
Pyronaridine-
artesunate
Artemether-
lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 18/275 6/139 38.9 % 1.52 [ 0.62, 3.73 ]
Roth 2018 4/77 6/67 21.1 % 0.58 [ 0.17, 1.97 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 1/181 3/161 6.2 % 0.30 [ 0.03, 2.82 ]
Sagara 2018 (Bougoula, Mali) 1/179 1/142 4.1 % 0.79 [ 0.05, 12.57 ]
Sagara 2018 (Kolle, Mali) 0/71 1/46 3.1 % 0.22 [ 0.01, 5.23 ]
Sagara 2018 (Sotuba, Mali) 0/141 2/130 3.4 % 0.18 [ 0.01, 3.81 ]
Tshefu 2010 9/672 4/294 23.1 % 0.98 [ 0.31, 3.17 ]
Total (95% CI) 1596 979 100.0 % 0.86 [ 0.49, 1.51 ]
Total events: 33 (Pyronaridine-artesunate), 23 (Artemether-lumefantrine)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.55, df = 6 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Not applicable
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69Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.2. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 2 Total
failure: day 28 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 2 Total failure: day 28 (PCR-adjusted)
Study or subgroup
Pyronaridine-
artesunate
Artemether-
lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 10/339 2/167 26.9 % 2.46 [ 0.55, 11.11 ]
Roth 2018 1/94 3/84 12.5 % 0.30 [ 0.03, 2.81 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 1/204 3/194 12.4 % 0.32 [ 0.03, 3.02 ]
Sagara 2018 (Bougoula, Mali) 0/206 4/189 7.5 % 0.10 [ 0.01, 1.88 ]
Sagara 2018 (Kolle, Mali) 0/80 1/74 6.3 % 0.31 [ 0.01, 7.46 ]
Sagara 2018 (Sotuba, Mali) 0/144 2/140 7.0 % 0.19 [ 0.01, 4.02 ]
Tshefu 2010 4/777 3/376 27.4 % 0.65 [ 0.15, 2.87 ]
Total (95% CI) 1844 1224 100.0 % 0.59 [ 0.26, 1.31 ]
Total events: 16 (Pyronaridine-artesunate), 18 (Artemether-lumefantrine)
Heterogeneity: Tau2 = 0.04; Chi2 = 6.19, df = 6 (P = 0.40); I2 =3%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 3 Total
failure: day 28 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 3 Total failure: day 28 (unadjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 36/341 23/172 17.3 % 0.79 [ 0.48, 1.29 ]
Roth 2018 8/95 10/85 14.9 % 0.72 [ 0.30, 1.73 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 5/206 42/215 14.8 % 0.12 [ 0.05, 0.31 ]
Sagara 2018 (Bougoula, Mali) 4/206 40/203 14.1 % 0.10 [ 0.04, 0.27 ]
Sagara 2018 (Kolle, Mali) 3/82 26/84 13.1 % 0.12 [ 0.04, 0.38 ]
Sagara 2018 (Sotuba, Mali) 2/145 10/145 10.8 % 0.20 [ 0.04, 0.90 ]
Tshefu 2010 9/784 11/386 15.0 % 0.40 [ 0.17, 0.96 ]
Total (95% CI) 1859 1290 100.0 % 0.27 [ 0.13, 0.58 ]
Total events: 67 (Pyronaridine-Artesunate), 162 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.81; Chi2 = 30.27, df = 6 (P = 0.00003); I2 =80%
Test for overall effect: Z = 3.38 (P = 0.00073)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PY-AS Favours AL
71Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.4. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 4 Total
failure: day 42 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 4 Total failure: day 42 (unadjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 76/325 36/166 16.7 % 1.08 [ 0.76, 1.53 ]
Roth 2018 19/86 21/77 12.6 % 0.81 [ 0.47, 1.39 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 34/205 69/215 16.4 % 0.52 [ 0.36, 0.74 ]
Sagara 2018 (Bougoula, Mali) 38/204 76/205 16.9 % 0.50 [ 0.36, 0.70 ]
Sagara 2018 (Kolle, Mali) 23/81 44/84 15.5 % 0.54 [ 0.36, 0.81 ]
Sagara 2018 (Sotuba, Mali) 3/143 23/144 4.9 % 0.13 [ 0.04, 0.43 ]
Tshefu 2010 76/771 52/374 17.1 % 0.71 [ 0.51, 0.99 ]
Total (95% CI) 1815 1265 100.0 % 0.61 [ 0.46, 0.82 ]
Total events: 269 (Pyronaridine-Artesunate), 321 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.10; Chi2 = 20.63, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 5 Early
treatment failure.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 5 Early treatment failure
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 2/341 0/172 100.0 % 2.53 [ 0.12, 52.39 ]
Roth 2018 0/95 0/85 Not estimable
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 0/206 0/215 Not estimable
Sagara 2018 (Bougoula, Mali) 0/206 0/203 Not estimable
Sagara 2018 (Kolle, Mali) 0/82 0/84 Not estimable
Sagara 2018 (Sotuba, Mali) 0/145 0/145 Not estimable
Tshefu 2010 0/784 0/386 Not estimable
Total (95% CI) 1859 1290 100.0 % 2.53 [ 0.12, 52.39 ]
Total events: 2 (Pyronaridine-Artesunate), 0 (Artemether-Lumefantrine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 6 Serious
adverse events.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 6 Serious adverse events
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 1/355 0/180 19.9 % 1.53 [ 0.06, 37.25 ]
Roth 2018 0/101 0/96 Not estimable
Tshefu 2010 3/849 2/423 80.1 % 0.75 [ 0.13, 4.46 ]
Total (95% CI) 1305 699 100.0 % 0.90 [ 0.19, 4.22 ]
Total events: 4 (Pyronaridine-Artesunate), 2 (Artemether-Lumefantrine)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 7 Adverse
events leading to withdrawal.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 7 Adverse events leading to withdrawal
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 6/355 3/180 30.6 % 1.01 [ 0.26, 4.01 ]
Roth 2018 1/101 1/96 7.9 % 0.95 [ 0.06, 14.98 ]
Tshefu 2010 20/849 6/423 61.5 % 1.66 [ 0.67, 4.10 ]
Total (95% CI) 1305 699 100.0 % 1.41 [ 0.68, 2.90 ]
Total events: 27 (Pyronaridine-Artesunate), 10 (Artemether-Lumefantrine)
Heterogeneity: Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 8 First
treatment, ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 8 First treatment, ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 1/355 1/180 21.7 % 0.51 [ 0.03, 8.06 ]
Roth 2018 0/101 0/96 Not estimable
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 5/212 2/220 32.0 % 2.59 [ 0.51, 13.23 ]
Sagara 2018 (Bougoula, Mali) 2/214 0/213 8.2 % 4.98 [ 0.24, 103.05 ]
Sagara 2018 (Kolle, Mali) 1/86 0/87 8.1 % 3.03 [ 0.13, 73.47 ]
Sagara 2018 (Sotuba, Mali) 3/146 0/145 8.2 % 6.95 [ 0.36, 133.41 ]
Tshefu 2010 7/849 1/423 21.8 % 3.49 [ 0.43, 28.25 ]
Total (95% CI) 1963 1364 100.0 % 2.92 [ 1.15, 7.41 ]
Total events: 19 (Pyronaridine-Artesunate), 4 (Artemether-Lumefantrine)
Heterogeneity: Chi2 = 2.04, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 9 First
treatment, AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 9 First treatment, AST increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 3/355 1/180 20.6 % 1.52 [ 0.16, 14.52 ]
Roth 2018 0/101 0/96 Not estimable
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 2/212 3/220 45.7 % 0.69 [ 0.12, 4.10 ]
Sagara 2018 (Bougoula, Mali) 1/214 1/213 15.6 % 1.00 [ 0.06, 15.81 ]
Sagara 2018 (Kolle, Mali) 0/86 0/87 Not estimable
Sagara 2018 (Sotuba, Mali) 3/146 0/145 7.8 % 6.95 [ 0.36, 133.41 ]
Tshefu 2010 8/849 0/423 10.4 % 8.48 [ 0.49, 146.57 ]
Total (95% CI) 1963 1364 100.0 % 2.20 [ 0.83, 5.82 ]
Total events: 17 (Pyronaridine-Artesunate), 5 (Artemether-Lumefantrine)
Heterogeneity: Chi2 = 3.49, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 10 First
treatment, bilirubin increase > 2.5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 10 First treatment, bilirubin increase > 2.5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 1/355 2/180 25.9 % 0.25 [ 0.02, 2.78 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 2/212 3/220 28.7 % 0.69 [ 0.12, 4.10 ]
Sagara 2018 (Bougoula, Mali) 0/214 1/213 14.6 % 0.33 [ 0.01, 8.10 ]
Sagara 2018 (Kolle, Mali) 0/86 1/87 14.5 % 0.34 [ 0.01, 8.16 ]
Sagara 2018 (Sotuba, Mali) 1/146 1/145 9.8 % 0.99 [ 0.06, 15.73 ]
Tshefu 2010 5/849 0/423 6.5 % 5.49 [ 0.30, 99.00 ]
Total (95% CI) 1862 1268 100.0 % 0.82 [ 0.33, 2.04 ]
Total events: 9 (Pyronaridine-Artesunate), 8 (Artemether-Lumefantrine)
Heterogeneity: Chi2 = 3.24, df = 5 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 11
Subsequent treatment(s), ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 11 Subsequent treatment(s), ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 1/139 0/145 26.3 % 3.13 [ 0.13, 76.16 ]
Sagara 2018 (Bougoula, Mali) 2/166 1/169 47.0 % 2.04 [ 0.19, 22.24 ]
Sagara 2018 (Kolle, Mali) 1/41 0/42 26.7 % 3.07 [ 0.13, 73.29 ]
Sagara 2018 (Sotuba, Mali) 0/77 0/86 Not estimable
Total (95% CI) 423 442 100.0 % 2.54 [ 0.49, 13.10 ]
Total events: 4 (Pyronaridine-Artesunate), 1 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 12
Subsequent treatment(s), AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 12 Subsequent treatment(s), AST increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 1/139 0/145 17.1 % 3.13 [ 0.13, 76.16 ]
Sagara 2018 (Bougoula, Mali) 3/166 1/169 34.4 % 3.05 [ 0.32, 29.07 ]
Sagara 2018 (Kolle, Mali) 2/41 1/42 31.3 % 2.05 [ 0.19, 21.73 ]
Sagara 2018 (Sotuba, Mali) 0/77 1/86 17.2 % 0.37 [ 0.02, 8.99 ]
Total (95% CI) 423 442 100.0 % 1.88 [ 0.50, 7.06 ]
Total events: 6 (Pyronaridine-Artesunate), 3 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 13
Subsequent treatment(s), bilirubin increase > 2.5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 13 Subsequent treatment(s), bilirubin increase > 2.5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) 1/139 3/145 40.0 % 0.35 [ 0.04, 3.30 ]
Sagara 2018 (Bougoula, Mali) 1/166 2/169 36.1 % 0.51 [ 0.05, 5.56 ]
Sagara 2018 (Kolle, Mali) 0/41 0/42 Not estimable
Sagara 2018 (Sotuba, Mali) 2/77 0/86 23.8 % 5.58 [ 0.27, 114.39 ]
Total (95% CI) 423 442 100.0 % 0.77 [ 0.16, 3.63 ]
Total events: 4 (Pyronaridine-Artesunate), 5 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.23; Chi2 = 2.28, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 14
Paediatric trials - total failure: day 28 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 14 Paediatric trials - total failure: day 28 (PCR-adjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 10/339 2/167 58.1 % 2.46 [ 0.55, 11.11 ]
Roth 2018 1/94 3/84 41.9 % 0.30 [ 0.03, 2.81 ]
Total (95% CI) 433 251 100.0 % 1.02 [ 0.13, 7.84 ]
Total events: 11 (Pyronaridine-Artesunate), 5 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 1.28; Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 15
Paediatric trials - total failure: day 42 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 15 Paediatric trials - total failure: day 42 (PCR-adjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 18/275 6/139 59.6 % 1.52 [ 0.62, 3.73 ]
Roth 2018 4/77 6/67 40.4 % 0.58 [ 0.17, 1.97 ]
Total (95% CI) 352 206 100.0 % 1.03 [ 0.41, 2.59 ]
Total events: 22 (Pyronaridine-Artesunate), 12 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.16; Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 16
Paediatric trials - total failure: day 28 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 16 Paediatric trials - total failure: day 28 (unadjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 36/341 23/172 76.4 % 0.79 [ 0.48, 1.29 ]
Roth 2018 8/95 10/85 23.6 % 0.72 [ 0.30, 1.73 ]
Total (95% CI) 436 257 100.0 % 0.77 [ 0.50, 1.18 ]
Total events: 44 (Pyronaridine-Artesunate), 33 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 17
Paediatric trials - total failure: day 42 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 17 Paediatric trials - total failure: day 42 (unadjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayentao 2012 76/325 36/166 70.4 % 1.08 [ 0.76, 1.53 ]
Roth 2018 19/86 21/77 29.6 % 0.81 [ 0.47, 1.39 ]
Total (95% CI) 411 243 100.0 % 0.99 [ 0.74, 1.33 ]
Total events: 95 (Pyronaridine-Artesunate), 57 (Artemether-Lumefantrine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 18
Paediatric trials - first treatment, ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 18 Paediatric trials - first treatment, ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 1/355 1/180 100.0 % 0.51 [ 0.03, 8.06 ]
Roth 2018 0/101 0/96 Not estimable
Total (95% CI) 456 276 100.0 % 0.51 [ 0.03, 8.06 ]
Total events: 1 (Pyronaridine-Artesunate), 1 (Artemether-Lumefantrine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Pyronaridine-artesunate versus artemether-lumefantrine, Outcome 19
Paediatric trials - first treatment, AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Pyronaridine-artesunate versus artemether-lumefantrine
Outcome: 19 Paediatric trials - first treatment, AST increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artemether-
Lumefantrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 3/355 1/180 100.0 % 1.52 [ 0.16, 14.52 ]
Roth 2018 0/101 0/96 Not estimable
Total (95% CI) 456 276 100.0 % 1.52 [ 0.16, 14.52 ]
Total events: 3 (Pyronaridine-Artesunate), 1 (Artemether-Lumefantrine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 1 Total
failure: day 28 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 1 Total failure: day 28 (PCR-adjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sagara 2018 (Bougoula, Mali) 1/87 0/94 25.5 % 3.24 [ 0.13, 78.46 ]
Sagara 2018 (Djoliba, Mali) 0/80 0/77 Not estimable
Sagara 2018 (Kolle, Mali) 0/10 0/10 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 0/223 3/218 29.6 % 0.14 [ 0.01, 2.69 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 1/208 2/205 44.9 % 0.49 [ 0.05, 5.39 ]
Sagara 2018 (Sotuba, Mali) 0/16 0/17 Not estimable
Total (95% CI) 624 621 100.0 % 0.55 [ 0.11, 2.77 ]
Total events: 2 (Pyronaridine-Artesunate), 5 (Artesunate-Amodiaquine)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.03, df = 2 (P = 0.36); I2 =2%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 2 Total
failure: day 42 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 2 Total failure: day 42 (PCR-adjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sagara 2018 (Bougoula, Mali) 0/83 0/88 Not estimable
Sagara 2018 (Djoliba, Mali) 0/73 0/67 Not estimable
Sagara 2018 (Kolle, Mali) 0/10 0/8 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 1/208 1/186 33.2 % 0.89 [ 0.06, 14.20 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 2/165 2/170 66.8 % 1.03 [ 0.15, 7.23 ]
Sagara 2018 (Sotuba, Mali) 0/16 0/17 Not estimable
Total (95% CI) 555 536 100.0 % 0.98 [ 0.20, 4.83 ]
Total events: 3 (Pyronaridine-Artesunate), 3 (Artesunate-Amodiaquine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 3 Total
failure: day 28 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 3 Total failure: day 28 (unadjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sagara 2018 (Bougoula, Mali) 2/87 5/95 9.4 % 0.44 [ 0.09, 2.19 ]
Sagara 2018 (Djoliba, Mali) 3/80 8/79 14.7 % 0.37 [ 0.10, 1.35 ]
Sagara 2018 (Kolle, Mali) 0/10 3/11 3.0 % 0.16 [ 0.01, 2.69 ]
Sagara 2018 (Mafrinyah, Guinea) 3/223 10/218 15.0 % 0.29 [ 0.08, 1.05 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 14/212 21/209 58.0 % 0.66 [ 0.34, 1.26 ]
Sagara 2018 (Sotuba, Mali) 0/16 0/17 Not estimable
Total (95% CI) 628 629 100.0 % 0.49 [ 0.30, 0.81 ]
Total events: 22 (Pyronaridine-Artesunate), 47 (Artesunate-Amodiaquine)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.26, df = 4 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 4 Total
failure: day 42 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 4 Total failure: day 42 (unadjusted)
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sagara 2018 (Bougoula, Mali) 4/87 6/94 3.5 % 0.72 [ 0.21, 2.47 ]
Sagara 2018 (Djoliba, Mali) 11/80 14/79 9.9 % 0.78 [ 0.38, 1.60 ]
Sagara 2018 (Kolle, Mali) 0/10 3/11 0.6 % 0.16 [ 0.01, 2.69 ]
Sagara 2018 (Mafrinyah, Guinea) 35/219 40/208 29.9 % 0.83 [ 0.55, 1.25 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 67/209 57/205 56.1 % 1.15 [ 0.86, 1.55 ]
Sagara 2018 (Sotuba, Mali) 0/16 0/17 Not estimable
Total (95% CI) 621 614 100.0 % 0.98 [ 0.78, 1.23 ]
Total events: 117 (Pyronaridine-Artesunate), 120 (Artesunate-Amodiaquine)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.07, df = 4 (P = 0.40); I2 =2%
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 5 First
treatment, ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 5 First treatment, ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bougoula, Mali) 1/94 0/98 19.6 % 3.13 [ 0.13, 75.80 ]
Sagara 2018 (Djoliba, Mali) 0/87 0/85 Not estimable
Sagara 2018 (Kolle, Mali) 0/11 0/11 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 1/235 1/233 40.2 % 0.99 [ 0.06, 15.76 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 1/215 1/214 40.2 % 1.00 [ 0.06, 15.81 ]
Sagara 2018 (Sotuba, Mali) 0/17 0/17 Not estimable
Total (95% CI) 659 658 100.0 % 1.41 [ 0.28, 7.09 ]
Total events: 3 (Pyronaridine-Artesunate), 2 (Artesunate-Amodiaquine)
Heterogeneity: Chi2 = 0.36, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 6 First
treatment, AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 6 First treatment, AST increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bougoula, Mali) 0/94 1/98 29.5 % 0.35 [ 0.01, 8.42 ]
Sagara 2018 (Djoliba, Mali) 0/87 0/85 Not estimable
Sagara 2018 (Kolle, Mali) 0/11 0/11 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 1/235 2/233 40.3 % 0.50 [ 0.05, 5.43 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 0/215 1/214 30.2 % 0.33 [ 0.01, 8.10 ]
Sagara 2018 (Sotuba, Mali) 0/17 0/17 Not estimable
Total (95% CI) 659 658 100.0 % 0.40 [ 0.08, 2.07 ]
Total events: 1 (Pyronaridine-Artesunate), 4 (Artesunate-Amodiaquine)
Heterogeneity: Chi2 = 0.05, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 7 First
treatment, bilirubin increase > 2.5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 7 First treatment, bilirubin increase > 2.5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bougoula, Mali) 0/94 0/98 Not estimable
Sagara 2018 (Djoliba, Mali) 0/87 0/85 Not estimable
Sagara 2018 (Kolle, Mali) 0/11 0/11 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 1/235 1/233 100.0 % 0.99 [ 0.06, 15.76 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 0/215 0/214 Not estimable
Sagara 2018 (Sotuba, Mali) 0/17 0/17 Not estimable
Total (95% CI) 659 658 100.0 % 0.99 [ 0.06, 15.76 ]
Total events: 1 (Pyronaridine-Artesunate), 1 (Artesunate-Amodiaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 8
Subsequent treatment(s), ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 8 Subsequent treatment(s), ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bougoula, Mali) 1/74 1/79 32.0 % 1.07 [ 0.07, 16.76 ]
Sagara 2018 (Djoliba, Mali) 1/71 1/67 34.0 % 0.94 [ 0.06, 14.79 ]
Sagara 2018 (Kolle, Mali) 0/2 0/6 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 1/79 0/80 16.4 % 3.04 [ 0.13, 73.46 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 2/165 0/145 17.6 % 4.40 [ 0.21, 90.86 ]
Sagara 2018 (Sotuba, Mali) 0/9 0/7 Not estimable
Total (95% CI) 400 384 100.0 % 1.93 [ 0.48, 7.76 ]
Total events: 5 (Pyronaridine-Artesunate), 2 (Artesunate-Amodiaquine)
Heterogeneity: Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 9
Subsequent treatment(s), AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 9 Subsequent treatment(s), AST increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bougoula, Mali) 0/74 1/79 41.2 % 0.36 [ 0.01, 8.59 ]
Sagara 2018 (Djoliba, Mali) 1/71 0/67 14.6 % 2.83 [ 0.12, 68.36 ]
Sagara 2018 (Kolle, Mali) 0/2 0/6 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 2/79 0/80 14.1 % 5.06 [ 0.25, 103.80 ]
Sagara 2018 (Ouagadougou, Burkina Faso) 2/165 1/145 30.2 % 1.76 [ 0.16, 19.18 ]
Sagara 2018 (Sotuba, Mali) 0/9 0/7 Not estimable
Total (95% CI) 400 384 100.0 % 1.80 [ 0.49, 6.62 ]
Total events: 5 (Pyronaridine-Artesunate), 2 (Artesunate-Amodiaquine)
Heterogeneity: Chi2 = 1.52, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Pyronaridine-artesunate versus artesunate-amodiaquine, Outcome 10
Subsequent treatment(s), bilirubin increase > 2.5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Pyronaridine-artesunate versus artesunate-amodiaquine
Outcome: 10 Subsequent treatment(s), bilirubin increase > 2.5 ULN
Study or subgroup
Pyronaridine-
Artesunate
Artesunate-
Amodiaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bougoula, Mali) 0/74 0/79 Not estimable
Sagara 2018 (Djoliba, Mali) 1/71 1/67 49.2 % 0.94 [ 0.06, 14.79 ]
Sagara 2018 (Kolle, Mali) 0/2 0/6 Not estimable
Sagara 2018 (Mafrinyah, Guinea) 0/79 0/80 Not estimable
Sagara 2018 (Ouagadougou, Burkina Faso) 3/165 1/145 50.8 % 2.64 [ 0.28, 25.07 ]
Sagara 2018 (Sotuba, Mali) 0/9 0/7 Not estimable
Total (95% CI) 400 384 100.0 % 1.80 [ 0.33, 9.83 ]
Total events: 4 (Pyronaridine-Artesunate), 2 (Artesunate-Amodiaquine)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 1 Total
failure: day 28 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 1 Total failure: day 28 (PCR-adjusted)
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rueangweerayut 2012 6/749 8/368 100.0 % 0.37 [ 0.13, 1.05 ]
Total (95% CI) 749 368 100.0 % 0.37 [ 0.13, 1.05 ]
Total events: 6 (Pyronaridine-artesunate), 8 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 2 Total
failure: day 42 (PCR-adjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 2 Total failure: day 42 (PCR-adjusted)
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rueangweerayut 2012 37/698 10/339 100.0 % 1.80 [ 0.90, 3.57 ]
Total (95% CI) 698 339 100.0 % 1.80 [ 0.90, 3.57 ]
Total events: 37 (Pyronaridine-artesunate), 10 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 3 Total
failure: day 28 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 3 Total failure: day 28 (unadjusted)
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rueangweerayut 2012 11/750 15/370 100.0 % 0.36 [ 0.17, 0.78 ]
Total (95% CI) 750 370 100.0 % 0.36 [ 0.17, 0.78 ]
Total events: 11 (Pyronaridine-artesunate), 15 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0095)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 4 Total
failure: day 42 (unadjusted).
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 4 Total failure: day 42 (unadjusted)
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rueangweerayut 2012 50/721 28/338 100.0 % 0.84 [ 0.54, 1.31 ]
Total (95% CI) 721 338 100.0 % 0.84 [ 0.54, 1.31 ]
Total events: 50 (Pyronaridine-artesunate), 28 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 5
Serious adverse events.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 5 Serious adverse events
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rueangweerayut 2012 6/848 3/423 100.0 % 1.00 [ 0.25, 3.97 ]
Total (95% CI) 848 423 100.0 % 1.00 [ 0.25, 3.97 ]
Total events: 6 (Pyronaridine-artesunate), 3 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 6
Adverse events leading to withdrawal.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 6 Adverse events leading to withdrawal
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rueangweerayut 2012 5/848 4/423 100.0 % 0.62 [ 0.17, 2.31 ]
Total (95% CI) 848 423 100.0 % 0.62 [ 0.17, 2.31 ]
Total events: 5 (Pyronaridine-artesunate), 4 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 7 First
treatment, ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 7 First treatment, ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rueangweerayut 2012 (1) 15/848 1/423 100.0 % 7.48 [ 0.99, 56.45 ]
Total (95% CI) 848 423 100.0 % 7.48 [ 0.99, 56.45 ]
Total events: 15 (Pyronaridine-artesunate), 1 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
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(1) Control: Mefloquine-Artesunate
Analysis 3.8. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 8 First
treatment, AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 8 First treatment, AST increase > 5 ULN
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rueangweerayut 2012 (1) 9/848 0/423 100.0 % 9.49 [ 0.55, 162.64 ]
Total (95% CI) 848 423 100.0 % 9.49 [ 0.55, 162.64 ]
Total events: 9 (Pyronaridine-artesunate), 0 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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(1) Control: Mefloquine-Artesunate
Analysis 3.9. Comparison 3 Pyronaridine-artesunate versus mefloquine plus artesunate, Outcome 9 First
treatment, bilirubin increase > 2.5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Pyronaridine-artesunate versus mefloquine plus artesunate
Outcome: 9 First treatment, bilirubin increase > 2.5 ULN
Study or subgroup
Pyronaridine-
artesunate
Mefloquine
plusarte-
sunate Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rueangweerayut 2012 (1) 7/848 1/423 100.0 % 3.49 [ 0.43, 28.29 ]
Total (95% CI) 848 423 100.0 % 3.49 [ 0.43, 28.29 ]
Total events: 7 (Pyronaridine-artesunate), 1 (Mefloquine plusartesunate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 1 Serious adverse events.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 1 Serious adverse events
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 (1) 1/355 0/180 6.7 % 1.53 [ 0.06, 37.25 ]
Nelwan 2015 (2) 2/60 3/120 20.3 % 1.33 [ 0.23, 7.77 ]
Poravuth 2011 (3) 2/228 0/228 5.1 % 5.00 [ 0.24, 103.57 ]
Roth 2018 (4) 0/101 0/96 Not estimable
Rueangweerayut 2012 (5) 6/848 3/423 40.7 % 1.00 [ 0.25, 3.97 ]
Shin 2011 (6) 0/15 0/15 Not estimable
Tshefu 2010 (7) 3/849 2/423 27.1 % 0.75 [ 0.13, 4.46 ]
Total (95% CI) 2456 1485 100.0 % 1.24 [ 0.54, 2.84 ]
Total events: 14 (Pyronaridine-Artesunate), 8 (Control)
Heterogeneity: Chi2 = 1.24, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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(1) Control: Artemether-Lumefantrine.
(2) Controls: Artesunate alone, Dihydroartemisinin-piperaquine (P vivax)
(3) Control: Chloroquine (p vivax)
(4) Control: Artemether-Lumefantrine.
(5) Control: Mefloquine plus artesunate
(6) Control: Chloroquine
(7) Control: Artemether-Lumefantrine
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Analysis 4.2. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 2 Adverse events leading to withdrawal.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 2 Adverse events leading to withdrawal
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 (1) 6/355 3/180 19.1 % 1.01 [ 0.26, 4.01 ]
Nelwan 2015 (2) 0/60 0/120 Not estimable
Poravuth 2011 (3) 0/228 2/228 12.0 % 0.20 [ 0.01, 4.14 ]
Roth 2018 (4) 1/101 1/96 4.9 % 0.95 [ 0.06, 14.98 ]
Rueangweerayut 2012 (5) 5/848 4/423 25.6 % 0.62 [ 0.17, 2.31 ]
Tshefu 2010 (6) 20/849 6/423 38.4 % 1.66 [ 0.67, 4.10 ]
Total (95% CI) 2441 1470 100.0 % 1.06 [ 0.58, 1.94 ]
Total events: 32 (Pyronaridine-Artesunate), 16 (Control)
Heterogeneity: Chi2 = 2.75, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.85)
Test for subgroup differences: Not applicable
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(1) Control: Artemether-Lumefantrine.
(2) Controls: Artesunate alone, Dihydroartemisinin-piperaquine (P vivax)
(3) Control: Chloroquine (p vivax)
(4) Control: Artemether-Lumefantrine.
(5) Control: Mefloquine plus artesunate
(6) Control: Artemether-Lumefantrine
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Analysis 4.3. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 3 First treatment, ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 3 First treatment, ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 (1) 1/355 1/180 12.7 % 0.51 [ 0.03, 8.06 ]
Nelwan 2015 (2) 0/60 0/120 Not estimable
Poravuth 2011 (3) 3/228 0/228 4.8 % 7.00 [ 0.36, 134.75 ]
Roth 2018 (4) 0/101 0/96 Not estimable
Rueangweerayut 2012 (5) 15/848 1/423 12.8 % 7.48 [ 0.99, 56.45 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (6) 5/212 2/220 18.8 % 2.59 [ 0.51, 13.23 ]
Sagara 2018 (Bougoula, Mali) (7) 2/214 0/213 4.8 % 4.98 [ 0.24, 103.05 ]
Sagara 2018 (Bougoula, Mali) (8) 1/94 0/98 4.7 % 3.13 [ 0.13, 75.80 ]
Sagara 2018 (Djoliba, Mali) (9) 0/87 0/85 Not estimable
Sagara 2018 (Kolle, Mali) (10) 1/86 0/87 4.8 % 3.03 [ 0.13, 73.47 ]
Sagara 2018 (Kolle, Mali) (11) 0/11 0/11 Not estimable
Sagara 2018 (Mafrinyah, Guinea) (12) 1/235 1/233 9.6 % 0.99 [ 0.06, 15.76 ]
Sagara 2018 (Ouagadougou, Burkina Faso) (13) 1/215 1/214 9.6 % 1.00 [ 0.06, 15.81 ]
Sagara 2018 (Sotuba, Mali) (14) 0/17 0/17 Not estimable
Sagara 2018 (Sotuba, Mali) (15) 3/146 0/145 4.8 % 6.95 [ 0.36, 133.41 ]
Shin 2011 (16) 0/15 0/15 Not estimable
Tshefu 2010 (17) 7/849 1/423 12.8 % 3.49 [ 0.43, 28.25 ]
Total (95% CI) 3773 2808 100.0 % 3.34 [ 1.63, 6.84 ]
Total events: 40 (Pyronaridine-Artesunate), 7 (Control)
Heterogeneity: Chi2 = 4.52, df = 10 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00097)
Test for subgroup differences: Not applicable
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(1) Control: artemether-lumefantrine
(2) Controls: artesunate alone, dihydroartemisinin-piperaquine (P vivax)
(3) Control: chloroquine (P vivax)
(4) Control: artemether-lumefantrine
(5) Control: Mefloquine plus artesunate
(6) Control: artemether-lumefantrine
(7) Control: artemether-lumefantrine
(8) Control: artesunate-amodiaquine
(9) Control: artesunate-amodiaquine
(10) Control: artemether-lumefantrine
(11) Control: artesunate-amodiaquine
(12) Control: artesunate-amodiaquine
(13) Control: artesunate-amodiaquine
(14) Control: artesunate-amodiaquine
(15) Control: artemether-lumefantrine
(16) Control: chloroquine
(17) Control: artemether-lumefantrine
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Analysis 4.4. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 4 First treatment, AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 4 First treatment, AST increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 (1) 3/355 1/180 10.1 % 1.52 [ 0.16, 14.52 ]
Nelwan 2015 (2) 0/60 0/120 Not estimable
Poravuth 2011 (3) 1/228 1/228 7.6 % 1.00 [ 0.06, 15.89 ]
Roth 2018 (4) 0/101 0/96 Not estimable
Rueangweerayut 2012 (5) 9/848 0/423 5.1 % 9.49 [ 0.55, 162.64 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (6) 2/212 3/220 22.5 % 0.69 [ 0.12, 4.10 ]
Sagara 2018 (Bougoula, Mali) (7) 0/94 1/98 11.2 % 0.35 [ 0.01, 8.42 ]
Sagara 2018 (Bougoula, Mali) (8) 1/214 1/213 7.7 % 1.00 [ 0.06, 15.81 ]
Sagara 2018 (Djoliba, Mali) (9) 0/87 0/85 Not estimable
Sagara 2018 (Kolle, Mali) (10) 0/86 0/87 Not estimable
Sagara 2018 (Kolle, Mali) (11) 0/11 0/11 Not estimable
Sagara 2018 (Mafrinyah, Guinea) (12) 1/235 2/233 15.3 % 0.50 [ 0.05, 5.43 ]
Sagara 2018 (Ouagadougou, Burkina Faso) (13) 0/215 1/214 11.5 % 0.33 [ 0.01, 8.10 ]
Sagara 2018 (Sotuba, Mali) (14) 0/17 0/17 Not estimable
Sagara 2018 (Sotuba, Mali) (15) 3/146 0/145 3.8 % 6.95 [ 0.36, 133.41 ]
Shin 2011 (16) 0/15 0/15 Not estimable
Tshefu 2010 (17) 8/849 0/423 5.1 % 8.48 [ 0.49, 146.57 ]
Total (95% CI) 3773 2808 100.0 % 1.80 [ 0.89, 3.65 ]
Total events: 28 (Pyronaridine-Artesunate), 10 (Control)
Heterogeneity: Chi2 = 7.94, df = 9 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Not applicable
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(1) Control: Artemether-Lumefantrine
(2) Controls: Artesunate alone, Dihydroartemisinin-piperaquine (P vivax)
(3) Control: Chloroquine (p vivax)
(4) Control: Artemether-Lumefantrine.
(5) Control: Mefloquine plus artesunate
(6) Control: Artemether-Lumefantrine
(7) Control: Artesunate-Amodiaquine
(8) Control: Artemether-Lumefantrine
(9) Control: Artesunate-Amodiaquine
(10) Control: Artesunate-Lumefantrine
(11) Control: Artesunate-Amodiaquine
(12) Control: Artesunate-Amodiaquine
(13) Control: Artesunate-Amodiaquine
(14) Control: Artesunate-Amodiaquine
(15) Control: Artemether-Lumefantrine
(16) Control: chloroquine
(17) Control: Artemether-Lumefantrine
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Analysis 4.5. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 5 First treatment, bilirubin increase > 2.5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 5 First treatment, bilirubin increase > 2.5 ULN
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kayentao 2012 (1) 1/355 2/180 18.8 % 0.25 [ 0.02, 2.78 ]
Nelwan 2015 (2) 0/60 0/120 Not estimable
Poravuth 2011 (3) 0/228 1/228 10.6 % 0.33 [ 0.01, 8.14 ]
Rueangweerayut 2012 (4) 7/848 1/423 9.5 % 3.49 [ 0.43, 28.29 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (5) 2/212 3/220 20.9 % 0.69 [ 0.12, 4.10 ]
Sagara 2018 (Bougoula, Mali) (6) 0/94 0/98 Not estimable
Sagara 2018 (Bougoula, Mali) (7) 0/214 1/213 10.7 % 0.33 [ 0.01, 8.10 ]
Sagara 2018 (Djoliba, Mali) (8) 0/87 0/85 Not estimable
Sagara 2018 (Kolle, Mali) (9) 0/11 0/11 Not estimable
Sagara 2018 (Kolle, Mali) (10) 0/86 1/87 10.6 % 0.34 [ 0.01, 8.16 ]
Sagara 2018 (Mafrinyah, Guinea) (11) 1/235 1/233 7.1 % 0.99 [ 0.06, 15.76 ]
Sagara 2018 (Ouagadougou, Burkina Faso) (12) 0/215 0/214 Not estimable
Sagara 2018 (Sotuba, Mali) (13) 0/17 0/17 Not estimable
Sagara 2018 (Sotuba, Mali) (14) 1/146 1/145 7.1 % 0.99 [ 0.06, 15.73 ]
Shin 2011 (15) 0/15 0/15 Not estimable
Tshefu 2010 (16) 5/849 0/423 4.7 % 5.49 [ 0.30, 99.00 ]
Total (95% CI) 3672 2712 100.0 % 1.03 [ 0.49, 2.18 ]
Total events: 17 (Pyronaridine-Artesunate), 11 (Control)
Heterogeneity: Chi2 = 5.54, df = 8 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PY-AS Favours control
111Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(1) Control: Artemether-Lumefantrine
(2) Controls: Artesunate alone, Dihydroartemisinin-piperaquine (P vivax)
(3) Control: Chloroquine (p vivax)
(4) Control: Mefloquine plus artesunate
(5) Control: Artemether-Lumefantrine
(6) Control: Artesunate-Amodiaquine
(7) Control: Artemether-Lumefantrine
(8) Control: Artesunate-Amodiaquine
(9) Control: Artesunate-Amodiaquine
(10) Control: Artesunate-Lumefantrine
(11) Control: Artesunate-Amodiaquine
(12) Control: Artesunate-Amodiaquine
(13) Control: Artesunate-Amodiaquine
(14) Control: Artemether-Lumefantrine
(15) Control: chloroquine
(16) Control: Artemether-Lumefantrine
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Analysis 4.6. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 6 Subsequent treatment(s), ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 6 Subsequent treatment(s), ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (1) 1/139 0/145 9.8 % 3.13 [ 0.13, 76.16 ]
Sagara 2018 (Bougoula, Mali) (2) 2/166 1/169 19.8 % 2.04 [ 0.19, 22.24 ]
Sagara 2018 (Bougoula, Mali) (3) 1/74 1/79 19.3 % 1.07 [ 0.07, 16.76 ]
Sagara 2018 (Djoliba, Mali) (4) 1/71 1/67 20.6 % 0.94 [ 0.06, 14.79 ]
Sagara 2018 (Kolle, Mali) (5) 1/41 0/42 9.9 % 3.07 [ 0.13, 73.29 ]
Sagara 2018 (Kolle, Mali) (6) 0/2 0/6 Not estimable
Sagara 2018 (Mafrinyah, Guinea) (7) 1/79 0/80 9.9 % 3.04 [ 0.13, 73.46 ]
Sagara 2018 (Ouagadougou, Burkina Faso) (8) 2/165 0/145 10.6 % 4.40 [ 0.21, 90.86 ]
Sagara 2018 (Sotuba, Mali) (9) 0/77 0/86 Not estimable
Sagara 2018 (Sotuba, Mali) (10) 0/9 0/7 Not estimable
Total (95% CI) 823 826 100.0 % 2.18 [ 0.76, 6.27 ]
Total events: 9 (Pyronaridine-Artesunate), 3 (Control)
Heterogeneity: Chi2 = 0.96, df = 6 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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(1) Control: Artemether-Lumefantrine
(2) Control: Artemether-Lumefantrine
(3) Control: Artesunate-Amodiaquine
(4) Control: Artesunate-Amodiaquine
(5) Control: Artemether-Lumefantrine
(6) Control: Artesunate-Amodiaquine
(7) Control: Artesunate-Amodiaquine
(8) Control: Artesunate-Amodiaquine
(9) Control: Artemether-Lumefantrine
(10) Control: Artesunate-Amodiaquine
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Analysis 4.7. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 7 Subsequent treatment(s), AST increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 7 Subsequent treatment(s), AST increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (1) 1/139 0/145 6.6 % 3.13 [ 0.13, 76.16 ]
Sagara 2018 (Bougoula, Mali) (2) 3/166 1/169 13.4 % 3.05 [ 0.32, 29.07 ]
Sagara 2018 (Bougoula, Mali) (3) 0/74 1/79 19.6 % 0.36 [ 0.01, 8.59 ]
Sagara 2018 (Djoliba, Mali) (4) 1/71 0/67 6.9 % 2.83 [ 0.12, 68.36 ]
Sagara 2018 (Kolle, Mali) (5) 2/41 1/42 13.3 % 2.05 [ 0.19, 21.73 ]
Sagara 2018 (Kolle, Mali) (6) 0/2 0/6 Not estimable
Sagara 2018 (Mafrinyah, Guinea) (7) 2/79 0/80 6.7 % 5.06 [ 0.25, 103.80 ]
Sagara 2018 (Ouagadougou, Burkina Faso) (8) 2/165 1/145 14.4 % 1.76 [ 0.16, 19.18 ]
Sagara 2018 (Sotuba, Mali) (9) 0/77 1/86 19.1 % 0.37 [ 0.02, 8.99 ]
Sagara 2018 (Sotuba, Mali) (10) 0/9 0/7 Not estimable
Total (95% CI) 823 826 100.0 % 1.82 [ 0.74, 4.44 ]
Total events: 11 (Pyronaridine-Artesunate), 5 (Control)
Heterogeneity: Chi2 = 2.80, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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(1) Control: Artemether-Lumefantrine
(2) Control: Artemether-Lumefantrine
(3) Control: Artesunate-Amodiaquine
(4) Control: Artesunate-Amodiaquine
(5) Control: Artemether-Lumefantrine
(6) Control: Artesunate-Amodiaquine
(7) Control: Artesunate-Amodiaquine
(8) Control: Artesunate-Amodiaquine
(9) Control: Artemether-Lumefantrine
(10) Control: Artesunate-Amodiaquine
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Analysis 4.8. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 8 Subsequent treatment(s), bilirubin increase > 2.5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 8 Subsequent treatment(s), bilirubin increase > 2.5 ULN
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (1) 1/139 3/145 39.2 % 0.35 [ 0.04, 3.30 ]
Sagara 2018 (Bougoula, Mali) (2) 1/166 2/169 26.5 % 0.51 [ 0.05, 5.56 ]
Sagara 2018 (Bougoula, Mali) (3) 0/74 0/79 Not estimable
Sagara 2018 (Djoliba, Mali) (4) 1/71 1/67 13.7 % 0.94 [ 0.06, 14.79 ]
Sagara 2018 (Kolle, Mali) (5) 0/41 0/42 Not estimable
Sagara 2018 (Kolle, Mali) (6) 0/2 0/6 Not estimable
Sagara 2018 (Mafrinyah, Guinea) (7) 0/79 0/80 Not estimable
Sagara 2018 (Ouagadougou, Burkina Faso) (8) 3/165 1/145 14.2 % 2.64 [ 0.28, 25.07 ]
Sagara 2018 (Sotuba, Mali) (9) 2/77 0/86 6.3 % 5.58 [ 0.27, 114.39 ]
Sagara 2018 (Sotuba, Mali) (10) 0/9 0/7 Not estimable
Total (95% CI) 823 826 100.0 % 1.13 [ 0.42, 3.01 ]
Total events: 8 (Pyronaridine-Artesunate), 7 (Control)
Heterogeneity: Chi2 = 3.11, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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(2) Control: Artemether-Lumefantrine
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(4) Control: Artesunate-Amodiaquine
(5) Control: Artemether-Lumefantrine
(6) Control: Artesunate-Amodiaquine
(7) Control: Artesunate-Amodiaquine
(8) Control: Artesunate-Amodiaquine
(9) Control: Artemether-Lumefantrine
(10) Control: Artesunate-Amodiaquine
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Analysis 4.9. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 9 Sensitivity analysis: first treatment, ALT increase > 5 × ULN.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 9 Sensitivity analysis: first treatment, ALT increase > 5 ULN
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poravuth 2011 (1) 3/228 0/228 6.1 % 7.00 [ 0.36, 134.75 ]
Rueangweerayut 2012 (2) 15/848 1/423 16.4 % 7.48 [ 0.99, 56.45 ]
Sagara 2018 (Bobo-Doiulasso, Burkina Faso) (3) 5/222 2/224 24.4 % 2.52 [ 0.49, 12.87 ]
Sagara 2018 (Bougoula, Mali) (4) 2/214 0/213 6.1 % 4.98 [ 0.24, 103.05 ]
Sagara 2018 (Bougoula, Mali) (5) 1/94 0/98 6.0 % 3.13 [ 0.13, 75.80 ]
Sagara 2018 (Djoliba, Mali) (6) 0/87 0/85 Not estimable
Sagara 2018 (Kolle, Mali) (7) 1/86 0/87 6.1 % 3.03 [ 0.13, 73.47 ]
Sagara 2018 (Kolle, Mali) (8) 0/11 0/11 Not estimable
Sagara 2018 (Mafrinyah, Guinea) (9) 1/235 1/233 12.3 % 0.99 [ 0.06, 15.76 ]
Sagara 2018 (Ouagadougou, Burkina Faso) (10) 0/224 0/224 Not estimable
Sagara 2018 (Sotuba, Mali) (11) 0/17 0/17 Not estimable
Sagara 2018 (Sotuba, Mali) (12) 3/146 0/145 6.2 % 6.95 [ 0.36, 133.41 ]
Tshefu 2010 (13) 7/849 1/423 16.4 % 3.49 [ 0.43, 28.25 ]
Total (95% CI) 3261 2411 100.0 % 4.07 [ 1.83, 9.05 ]
Total events: 38 (Pyronaridine-Artesunate), 5 (Control)
Heterogeneity: Chi2 = 2.03, df = 8 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.44 (P = 0.00058)
Test for subgroup differences: Not applicable
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(1) Control: Chloroquine (p vivax)
(2) Control: Mefloquine plus artesunate
(3) Control: Artemether-Lumefantrine
(4) Control: Artemether-Lumefantrine
(5) Control: Artesunate-Amodiaquine
(6) Control: Artesunate-Amodiaquine
(7) Control: Artemether-Lumefantrine
(8) Control: Artesunate-Amodiaquine
(9) Control: Artesunate-Amodiaquine
(10) Control: Artesunate-Amodiaquine
(11) Control: Artesunate-Amodiaquine
(12) Control: Artemether-Lumefantrine
(13) Control: Artemether-Lumefantrine
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Analysis 4.10. Comparison 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes
(safety outcomes only), Outcome 10 Other adverse events.
Review: Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Pyronaridine-artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)
Outcome: 10 Other adverse events
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Blood and lymphatic: anaemias
Kayentao 2012 34/355 14/180 23.0 % 1.23 [ 0.68, 2.23 ]
Rueangweerayut 2012 31/848 14/423 23.1 % 1.10 [ 0.59, 2.05 ]
Sagara 2018 (1) 15/669 8/668 9.9 % 1.87 [ 0.80, 4.39 ]
Sagara 2018 (2) 33/673 35/671 43.4 % 0.94 [ 0.59, 1.49 ]
Shin 2011 1/15 0/15 0.6 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 2560 1957 100.0 % 1.15 [ 0.86, 1.54 ]
Total events: 114 (Pyronaridine-Artesunate), 71 (Control)
Heterogeneity: Chi2 = 2.41, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Blood and lymphatic: eosinophilic disorders
Rueangweerayut 2012 20/848 5/423 16.1 % 2.00 [ 0.75, 5.28 ]
Tshefu 2010 60/849 26/423 83.9 % 1.15 [ 0.74, 1.79 ]
Subtotal (95% CI) 1697 846 100.0 % 1.29 [ 0.86, 1.93 ]
Total events: 80 (Pyronaridine-Artesunate), 31 (Control)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 1.22 (P = 0.22)
3 Blood and lymphatic: leukocytoses
Rueangweerayut 2012 8/848 9/423 50.0 % 0.44 [ 0.17, 1.14 ]
Sagara 2018 (3) 13/673 12/671 50.0 % 1.08 [ 0.50, 2.35 ]
Subtotal (95% CI) 1521 1094 100.0 % 0.76 [ 0.42, 1.37 ]
Total events: 21 (Pyronaridine-Artesunate), 21 (Control)
Heterogeneity: Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.91 (P = 0.36)
4 Blood and lymphatic: neutropaenias
Sagara 2018 56/673 64/671 64.0 % 0.87 [ 0.62, 1.23 ]
Tshefu 2010 41/849 27/423 36.0 % 0.76 [ 0.47, 1.21 ]
Subtotal (95% CI) 1522 1094 100.0 % 0.83 [ 0.63, 1.10 ]
Total events: 97 (Pyronaridine-Artesunate), 91 (Control)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
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(. . . Continued)
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.31 (P = 0.19)
5 Cardiac: cardiac arrhythmias
Nelwan 2015 1/60 0/120 100.0 % 5.95 [ 0.25, 143.93 ]
Subtotal (95% CI) 60 120 100.0 % 5.95 [ 0.25, 143.93 ]
Total events: 1 (Pyronaridine-Artesunate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
6 Cardiac: cardiac signs and symptoms
Poravuth 2011 3/228 6/228 12.8 % 0.50 [ 0.13, 1.97 ]
Ringwald 1996 (4) 2/47 2/49 4.2 % 1.04 [ 0.15, 7.10 ]
Ringwald 1998 (5) 3/44 1/44 2.1 % 3.00 [ 0.32, 27.74 ]
Roth 2018 1/101 0/96 1.1 % 2.85 [ 0.12, 69.19 ]
Rueangweerayut 2012 26/848 28/423 79.8 % 0.46 [ 0.28, 0.78 ]
Subtotal (95% CI) 1268 840 100.0 % 0.57 [ 0.37, 0.89 ]
Total events: 35 (Pyronaridine-Artesunate), 37 (Control)
Heterogeneity: Chi2 = 4.15, df = 4 (P = 0.39); I2 =4%
Test for overall effect: Z = 2.47 (P = 0.014)
7 Cardiac: myocardial disorders
Shin 2011 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
8 Ear: ear disorders
Roth 2018 0/101 1/96 100.0 % 0.32 [ 0.01, 7.69 ]
Subtotal (95% CI) 101 96 100.0 % 0.32 [ 0.01, 7.69 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
9 Gastrointestinal: diarrhoea (excl infective)
Ringwald 1996 (6) 10/47 1/49 13.8 % 10.43 [ 1.39, 78.30 ]
Ringwald 1998 (7) 5/44 1/44 14.1 % 5.00 [ 0.61, 41.08 ]
Roth 2018 2/101 4/96 57.9 % 0.48 [ 0.09, 2.54 ]
Shin 2011 1/15 1/15 14.1 % 1.00 [ 0.07, 14.55 ]
Subtotal (95% CI) 207 204 100.0 % 2.56 [ 1.10, 5.99 ]
Total events: 18 (Pyronaridine-Artesunate), 7 (Control)
Heterogeneity: Chi2 = 6.61, df = 3 (P = 0.09); I2 =55%
Test for overall effect: Z = 2.18 (P = 0.029)
10 Gastrointestinal: dyspeptic signs and symptoms
0.01 0.1 1 10 100
Favours PY-AS Favours control
(Continued . . . )
119Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(. . . Continued)
Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shin 2011 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Pyronaridine-Artesunate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
11 Gastrointestinal: GI and abdominal pains
Nelwan 2015 1/60 0/120 0.3 % 5.95 [ 0.25, 143.93 ]
Ringwald 1996 (8) 13/47 2/49 1.8 % 6.78 [ 1.62, 28.43 ]
Ringwald 1998 (9) 9/44 5/44 4.7 % 1.80 [ 0.66, 4.94 ]
Roth 2018 3/101 6/96 5.8 % 0.48 [ 0.12, 1.85 ]
Sagara 2018 (10) 35/669 37/668 34.7 % 0.94 [ 0.60, 1.48 ]
Sagara 2018 (11) 23/673 25/671 23.5 % 0.92 [ 0.53, 1.60 ]
Shin 2011 1/15 0/15 0.5 % 3.00 [ 0.13, 68.26 ]
Tshefu 2010 50/849 23/423 28.8 % 1.08 [ 0.67, 1.75 ]
Subtotal (95% CI) 2458 2086 100.0 % 1.12 [ 0.87, 1.45 ]
Total events: 135 (Pyronaridine-Artesunate), 98 (Control)
Heterogeneity: Chi2 = 10.95, df = 7 (P = 0.14); I2 =36%
Test for overall effect: Z = 0.90 (P = 0.37)
12 Gastrointestinal: nausea and vomiting symptoms
Kayentao 2012 25/355 8/180 8.6 % 1.58 [ 0.73, 3.44 ]
Nelwan 2015 2/60 4/120 2.2 % 1.00 [ 0.19, 5.31 ]
Poravuth 2011 2/228 7/228 5.7 % 0.29 [ 0.06, 1.36 ]
Ringwald 1996 (12) 4/47 5/49 4.0 % 0.83 [ 0.24, 2.92 ]
Ringwald 1998 (13) 3/44 4/44 3.3 % 0.75 [ 0.18, 3.16 ]
Roth 2018 10/101 5/96 4.2 % 1.90 [ 0.67, 5.36 ]
Rueangweerayut 2012 18/848 9/423 9.8 % 1.00 [ 0.45, 2.20 ]
Sagara 2018 (14) 23/673 17/671 13.9 % 1.35 [ 0.73, 2.50 ]
Sagara 2018 (15) 38/669 58/668 47.2 % 0.65 [ 0.44, 0.97 ]
Shin 2011 0/15 1/15 1.2 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 3040 2494 100.0 % 0.91 [ 0.71, 1.17 ]
Total events: 125 (Pyronaridine-Artesunate), 118 (Control)
Heterogeneity: Chi2 = 10.81, df = 9 (P = 0.29); I2 =17%
Test for overall effect: Z = 0.74 (P = 0.46)
13 General: asthenic conditions
Poravuth 2011 12/228 11/228 91.5 % 1.09 [ 0.49, 2.42 ]
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Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Roth 2018 4/101 1/96 8.5 % 3.80 [ 0.43, 33.41 ]
Subtotal (95% CI) 329 324 100.0 % 1.32 [ 0.64, 2.75 ]
Total events: 16 (Pyronaridine-Artesunate), 12 (Control)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.75 (P = 0.46)
14 General: general signs and symptoms
Kayentao 2012 19/355 8/180 100.0 % 1.20 [ 0.54, 2.70 ]
Subtotal (95% CI) 355 180 100.0 % 1.20 [ 0.54, 2.70 ]
Total events: 19 (Pyronaridine-Artesunate), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
15 General: feelings and sensations
Roth 2018 2/101 0/96 100.0 % 4.75 [ 0.23, 97.79 ]
Subtotal (95% CI) 101 96 100.0 % 4.75 [ 0.23, 97.79 ]
Total events: 2 (Pyronaridine-Artesunate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
16 General: febrile disorders
Kayentao 2012 23/355 8/180 91.3 % 1.46 [ 0.67, 3.19 ]
Nelwan 2015 0/60 1/120 8.7 % 0.66 [ 0.03, 15.99 ]
Subtotal (95% CI) 415 300 100.0 % 1.39 [ 0.65, 2.96 ]
Total events: 23 (Pyronaridine-Artesunate), 9 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
17 General: pain and discomfort
Roth 2018 0/101 2/96 100.0 % 0.19 [ 0.01, 3.91 ]
Subtotal (95% CI) 101 96 100.0 % 0.19 [ 0.01, 3.91 ]
Total events: 0 (Pyronaridine-Artesunate), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
18 Infections and infestations: eye and eyelid
Shin 2011 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Pyronaridine-Artesunate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
19 Infections and infestations: LRTI and lung
Kayentao 2012 28/355 10/180 4.4 % 1.42 [ 0.71, 2.86 ]
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Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sagara 2018 (16) 156/669 142/668 47.1 % 1.10 [ 0.90, 1.34 ]
Sagara 2018 (17) 115/673 146/671 48.5 % 0.79 [ 0.63, 0.98 ]
Subtotal (95% CI) 1697 1519 100.0 % 0.96 [ 0.83, 1.11 ]
Total events: 299 (Pyronaridine-Artesunate), 298 (Control)
Heterogeneity: Chi2 = 6.11, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.55 (P = 0.58)
20 Infections and infestations: URTI
Kayentao 2012 42/355 19/180 9.5 % 1.12 [ 0.67, 1.87 ]
Nelwan 2015 1/60 0/120 0.1 % 5.95 [ 0.25, 143.93 ]
Poravuth 2011 13/228 6/228 2.3 % 2.17 [ 0.84, 5.60 ]
Roth 2018 3/101 4/96 1.5 % 0.71 [ 0.16, 3.10 ]
Rueangweerayut 2012 21/848 11/423 5.5 % 0.95 [ 0.46, 1.96 ]
Sagara 2018 (18) 112/669 110/668 41.5 % 1.02 [ 0.80, 1.29 ]
Sagara 2018 (19) 100/673 103/671 38.9 % 0.97 [ 0.75, 1.25 ]
Shin 2011 0/15 1/15 0.6 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 2949 2401 100.0 % 1.03 [ 0.88, 1.20 ]
Total events: 292 (Pyronaridine-Artesunate), 254 (Control)
Heterogeneity: Chi2 = 4.65, df = 7 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
21 Investigations: ECG
Nelwan 2015 0/60 1/120 0.5 % 0.66 [ 0.03, 15.99 ]
Poravuth 2011 1/228 6/228 3.0 % 0.17 [ 0.02, 1.37 ]
Sagara 2018 (20) 34/669 91/668 45.8 % 0.37 [ 0.26, 0.55 ]
Sagara 2018 (21) 55/673 99/671 49.9 % 0.55 [ 0.41, 0.76 ]
Shin 2011 0/15 1/15 0.8 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 1645 1702 100.0 % 0.46 [ 0.36, 0.58 ]
Total events: 90 (Pyronaridine-Artesunate), 198 (Control)
Heterogeneity: Chi2 = 3.53, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 6.46 (P < 0.00001)
22 Investigations: skeletal/cardiac muscle analyses
Nelwan 2015 1/60 0/120 4.0 % 5.95 [ 0.25, 143.93 ]
Poravuth 2011 9/228 8/228 96.0 % 1.13 [ 0.44, 2.86 ]
Subtotal (95% CI) 288 348 100.0 % 1.32 [ 0.55, 3.15 ]
Total events: 10 (Pyronaridine-Artesunate), 8 (Control)
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
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Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
23 Investigations: physical exam
Shin 2011 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
24 Investigations: platelet
Kayentao 2012 33/355 19/180 98.1 % 0.88 [ 0.52, 1.50 ]
Shin 2011 1/15 0/15 1.9 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 370 195 100.0 % 0.92 [ 0.55, 1.56 ]
Total events: 34 (Pyronaridine-Artesunate), 19 (Control)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
25 Investigations: protein
Kayentao 2012 21/355 16/180 100.0 % 0.67 [ 0.36, 1.24 ]
Subtotal (95% CI) 355 180 100.0 % 0.67 [ 0.36, 1.24 ]
Total events: 21 (Pyronaridine-Artesunate), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
26 Metabolism and nutrition: appetite disorders
Poravuth 2011 19/228 10/228 60.1 % 1.90 [ 0.90, 4.00 ]
Roth 2018 4/101 6/96 36.9 % 0.63 [ 0.18, 2.18 ]
Shin 2011 1/15 0/15 3.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 344 339 100.0 % 1.47 [ 0.80, 2.68 ]
Total events: 24 (Pyronaridine-Artesunate), 16 (Control)
Heterogeneity: Chi2 = 2.44, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 1.24 (P = 0.22)
27 Metabolism and nutrition: hypoglycaemia conditions
Kayentao 2012 32/355 19/180 100.0 % 0.85 [ 0.50, 1.46 ]
Subtotal (95% CI) 355 180 100.0 % 0.85 [ 0.50, 1.46 ]
Total events: 32 (Pyronaridine-Artesunate), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
28 Metabolism and nutrition: metabolic disorders
Sagara 2018 (22) 1/669 2/668 3.8 % 0.50 [ 0.05, 5.49 ]
Sagara 2018 (23) 46/673 51/671 96.2 % 0.90 [ 0.61, 1.32 ]
Subtotal (95% CI) 1342 1339 100.0 % 0.88 [ 0.61, 1.29 ]
Total events: 47 (Pyronaridine-Artesunate), 53 (Control)
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Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
29 MSK and connective tissue: muscle pains
Poravuth 2011 30/228 21/228 44.3 % 1.43 [ 0.84, 2.42 ]
Roth 2018 1/101 1/96 2.2 % 0.95 [ 0.06, 14.98 ]
Rueangweerayut 2012 53/848 19/423 53.5 % 1.39 [ 0.83, 2.32 ]
Subtotal (95% CI) 1177 747 100.0 % 1.40 [ 0.97, 2.01 ]
Total events: 84 (Pyronaridine-Artesunate), 41 (Control)
Heterogeneity: Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.071)
30 MSK and connective tissue: pain and discomfort
Roth 2018 0/101 1/96 100.0 % 0.32 [ 0.01, 7.69 ]
Subtotal (95% CI) 101 96 100.0 % 0.32 [ 0.01, 7.69 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
31 Nervous system: headaches
Nelwan 2015 0/60 1/120 0.5 % 0.66 [ 0.03, 15.99 ]
Poravuth 2011 45/228 34/228 18.2 % 1.32 [ 0.88, 1.99 ]
Ringwald 1996 (24) 2/47 0/49 0.3 % 5.21 [ 0.26, 105.71 ]
Ringwald 1998 (25) 4/44 1/44 0.5 % 4.00 [ 0.47, 34.38 ]
Roth 2018 10/101 10/96 5.5 % 0.95 [ 0.41, 2.18 ]
Rueangweerayut 2012 101/848 44/423 31.4 % 1.15 [ 0.82, 1.60 ]
Sagara 2018 (26) 15/669 14/668 7.5 % 1.07 [ 0.52, 2.20 ]
Sagara 2018 (27) 9/673 12/671 6.4 % 0.75 [ 0.32, 1.76 ]
Shin 2011 4/15 1/15 0.5 % 4.00 [ 0.50, 31.74 ]
Tshefu 2010 71/849 41/423 29.2 % 0.86 [ 0.60, 1.24 ]
Subtotal (95% CI) 3534 2737 100.0 % 1.09 [ 0.90, 1.32 ]
Total events: 261 (Pyronaridine-Artesunate), 158 (Control)
Heterogeneity: Chi2 = 7.43, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
32 Nervous system: sleep disturbance
Nelwan 2015 0/60 1/120 100.0 % 0.66 [ 0.03, 15.99 ]
Subtotal (95% CI) 60 120 100.0 % 0.66 [ 0.03, 15.99 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
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Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.25 (P = 0.80)
33 Nervous system: paraesthesias and dysasthesias
Shin 2011 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
34 Respiratory: coughing and assoc symptoms
Kayentao 2012 44/355 28/180 18.3 % 0.80 [ 0.51, 1.24 ]
Poravuth 2011 5/228 5/228 2.5 % 1.00 [ 0.29, 3.41 ]
Roth 2018 18/101 15/96 7.6 % 1.14 [ 0.61, 2.13 ]
Rueangweerayut 2012 30/848 10/423 6.6 % 1.50 [ 0.74, 3.03 ]
Sagara 2018 (28) 56/669 54/668 26.6 % 1.04 [ 0.72, 1.48 ]
Sagara 2018 (29) 40/673 42/671 20.7 % 0.95 [ 0.62, 1.44 ]
Tshefu 2010 49/849 27/423 17.8 % 0.90 [ 0.57, 1.43 ]
Subtotal (95% CI) 3723 2689 100.0 % 0.99 [ 0.82, 1.19 ]
Total events: 242 (Pyronaridine-Artesunate), 181 (Control)
Heterogeneity: Chi2 = 2.70, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
35 Respiratory: upper respiratory tract signs and symptoms
Nelwan 2015 0/60 1/120 49.8 % 0.66 [ 0.03, 15.99 ]
Roth 2018 1/101 0/96 25.4 % 2.85 [ 0.12, 69.19 ]
Shin 2011 1/15 0/15 24.8 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 176 231 100.0 % 1.80 [ 0.32, 10.07 ]
Total events: 2 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: Chi2 = 0.56, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
36 Renal and urinary: urinary abnormalities
Roth 2018 2/101 1/96 100.0 % 1.90 [ 0.18, 20.63 ]
Subtotal (95% CI) 101 96 100.0 % 1.90 [ 0.18, 20.63 ]
Total events: 2 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
37 Skin and subcutaneous tissue: dermatitis and eczema
Nelwan 2015 0/60 2/120 77.4 % 0.40 [ 0.02, 8.14 ]
Ringwald 1996 (30) 1/47 0/49 22.6 % 3.13 [ 0.13, 74.85 ]
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Study or subgroup
Pyronaridine-
Artesunate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 107 169 100.0 % 1.01 [ 0.15, 6.99 ]
Total events: 1 (Pyronaridine-Artesunate), 2 (Control)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
38 Skin and subcutaneous tissue: pruritis
Ringwald 1996 (31) 7/47 18/49 48.1 % 0.41 [ 0.19, 0.88 ]
Ringwald 1998 (32) 2/44 19/44 51.9 % 0.11 [ 0.03, 0.43 ]
Subtotal (95% CI) 91 93 100.0 % 0.25 [ 0.13, 0.49 ]
Total events: 9 (Pyronaridine-Artesunate), 37 (Control)
Heterogeneity: Chi2 = 2.97, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 4.07 (P = 0.000048)
39 Skin and subcutaneous tissue: rashes, eruptions, exanthems
Roth 2018 2/101 1/96 100.0 % 1.90 [ 0.18, 20.63 ]
Subtotal (95% CI) 101 96 100.0 % 1.90 [ 0.18, 20.63 ]
Total events: 2 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
40 Skin and subcutaneous tissue: urticaria
Shin 2011 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
41 Vascular: vascular hypotensive disorders
Shin 2011 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (Pyronaridine-Artesunate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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A D D I T I O N A L T A B L E S
Table 1. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin increase grading
Trial ALT increased (grade 3 and
above)
AST increased (grade 3 and
above)
Blood bilirubin increased
Kayentao 2012 10 × ULN 10 × ULN 3 × ULN
Poravuth 2011
Rueangweerayut 2012
Sagara 2018
Tshefu 2010
5 × ULN 5 × ULN 2.5 × ULN
Roth 2018
Shin 2011
3 × ULN 3 × ULN -
Nelwan 2015 3 × ULN if associated with
bilirubin > 2 × ULN
- -
Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal.
Table 2. Serious adverse events
Study Pyronaridine-artesunate Comparator(s)
Kayentao 2012 Severe malaria (1)a Artemether-lumefantrine
-
Nelwan 2015 Head trauma (1)a
Typhoid fever (1)b
Nephrolithiasis (1)b
Artesunate only
Metacarpal fracture (1)a
Acute gastroenteritis (1)a
Suspected ureteric stone (1)b
Dihydroartemisinin-piperaquine
Dengue fever (1)a
Poravuth 2011 Pyrexia (1)a
Typhoid fever (1)a
Chloroquine
-
Ringwald 1996 - -
Ringwald 1998 - -
Roth 2018 - -
Rueangweerayut 2012 Autoimmune haemolytic anaemia (1)a
Cholera (1)a
Pneumonia (1)a
Acute pyelonephritis (1)a
Wound infection (1)a
Mefloquine plus artesunate
Cerebral malaria (1)a
Seizure (1)c
Grand mal seizure (1)c
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Table 2. Serious adverse events (Continued)
Abortion (1)a
Depression (1)a
Tshefu 2010 Parotitis (1)a
Typhoid fever (1)a
Urinary tract infection (1)a
Artemether-lumefantrine
Cerebral malaria (1)a
Immunosuppression (1)a
Sagara 2018d Elevated ALT (2)c
Elevated AST (2)c
Transaminases increased (4)c
Drug-induced liver injury (1)c
Hypercreatininemia (1)c
Artemether-lumefantrine
Drug-induced liver injury (1)c
Toxic epidermal necrolysis (1)c
Artesunate-amodiaquine
Drug-induced liver injury (1)c
Transaminases increased (2)c
Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase.
aStudy authors judged as unrelated to drug.
bStudy authors judged as unlikely related to drug.
cStudy authors judged as treatment-related.
dAuthors do not report the nature of the serious adverse events they judged to be unrelated to drug. Some of the listed events in the
comparator groups may have occurred in comparisons with dihydroartemisinin-piperaquine, but we were unable to extract data in
relation to this.
Table 3. Pyronaridine-artesunate (PY-AS) versus artemether-lumefantrine (AL): other reported outcomes
Trial Fever clearance time Parasite clearance time
PY-AS AL PY-AS AL
Kayentao 2012 Median 8.1 h (95% CI 8.0
to 8.1)
Median 8.1 h (95% CI 8.0
to 15.8)
Median 24.1 h (95% CI
24.0 to 24.1)
Median 24.2 h (95% CI
24.1 to 32.0)
Roth 2018 Median 1 day (1-1) Median 1 day (1-1) Median 1 day (1-2) Median 2 days (1-2)
Tshefu 2010 Mean 13.6 h (SD 8.9) Mean 14.8 h (SD 10.1) 23.3 h (SD 8.8) 26.5 h (10.1)
Abbreviations: AL: artemether-lumefantrine; PY-AS: pyronaridine-artesunate.
Table 4. Pyronaridine-artesunate (PY-AS) versus mefloquine plus artesunate (MQ+AS): other reported outcomes
Trial Fever clearance time Parasite clearance time Gametocyte clearance time
PY-AS MQ+AS PY-AS MQ+AS PY-AS MQ+AS
Rueangweerayut
2012
Mean 19.3 h
(SD 12.9)
Mean 19.2 h
(SD 12.5)
Mean 35.9 h
(SD 19.8)
Mean 38.5 h
(SD 20.1)
Mean 25.5 h
(SD 23.3)
Mean 30.9 h
(SD 19.9)
Abbreviations: MQ+AS: mefloquine plus artesunate; PY-AS: pyronaridine-artesunate.
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Table 5. Pyronaridine-artesunate (PY-AS) versus other antimalarials: electrocardiogram (ECG) abnormalities
Comparator drug Trial Pyronaridine-artesunate Comparator
ECG abnormalities Number of partici-
pants
ECG abnormalities Number of partici-
pants
Artemether-
lumefantrine
Sagara 2018 55 673 99 671
Amodiaquine-
artesunate
Sagara 2018 34 669 91 668
Chloroquine Poravuth 2011a 1 228 6 228
Shin 2011a 0 15 1 15
Dihy-
droartemisinin-
piperaquine or arte-
sunate alone
Nelwan 2015b 0 60 1 120
Total 90 1645 198 1702
aP vivax participants only.
bPyronaridine alone used as study drug.
A P P E N D I C E S
Appendix 1. Case definition in drug-induced liver injury
Aithal 2011 is a consensus statement from an Expert Working Group of clinicians and scientists on the case definition of drug-induced
liver injury. The criteria are as follows.
Clinical chemistry criteria for drug-induced liver injury
Any one of the following.
• More than or equal to five-fold elevation above the ULN for ALT.
• More than or equal to two-fold elevation above the ULN for ALP (particularly with accompanying elevations in concentrations
of 5′-nucleotidase or γ -glutamyl transpeptidase in the absence of known bone pathology driving the rise in ALP level).
• More than or equal to three-fold elevation in ALT concentration and simultaneous elevation of bilirubin concentration
exceeding 2 × ULN.
Drug-induced liver injury severity index
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Category Severity Description
1 Mild Elevated ALT/ALP concentration reaching clinical chemistry criteria for drug-induced liver
injury, but bilirubin concentration < 2 × ULN
2 Moderate Elevated ALT/ALP concentration reaching criteria for drug-induced liver injury, and bilirubin
concentration ≥ 2 × ULN, or symptomatic hepatitis
3 Severe Elevated ALT/ALP concentration reaching criteria for drug-induced liver injury, bilirubin
concentration ≥ 2× ULN, and one of the following
• International normalized ratio ≥ 1.5
• Ascites and/or encephalopathy, disease duration < 26 weeks, and absence of underlying
cirrhosis
• Other organ failure considered to be due to drug-induced liver injury
4 Fatal or transplantation Death or transplantation due to drug-induced liver injury
Abbreviations: ALP: alkaline phosphatase; ALT: alanine aminotransferase; ULN: upper limit of normal.
Appendix 2. Search strategy
Search set CIDG SRa CENTRAL MEDLINEb Embaseb LILACSb
1 Malaria Malaria ti, ab, kw Malaria ti, ab, Mesh Malaria.mp Emtree malaria
2 pyronaridine Pyronaridine ti, ab, kw “pyronari-
dine”ti, ab, Supplemen-
tary Concept
pyronaridine/ or arte-
sunate plus pyronari-
dine/ or pyronaridine.
mp
pyronaridine
3 pyramax Pyramax ti, ab, kw “Naphthyridines” Mesh Pyramax.mp pyramax
4 2 or 3 2 or 3 Pyramax ti, ab 2 or 3 2 or 3
5 1 and 4 1 and 4 2 or 3 or 4 1 and 4 1 and 4
6 - - 1 and 5 -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011).
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Appendix 3. Authors’ judgement on risk of bias
Potential bias Authors’ judgementa
Random sequence generation (selection bias) High - not randomized or quasi-randomized
Unclear - states “randomized”, but does not report method
Low - describes method of randomization
Allocation concealment (selection bias) High - not concealed, open-label trial for individually randomized, method of
concealment not adequate
Unclear - details of method not reported or insufficient details
Low - central allocation, sequentially numbered opaque sealed envelopes
Blinding (performance bias and detection bias) High - personnel, participants or outcome assessors not blinded
Unclear - no details reported, insufficient details reported
Low - personnel, participants and outcome assessors blinded
Incomplete outcome data (attrition bias) High - losses to follow-upnot evenly distributed across intervention and control
group
Unclear - no details reported, insufficient details reported
Low - losses to follow-up evenly distributed across groups, reasons for loss to
follow-up and exclusions clearly stated
Selective reporting (reporting bias) High - did not fully report measured or relevant outcomes
Unclear - not enough information reported to judge
Low - all stated outcomes reported
Other bias High - other source of bias identified by review authors
Low - no obvious other source of bias of concern to review authors
Adverse event monitoring (detection bias) High - passive methods relying on spontaneous patient report only, undefined
adverse events
Unclear - not enough information reported to judge
Low - key adverse events defined, prespecified active detection method
Incomplete adverse event reporting (reporting bias) High - adverse event severity undefined, combination of treatment groups,
post hoc cut-offs for reporting adopted
Unclear - not enough information reported to judge
Low - clear reporting on important adverse events with numerical data by
intervention group
aIndicative reasons for judgements only; this list is not intended to be exhaustive.
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Appendix 4. Planned sensitivity analysis
Analysisa Participants PCRb-unadjusted PCR-adjusted
Numerator Denominator Numerator Denominator
Primary analysis Exclusions after en-
rolment
Excludedc Excluded Excluded Excluded
Missing or indeter-
minate PCR
Included as failures Included Excluded Excluded
New infections Included as failures Included Excluded Excluded
Sensitivity analysis 1
d
As ‘Primary analysis’
except: missing or
indeterminate PCR
- - Included as failures Included
Sensitivity analysis 2
e
As ‘Sensitivity anal-
ysis 1’ except: new
infections
- - Included as successes Included
Sensitivity analysis 3
f
As ‘Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as failures Included Included as failures Included
Sensitivity analysis 4
g
As ‘Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as
successes
Included Included as successes Included
aRemove participants that did not satisfy the inclusion criteria after randomization from all calculations.
bPCR: polymerase chain reaction.
c‘Excluded’ means removed from the calculation.
dTo reclassify all indeterminate or missing PCR results as treatment failures in the PCR-adjusted analysis.
eTo reclassify all PCR-confirmed new infections as treatment successes in the PCR-adjusted analysis. (This analysis may overestimate
efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may
have gone on to develop a recrudescence after the new infection).
fTo reclassify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment failures. For PCR-unadjusted total failure this represents a true worse-case scenario.
gTo reclassify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment successes.
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WH A T ’ S N E W
Date Event Description
8 January 2019 New citation required and conclusions have changed We included four new studies: three published after the
previous version of this review, Bukirwa 2014, and one that
was not identified in the previous review. During re-ex-
traction of data from the previous studies we used a trans-
parent, itemized, and replicable procedure that differed
from Bukirwa 2014. The inclusion of new studies has al-
lowed a new comparison of pyronaridine-artesunate and
artesunate-amodiaquine, and has led to changes in the cer-
tainty of the evidence in relation to the primary outcomes.
This review update gives higher-certainty evidence in rela-
tion to the effect of pyronaridine-artesunate on raised ala-
nine aminotransferase (ALT)
8 January 2019 New search has been performed There is a new author team: Joseph Pryce, Paul Hine (new
contact person)
We use the term pyronaridine-artesunate in preference to
artesunate-pyronaridine to reflect how most authors refer
to the intervention. We updated the background to reflect
changes in global epidemiology, currentWorldHealthOr-
ganization (WHO) guidelines, and other developments.
We added the term ‘pyramax’ to the search strategy
We replaced the quantitative analysis of secondary out-
comes ‘parasite clearance’, ‘fever clearance’, and ‘gameto-
cyte carriage’ with a narrative synthesis, and comment on
the reasons for doing so. We simplified the ‘Adverse events’
outcomes to reflect that elevated liver function tests are a
primary area of interest
We itemized the procedure for data extraction to ensure
that the process is transparent and replicable in future re-
view updates. We have added further commentary regard-
ing the data extraction process. We simplified the ‘Risk
of bias’ assessment for adverse events. We abbreviated the
content of tables to enable clear and succinct presentation.
We incorporated risk of bias for adverse events assessments
into the main ‘Risk of bias’ tables. We added an appendix
to summarize our ‘Risk of bias’ assessment process
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H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 3, 2014
Date Event Description
11 November 2008 Amended We converted to the new review format with minor editing.
C O N T R I B U T I O N S O F A U T H O R S
For this update, Joseph Pryce (JP) and Paul Hine (PH) extracted data from all studies, and verified characteristics of studies and previous
‘Risk of bias’ assessments. PH rewrote the Background,Methods, Discussion, and Authors’ conclusions, with contributions from JP. PH
and JP completed the analysis, ‘Summary of findings’ tables, and results. Both review authors read and approved the final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
JP has no known conflicts of interests.
PH was previously employed full-time by Cochrane Infectious Diseases Group (CIDG), and currently works full-time within the UK
National Health Service (NHS). He received a Registration Scholarship to attend the 23rd Annual British HIV Association Conference
2017 from ViiV healthcare. ViiV had no involvement in the selection of recipients of the scholarship. In 2018, he attended a CPD-
certified clinical research training programme organized and funded by Gilead Sciences Europe Ltd. To the best of his knowledge,
neither financial or non-financial conflicts of interests have influenced the current submitted work.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
Project number 300342-104
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between protocol and 2014 review
We stated in the protocol that we intended to assess the methods used to generate the allocation sequence and conceal allocation
concealment as adequate, inadequate, or unclear according to Jni 2001, and note who was blinded to the interventions in each trial.
However, since the introduction of Review Manager 2011, we made these assessments using the methods described in Higgins 2011.
In keeping with the Cochrane Collaboration policy to use ’Summary of findings’ tables, which was introduced after publication of the
protocol, we generated them using GRADE profiler ( GRADE 2008) and interpreted the evidence for each outcome and comparison
using the GRADE approach ( Schnemann 2008).
We revised the list of outcomes to reflect current WHO standards for assessing outcomes in antimalarial trials.
Although gametocyte carriage was not included as an outcome in the protocol, we included it as a secondary outcome due to its
importance in malaria transmission.
In the protocol we stated that we intended to assess the effectiveness of pyronaridine both as a monotherapy and in combination with an
artemisinin. However, we revised this to focus only on pyronaridine-artemisinin combinations. In addition, due to concerns regarding
pyronaridine’s effect on the liver, assessment of the effects of the comparisons on liver function now include randomized comparisons in
both falciparum and vivax malaria. Accordingly, we updated the background and methods sections considerably to reflect the changing
scenario in malaria policies and epidemiology.
PT and HB joined the review team. Rajeev Aravindakshan withdrew from the team due to conflicting demands on his time.
Differences between protocol and 2018 review update
There is a new author team: Joseph Pryce and Paul Hine.
We use the term pyronaridine-artesunate in preference to artesunate-pyronaridine to reflect how most authors refer to the intervention;
we changed the title accordingly. We did not proceed with quantitative analysis of secondary outcomes ‘parasite clearance’, ‘fever
clearance’, and ‘gametocyte carriage’. The original protocol did not clearly define these outcomes, including whether they refer to
durations, rates, or proportions of patients at given time points. We encountered considerable heterogeneity in these measures between
studies, and therefore present a narrative synthesis. We simplified the ‘Adverse events’ outcomes to reflect areas which are of most
interest.
We added the term ‘pyramax’ to the search strategy. We simplified the assessment of risk of bias for adverse events.
N O T E S
Not applicable.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimalarials [adverse effects; therapeutic use]; Artemisinins [adverse effects; ∗therapeutic use]; Drug Therapy, Combination [meth-
ods]; Ethanolamines [adverse effects; therapeutic use]; Fluorenes [adverse effects; therapeutic use]; Liver [drug effects; metabolism];
Malaria, Falciparum [∗drug therapy]; Mefloquine [adverse effects; therapeutic use]; Naphthyridines [adverse effects; ∗therapeutic use];
Randomized Controlled Trials as Topic
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MeSH check words
Adult; Child; Humans
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